Compounds that inhibit WNK2 activity and methods for treating osteoarthritis
Compounds targeting WNK2 activity in osteoarthritis offer a therapeutic solution by reducing WNK2 expression and pSPAK levels, effectively treating and ameliorating osteoarthritis symptoms beyond symptom management.
Patent Information
- Application Number
- PCT/US2026/027350
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for osteoarthritis are limited to symptom management, and there is a need for new strategies to address the progressive nature of the disease.
Administering therapeutically effective amounts of compounds M1 to M53 to subjects to treat osteoarthritis, reduce pSPAK expression in affected tissues, and decrease WNK2 expression in chondrocytes and other cells, thereby targeting the underlying mechanisms of osteoarthritis progression.
The compounds effectively treat osteoarthritis by reducing WNK2 activity, ameliorating symptoms, and altering gene expression associated with osteoarthritis progression, providing a more direct approach than existing therapies.
Smart Images

Figure US2026027350_12112026_PF_FP_ABST
Abstract
Description
[0001] Attorney’s Docket No.: 21101.0498P1
[0002] COMPOUNDS THAT INHIBIT WNK2 ACTIVITY AND METHODS FOR TREATING OSTEOARTHRITIS
[0003] CROSS REFERENCE TO RELATED APPLICATIONS
[0004] This application claims the benefit of U. S. Provisional Application No. 63 / 802,980, filed May 9, 2025. The content of this earlier filed application is hereby incorporated by reference herein in its entirety.
[0005] GOVERNMENT SUPPORT
[0006] This invention was made with government support under AG063534 awarded by the National Institutes of Health. The government has certain rights in this invention.
[0007] INCORPORATION OF THE SEQUENCE LISTING
[0008] The present application contains a sequence listing that is submitted concurrent with the filing of this application, containing the file name “21101_0498Pl_SL.xml” which is 32,768 bytes in size, created on April 6, 2026. and is herein incorporated by reference in its entirety.
[0009] BACKGROUND
[0010] Osteoarthritis is the most common form of arthritis. It is a progressive disease with no cure. Currently available therapeutics are limited to managing the symptoms. Thus, new treatment strategies are needed.
[0011] SUMMARY
[0012] Disclosed herein are methods of treating osteoarthritis in a subject, the methods comprising: administering to the subject a therapeutically effective amount of a compound wherein the compound is Ml, M2, M3, M4, M5, M6, M7, M8, M9, M10, M11, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26, M27, M28, M29, M30. M31, M32, M33, M34, M35, M36, M37, M38, M39, M40, M41. M42. M43, M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53, thereby treating osteoarthritis in the subject.Attorney’s Docket No.: 21101.0498P1
[0013] Disclosed herein are methods of ameliorating one or more symptoms of osteoarthritis in a subject, the methods comprising: administering to the subject a therapeutically effective amount of a compound wherein the compound is Ml, M2, M3, M4, M5, M6, M7, M8, M9, M10, M11, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39, M40, M41. M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, M52. or M53, thereby ameliorating one or more symptoms of osteoarthritis in the subject.
[0014] Disclosed herein are methods of reducing pSPAK expression in damaged cartilage, menisci, bone, synovium, ligaments, tendons, fat pad, muscle, epidermis, bursa, vasculature, lymphatic system, or connective tissue, the methods comprising: administering to a subject a therapeutically effective amount of a compound wherein the compound is Ml, M2, M3, M4. M5, M6, M7, M8, M9, M10, M11, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39, M40, M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51. M52. or M53, thereby reducing pSPAK expression in damaged cartilage, menisci, bone, synovium, ligaments, tendons, fat pad, muscle, epidermis, bursa, vasculature, lymphatic system, and connective tissue.
[0015] Disclosed herein are methods of reducing WNK2 expression in chondrocytes, synovial cells, ligaments, tenocytes. myocytes, lymphatic cells, vascular cells, epidermal cells, or adipocytes in a subject, the method comprising: administering to the subject a therapeutically effective amount of a compound wherein the compound is Ml, M2, M3, M4, M5, M6, M7, M8, M9, M10, M11, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39. M40. M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51. M52. thereby reducing WNK2 expression in chondrocytes, synovial cells, ligaments, tenocytes, myocytes, lymphatic cells, vascular cells, epidermal cells, or adipocytes.
[0016] Other features and advantages of the present compositions and methods are illustrated in the description below, the drawings, and the claims.
[0017] BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1A-G show WNK2 expression is elevated in hypertrophic chondrocytes present in human osteoarthritic tissue and injured mouse knee joints. FIG. 1A shows Safranin O / Fast Green (Saf O / FG) stained human cartilage from the humeral head of healthy (normal) and OA patients (OA). FIG. IB shows that immunohistochemical staining demonstrates WNK2Attorney’s Docket No.: 21101.0498P1
[0018] expression in normal and osteoarthritic cartilage. WNK2 is detected at low levels in healthy human chondrocytes (FIG. IB) and in the superficial layer of chondrocytes in uninjured mouse medial femoral condyle (FIG. ID). Toluidine Blue stained tissue sections (FIG. 1C -medial femoral condyle and FIG. IE - osteophyte tissue) indicating loss of the superficial layer of articular cartilage after DMM surgery (FIG. 1C). In contrast, WNK2 is highly expressed in hypertrophic chondrocytes in damaged human OA cartilage (FIG. IB) and in hypertrophic chondrocytes of the mouse medial femoral condyle 8 weeks post-DMM surgery (FIGS. 1C and D). WNK2 is also highly expressed in osteophyte tissue 8 weeks post-DMM surgery' (FIG. IE). Arrows mark normal chondrocytes and arrowheads mark hypertrophic chondrocytes. Scale bar = 100pm. FIG. IF shows that Wnk2 is acutely downregulated after ACL rupture (non-invasive injury) and restored 21 days post-ACL rupture. qPCR analysis using RNA isolated from whole control and ACL ruptured mouse knee joints 5 and 21days post-ACL rupture. Error bars represent mean with 95% confidence interval and statistically significant differences of / ? < 0.05 (*) were determined by one-way ANOVA with Tukey’s multiple comparisons test, n=3. FIG. 1G shows that O A- associated markers are upregulated in the mouse knee joint 5 days post-ACL rupture. Error bars represent mean with 95% confidence interval and statistically significant differences of / ’ < 0.05 (*) were determined by a two-tailed unpaired t-test, n=4.
[0019] FIGS. 2A-C show WNK2 mediates the acute response to hyperosmotic stress in chondrocytes. FIG. 2A shows a schematic representation of the WNK2 locus and the guide RNAs (arrows) used to delete exon 2 of WNK2 in T / C-28a2 chondrocytes using CRISPR / Cas9 genome editing. FIG. 2B shows that WNK2- chondrocytes do not respond to acute physiological levels of hyperosmotic stress. Immunoblot analysis indicating phosphorylated SPAK (pSPAK) protein levels in WT and WNK2- chondrocytes in response to acute hyperosmotic stress. FIG. 2C shows pSPAK levels in WT chondrocytes exposed to hyperosmotic stress in the presence of a WNK1-4 inhibitor (WNK463). Ratio indicates the levels of pSPAK in each treatment relative to isotonic conditions. GAPDH is used as a loading control. Iso - isotonic conditions and Sor - sorbitol concentration in cell culture media.
[0020] FIGS. 3A-H shows that chronic hyperosmotic stress or WNK2 overexpression induces a remodeling response in chondrocytes, while loss of WNK2 function reduces OA- associated gene expression. FIGS. 3 A, 3C, 3E, and 3G shows comparative analysis of RNA-seq performed on RNA isolated from control or treated chondrocytes. The volcano plots indicate genes significantly upregulated (right side) or downregulated (left side) in (FIG. 3A) WTAttorney’s Docket No.: 21101.0498P1
[0021] chondrocytes treated for 7 days with lOOmM sorbitol (Sor) compared with control chondrocytes (Ctr), (FIG. 3C) WNK2~ chondrocytes (WNK2) compared with WT chondrocytes (WT) cultured in isotonic media, (FIG. 3E) WNK2~ chondrocytes (WNK2) compared with WT chondrocytes (WT) cultured in hyperosmotic media for 7 days (Sor treated), and (FIG. 3G) WT chondrocytes transfected with WT WNK2 (WNK2 Trans) as compared with control chondrocytes (Ctr) cultured in isotonic media. FIGS. 3B, 3D, 3F, and 3H show bubble plots illustrate the top pathways identified from the differentially expressed genes in A, C, E and G using Ingenuity Pathway Analysis. In the bubble plots, the x-axis represents the gene ratio (number of genes in a pathway significantly altered by each treatment relative to the total number of genes in that pathway) while the y-axis displays the Ingenuity Pathway Analysis pathways. Each bubble represents a specific pathway, with the color of the bubble indicating the positive (increased pathway gene expression, red) or negative (decrease pathway gene expression, blue) Z score. Darker colors indicate higher significance. The Z score is indicated next to each bubble. The size of the bubble indicates the -Log (p value) and corresponds to the level of significant enrichment, n = 4 for each condition.
[0022] FIGS. 4A-D show WNK2 acts synergistically with chronic hyperosmotic stress to induce expression of OA-associated genes and pathways. FIGS. 4A and 4B show comparative analysis of RNA-seq performed on RNA isolated from WT or WNK2' chondrocytes. FIG. 4A show the volcano plot indicating the genes significantly upregulated (right side) or downregulated (left side) in WT chondrocytes transfected for 48 hours with WNK2 and then treated for 7 days with lOOmM sorbitol (WNK2 Trans) compared with control chondrocytes treated for 7 days with lOOmM (No Trans), n = 4 for each condition. FIG. 4B show a bubble plot illustrating the top pathways identified from the differentially expressed genes in FIG. 4A. FIG. 4C shows a common set of differentially expressed genes (DEGs) from 5 published human OA gene expression; 82 up-regulated and 52 down-regulated DEGs shared between at least 3 studies were considered for comparison. The boxplot indicates Log2Fold change for samples with and without WNK2 transfection (WNK2 Trans) and sorbitol treatment (Sor - lOOmM) in WT and WNK2 chondrocytes. These genes were ranked by fold change and compared to a ranked list of fold changes for genes outside of the OA set (* = Mann-Whitney p value < 0.01). FIG. 4D shows the expression of selected OA-associated genes in WT and WNK2' transfected (Trans) or sorbitol (Sor) treated cells. Gene expression for the treatment groups was normalized to the respective counterpart. Blue tiles indicate repression of gene expression, and red tiles indicate induction of geneAttorney’s Docket No.: 21101.0498P1
[0023] expression. Relative transcript abundance represents the mean of the normalized transcript counts of the samples. Green tiles indicate a high (>1000) relative transcript abundance and white tiles indicate a low (<10) relative transcript abundance. ECM - Extra cellular matrix, Inflamma. - Inflammation, TF - transcription factors, Hypo - genes associated with hypertrophy, and IC - ion channels.
[0024] FIGS. 5A-G show WNK2 variants associated with familial OA amplify the pro-0 A transcriptional response to hyperosmotic stress. Bubble plots illustrate the top pathways identified from the differentially expressed genes identified from RNA-seq performed on WT chondrocytes overexpressing WT WNK2, WNK2H758N, WNK2R2054, or WNK2Ll005Fcultured in isotonic (FIGS. 5A-C) or hyperosmotic media (FIGS. 5D-F). FIG. 5G shows the expression of selected WNT pathway genes altered by WNK2 variant overexpression and hyperosmotic stress. The WT WNK2 overexpressing chondrocytes were compared with WT chondrocytes and the WNK2 variant overexpressing chondrocytes were compared with WT chondrocytes overexpressing WT WNK2. Cells were exposed to chronic hyperosmotic stress, n = 4 for each condition.
[0025] FIG. 6 shows graphical abstract illustrating the proposed role of WNK2 activity in chondrocytes and its contribution to osteoarthritis (OA) pathogenesis. The diagram illustrates the dynamic regulation of WNK2 and how alterations in its expression, combined with hyperosmotic stress, contribute to osteoarthritis (OA) progression.
[0026] FIGS. 7A-C show WNK2 expression is elevated in chondrocytes present in injured human osteoarthritic tissue and mouse joints. FIGS. 7A-7B show representative images of humeral head cartilage isolated from OA patients stained with Safranin O and Fast Green (Saf O / FG) and immunohistochemical staining for WNK2 expression. Arrowheads mark regions with severely damaged cartilage and overexpressed WNK2 in hypertrophic chondrocytes. FIG. 7C shows immunohistochemical staining demonstrating WNK2 expression in uninjured (normal) and in hypertrophic chondrocytes of the mouse tibia 8 weeks post injury (OA). No primary antibody controls have no positive signal in human or mouse tissue. Scale bar = 100pm.
[0027] FIGS. 8A-B show the generation and validation of WNK2 T / C-28a2 chondrocytes. FIG. 8A shows a schematic illustration of the human WNK2 locus. Primers used to amplify exon 2 are indicated as arrows. Agarose gel image depicting PCR amplification using DNA isolated from putative mutant clones. Wild-type indicates DNA isolated from unmodified control chondrocytes. GAPDH PCR amplification is used as a control. FIG. 8B shows a schematic illustration of the human WNK2 locus indicating primers (arrows) used to amplifyAttorney’s Docket No.: 21101.0498P1
[0028] WNK2 from control and clone C8-F1 cDNA. This amplicon was subjected to Sanger sequencing and the chromatogram indicates deletion of exon 2 from clone C8-F1 cDNA. which removes the nascent start codon.
[0029] FIGS. 9A-D show SPAK and pSPAK are expressed in undamaged and damaged human osteoarthritic tissue. FIGS. 9A-9C show representative images of humeral head cartilage isolated from OA patients immunostained for SAPK (FIGS. 9A and 9C) and pSPAK (FIGS. 9B and 9D). Arrows indicate SPAK and pSPAK expression in chondrocytes in undamaged cartilage. Arrowheads mark SPAK and pSPAK expression in severely damaged cartilage. Scale bar = 100pm.
[0030] FIGS. 10A-D show WNK2 mediates the acute response to hyperosmotic stress in chondrocytes. FIG. 10A shows pSPAK levels in WT and WNK2- chondrocytes exposed to increasing levels of hyperosmotic stress. FIG. 10B shows pSPAK levels in WT chondrocytes exposed to hyperosmotic stress in the presence of a WNK1-4 inhibitor (WNK463, 100μM). Both blots are unmodified / uncropped. FIGS. 10C and 10D show unmodified / uncropped immunoblots used to generate FIGS. 2B and 2C. Ratio indicates the levels of pSPAK in each treatment relative to isotonic conditions. GAPDH is used as a loading control.
[0031] FIGS. 11A-F show dose response of hyperosmotic stress in T / C-28a2 human chondrocytes. T / C-28a2 human chondrocytes were treated with 25, 50, and 100 mM sorbitol (Sor). No treatment was considered isotonic (Iso). (FIGS. 11A-1 ID) qPCR analysis of the OA-associated genes, COL2A1, MMP13, ADAMTS-1 and SOX9,' qPCR analysis of WNK2 (FIG. 1 IE) and SLC12A2 (FIG. 1 IF). Data are expressed as Fold Change (mean with 95% confidence interval) relative to Iso treated T / C-28a2 human chondrocytes, n = 6-9 samples / condition. Error bars represent 95% confidence interval and a statistically significant difference ofp < 0.05 (*) was determined by one-way ANOVA with Tukey’s multiple comparisons test.
[0032] FIGS. 12A-C show the PCA plot and interaction analysis of gene expression across treatments. Comparative analysis of RNA-seq performed on chondrocytes transfected with WT WNK2 or WNK2 OA-associated variant plasmids (48-hour transfection) and treated with lOOmM sorbitol (Sor) for 7 days. FIG. 12A shows the PCA plot of 48 samples across 12 treatments, using the first two principal components derived from the rlog-transformed values of the top 500 most variable genes. FIG. 12B shows interaction model 1: The top 25 interaction terms between ‘‘treatment’' (with and without sorbitol) and “genotype” (WT and WNK2' chondrocytes), with Z-scores representing the standardized effect size of these interactions. FIG. 12C show interaction model 2: The 25 interaction terms betweenAttorney’s Docket No.: 21101.0498P1
[0033] “transfection” XXX-WNK2. WNK2H758N, WNK2R2054Q, or WNK2L1005F) and “treatment”, where Z-scores indicate the direction and magnitude of combined effects on gene expression.
[0034] FIGS. 13A-E show WNK2 overexpression and hyperosmotic stress significantly alters the expression known OA-associated markers. T / C-28a2 human chondrocytes were transfected with WNK2 for 48 hours and then treated for 7 days with 100 mM sorbitol (Sor). FIGS. 13A-13C show qPCR analysis of OA-associated genes MMP13, ADAMTS-1 and SOX9 (FIG. 13D) qPCR analysis of WNK2 and (FIG. 13E) SLC12A2. Data are expressed as Fold Change (mean with 95% confidence interval) relative to control and untransfected T / C-28a2 human chondrocytes, n = 3-8 samples / condition. Error bars represent 95% confidence interval and a statistically significant difference of p < 0.05 (*) was determined by one-way ANOVA with Tukey's multiple comparisons test.
[0035] FIGS. 14A-D show' that primary human chondrocytes have a similar transcriptional response to WNK2 overexpression and hyperosmotic stress as compared to T / C-28a2 chondrocytes. FIGS. 14A-14C show that primary human chondrocytes electroporated with WNK2 (WT or WNK2R20549) and after 48 hours they were treated for 7 days with 100 mM sorbitol (Sor). qRT-PCR analysis was used to quantify gene expression. FIG. 14A shows the comparison of primary' human chondrocytes overexpressing WNK2 exposed to isotonic (iso) or hyperosmotic (Sor) treatment for 7 days. FIG. 14B shows the comparison of primary' human chondrocytes overexpressing WNK2R3054~ exposed to isotonic (Iso) or hyperosmotic (Sor) treatment for 7 days. FIG. 14C shows the comparison of primary human chondrocytes overexpressing WT or WNK2R2, M~ and exposed to hyperosmotic (Sor) treatment for 7 days. FIG. 14D show s RNA-seq data from T / C-28a2 chondrocytes indicating expression of genes analyzed in FIGS. 14A-C. NA indicates that SOX9 mRNA was not detected in T / C-28a2 chondrocytes. Statistically significant differences ofp < 0.05 (*) and p < 0.01 (**) were determined by a two-tailed unpaired t-test, n=4 biological replicates.
[0036] FIGS. 15A-C show' OA-associated WNK2 variants amply the chondrocyte response to hyperosmotic stress. FIGS. 15A-15C show the volcano plots indicating genes significantly upregulated (right side above threshold line) or downregulated (left side above threshold line) in WT chondrocytes expressing WNK2H"58R, WNK2R2054Q, or WNK2LI005Fcompared with WT WNK2 expressing chondrocytes.
[0037] FIGS. 16A-C show' the 3D structure of WNK2 protein whole and PKD domain. FIG.
[0038] 16A shows the predicted 3D structure of the full-length WNK2 protein using AlphaFold2. FIG. 16B shows the predicted protein kinase domain (WNK2- PKD) model using AlphaFold2, that show's secondary' structure elements with helices, sheets (beta strands), andAttorney’s Docket No.: 21101.0498P1
[0039] loops or turns. The N-terminal (N-term) and C-terminal (C-term) regions are labeled. FIG.
[0040] 16C shows the confidence levels of the WNK2-PKD prediction based on pLDDT scores. Very high confidence (pLDDT > 90), confident regions (70 < pLDDT < 90), low confidence (50 < pLDDT < 70), and very low confidence (pLDDT < 50) are indicated.
[0041] FIG. 17 shows the 3D structure of selected binding pocket WNK2 PKD domain. Left panel: The predicted structure of WNK2-PKD highlighting the binding pocket (BP-4) in yellow and blue. The N-terminal (N-term) and C-terminal (C-term) regions are labeled, along with the secondary structure elements depicted (alpha-helices), (beta-sheets), and (loops and turns). Right panel: A closer view of the binding pocket (BP-4), showing the amino acid residues contributing to the binding interface. Important residues include Leul 16, Glu245, Glu249, Arg247. Tyr218, Ser214, and others, which are important for ligand interactions and selectivity.
[0042] FIGS. 18A-F show the interaction profiles of selected inhibitors (M01 to M06) with the binding pocket BP-4 of WNK2-PKD. FIGS. 18A-F display the 2D interaction diagrams of the top six inhibitors (M01 to M06) with the binding pocket BP-4 of the WNK2 protein kinase domain (WNK2-PKD), generated using MOE. Each panel shows the interactions between the protein and a bound ligand (stick representation). Important interactions are highlighted: (1) hydrogen bonds as dashed lines between donor and acceptor atoms, (2) hydrophobic contacts as blue spheres around interacting residues. (3) aromatic interactions as pink spheres between aromatic rings. The ligand is shown in stick representation with different colors representing different chemical groups: carbon (grey), oxygen (red), nitrogen (blue), and Florine (green).
[0043] FIG. 19 shows the cell viability' assay of WNK2 inhibitors using XTT. The doseresponse curves are shown for the six inhibitors (M01 to M06) tested using the XTT assay, which measures cell viability as a percentage. The X-axis represents the inhibitor concentration (pM) on a logarithmic scale, while the Y-axis represents cell viability (%). ICso values (the concentration at which 50% cell viability' is inhibited) are indicated for each inhibitor in the inset boxes of their respective panels.
[0044] FIGS. 20A-E show WNK2 activity and M01 to M06 inhibitions on WNKs using pSPAK level under osmotic stress conditions. FIG. 20A depicts a graphical representation of WNK2 activity. WNK2 phosphorylates SPAK and OSR1 in response to osmotic stress, initiating downstream signaling pathways and altering gene expression. This process regulates ion transporters NKCC1 and KCC2 to maintain osmotic homeostasis in cells. FIG.
[0045] 20B shows the Western blot analysis of pSPAK levels under isotonic (Top) (ISO; 300Attorney’s Docket No.: 21101.0498P1
[0046] mOsm) and sorbitol-induced hyperosmotic (Bottom) (Sor; 200 mM / 500 mOsm) stress conditions. GAPDH was used as a loading control. (Top and Bottom) Lane labels: 1-M01, 2-M02, 3-M03, 4-M04, 5-M05, 6-M06, +C (WNK463, positive control, with Sorbitol), -C (WNK463, positive control, without Sorbitol) and D-DMSO. Dose-dependent effect of M04 inhibitor (FIG. 20C), M01 inhibitor (FIG. 20D) and M03 inhibitor (FIG. 20E) on pSPAK levels under isotonic (Top) (ISO; 300 mOsm) and sorbitol-induced hyperosmotic (Bottom) (Sor; 200 mM / 500 mOsm) stress conditions. Lane labels: -C (WNK463, positive control, without Sorbitol), +C (WNK463, positive control, with Sorbitol), D-DMSO, B-Blank, IpM, lOpM, 50pM, lOOpM, 200pM and 400pM of inhibitors M04, M01 and M03. GAPDH was used as a loading control.
[0047] FIGS. 21A-D show inhibition of WNK1-4 kinase activity by M04 in an ADP-Glo™ Kinase Assay. Kinase activity of WNK1 (FIG. 21A), WNK2 (FIG. 21B), WNK3 (FIG. 21C), and WNK4 (FIG. 2 ID) was measured using the ADP-Glo Kinase Assay. Luminescence (relative light units, RLU) was measured after subtraction of background signal (black). Kinase reactions were performed in the presence of DMSO (vehicle control), increasing concentrations of the inhibitor M04 in (1, 10, 50, 100, and 200 pM), or the WNK-specific inhibitor WNK463 (200 pM) (positive control). Dose-dependent decreases in luminescence indicate inhibition of kinase activity by M04. Data represent the mean ± SD from [n=4] independent experiments.
[0048] FIG. 22 shows the graphical representation of drug screening pipeline.
[0049] FIGS. 23A-B shows the sequence analysis of WNK family proteins and identification of target residues for WNK2-Specific Inhibitor Design. FIG. 23 A shows the FASTA sequence of WNK2 (NP_001269323; SEQ ID NO: 31) used for AlphaFold 2 structural modeling. The sequence represents the WNK2 protein kinase domain, which was utilized to predict the three-dimensional structure and identify potential binding pockets for inhibitor design. FIG. 23B shows the ClustalW alignment of the protein kinase domains from four WNK family members: WNK1 (NP_998820.3; SEQ ID NO: 32), WNK2 (NP_001269323; SEQ ID NO: 31), WNK3 (NP_065973.2; SEQ ID NO: 33), and WNK4 (NP_115763.2; SEQ ID NO: 34). The residues Glu245 and Glu249, which are uniquely present in WNK2 and targeted for inhibitor development, are highlighted within boxes. These residues represent the core focus for selective inhibitor design due to their absence in other WNK family members. Asterisks (*) denote positions with identical residues across the four WNK family members.
[0050] FIGS. 24A-H show M01 to M06 inhibitions on WNKs using pSPAK level under osmotic stress conditions. Original figures used for FIG. 20. FIG. 24A shows the WesternAttorney’s Docket No.: 21101.0498P1
[0051] blot analysis of pSPAK levels under isotonic (ISO; 300 mOsm) stress condition. Lane labels: 1-M0L 2-M02, 3-M03, 4-M04, 5-M05, 6-M06, +C (WNK463, positive control, with Sorbitol), -C (WNK463, positive control, without Sorbitol) and D-DMSO. FIG. 24B shows the Western blot analysis of pSPAK levels under sorbitol-induced hyperosmotic (Sor; 200 mM / 500 mOsm) stress condition. GAPDH was used as a loading control. Lane labels: 1-M01, 2-M02, 3-M03, 4-M04, 5-M05, 6-M06, +C (WNK463, positive control, with Sorbitol), -C (WNK463, positive control, without Sorbitol) and D-DMSO. Dose-dependent effect of M04 inhibitor (FIG. 24C and FIG. 24D), M01 inhibitor (FIG. 24E and FIG. 24F) and M03 (FIG. 24G and FIG. 24H) inhibitor (FIG. 24E) on pSPAK levels under isotonic (ISO; 300 mOsm) and sorbitol-induced hyperosmotic (Sor; 200 mM / 500 mOsm) stress conditions. Lane labels: -C (WNK463, positive control, without Sorbitol), +C (WNK463, positive control, with Sorbitol), D-DMSO, B-Blank, IpM, lOpM, 50pM, lOOpM, 200(iM and 400pM of inhibitors M04, M01 and M03. GAPDH was used as a loading control.
[0052] FIGS. 25A-C show the analysis of WNK2-PKD protein dynamics in the presence and absence of M04. FIG. 25 A shows RMSF plots showing the fluctuations of residues in WNK2-PKD and WNK2-PKD+M04. X -axis represents amino acids number and Y-axis represents RMSF in nanometers (nm). FIG. 25B depicts RMSD plots showing the time evolution of the root-mean-square deviation of the protein backbone atoms from the initial structure. X-axis represents simulation time and Y-axis represents RMSD in nm. FIG. 25C shows the radius of gyration plots showing the overall size and compactness of the protein over time. X -axis represents time and Y-axis represents Radius of Gyrates in nm.
[0053] FIGS. 26A-F show the cell viability assay of WNK2-PKD interaction molecules using the XTT viability assay. FIGS. 26A-F show the dose-response curves for the six molecules (M01, M02, M03, M04, M05, and M06) tested using the XTT assay. The X-axis represents the inhibitor concentration (|1M) on a logarithmic scale, while the Y-axis represents cell viability (%). ICso values (the concentration at which 50% cell viability is inhibited) are indicated for each inhibitor in the inset boxes of their respective panels.
[0054] FIG. 27 shows that the (R)-enantiomer of M04 inhibits WNK2 activity and pSPAK in response to osmotic stress. Immunoblot analysis of pSPAK levels under sorbitol-induced hyperosmotic stress conditions (Sor, 200 mM sorbitol, 500 mOsm). Cells were treated for 5 minutes in the presence of DMSO control, 400uM racemic M04, 400uM (R)-M04, 400uM (S)-M04, or lOOuM WNK463. GAPDH was used as a loading control.
[0055] FIGS. 28A-B show that M04 inhibition of WNK2 alters the transcriptional response of chondrocytes in response to IL i treatment. RT-qPCR analysis of ILlfi, II.6. CCL2,Attorney’s Docket No.: 21101.0498P1
[0056] COL2A1, ACAN, FGF1 andMMP13 gene expression in (FIG. 28A) T / C-28a2 chondrocytes and (FIG. 28B) primary human chondrocytes cultured in hyperosmotic media (lOOmM sorbitol) and treated with IL 1 (lOng / ml) for 24 hours in the presence of DMSO, lOOuM M04, or 10 pM WNK463. Gene expression was normalized to ACTB and relative expression was calculated using the AACq method. mRNA levels are reported as fold-change (mean ± SEM) relative to DMSO treated Ctrl samples. Statistically significant differences of p < 0.05 (*). p < 0.01 (**), p < 0.001 (***). and p < 0.0001 (****) were determined by two-way ANOVA with Tukey’s multiple comparisons test, n=3 or 4 biological replicates as indicated in the scatter plots.
[0057] DETAILED DESCRIPTION
[0058] Many modifications and other embodiments of the present disclosure set forth herein will come to mind to one skilled in the art to which this disclosure pertains having the benefit of the teachings presented in the foregoing descriptions and the associated drawings.
[0059] Therefore, it is to be understood that the present disclosure is not to be limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended claims. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.
[0060] Before the present compositions and methods are disclosed and described, it is to be understood that they are not limited to specific synthetic methods unless otherwise specified, or to particular reagents unless otherwise specified, as such may, of course, vary. It is also to be understood that the terminology' used herein is for the purpose of describing particular aspects only and is not intended to be limiting. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, example methods and materials are now described.
[0061] Moreover, it is to be understood that unless otherwise expressly stated, it is in no way intended that any method set forth herein be construed as requiring that its steps be performed in a specific order. Accordingly, where a method claim does not actually recite an order to be followed by its steps or it is not otherwise specifically stated in the claims or descriptions that the steps are to be limited to a specific order, it is in no w ay intended that an order be inferred, in any respect. This holds for any possible non-express basis for interpretation, including matters of logic with respect to arrangement of steps or operational flow, plainAttorney’s Docket No.: 21101.0498P1
[0062] meaning derived from grammatical organization or punctuation, and the number or type of aspects described in the specification.
[0063] All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and / or materials in connection with which the publications are cited. The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of pnor disclosures. Further, the dates of publication provided herein can be different from the actual publication dates, which can require independent confirmation.
[0064] Definitions
[0065] As used in the specification and in the claims, the term "‘comprising'’ can include the aspects “consisting of’ and “consisting essentially of.” “Comprising” can also mean “including but not limited to.”
[0066] As used in the specification and the appended claims, the singular forms “a,” “an” and “the” can include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a compound” includes mixtures of compounds; reference to “a pharmaceutical carrier” includes mixtures of two or more such carriers, and the like.
[0067] The word “or” as used herein means any one member of a particular list and also includes any combination of members of that list.
[0068] As used herein, the terms “optional” or “optionally” mean that the subsequently described event or circumstance may or may not occur and that the description includes instances where said event or circumstance occurs and instances where it does not.
[0069] As used herein, the term “sample” is meant a tissue or organ from a subject; a cell (either within a subject, taken directly from a subject, or a cell maintained in culture or from a cultured cell line); a cell lysate (or lysate fraction) or cell extract; or a solution containing one or more molecules derived from a cell or cellular material (e.g., a polypeptide or nucleic acid), which is assayed as described herein. A sample may also be any body fluid or excretion (for example, but not limited to, blood, urine, stool, saliva, tears, bile) that contains cells or cell components.
[0070] As used herein, the term “subject” refers to the target of administration, e g., a human. The subject of the disclosed methods can be a vertebrate, such as a mammal, a fish, a bird, a reptile, or an amphibian. The term “subject” also includes domesticated animals (e.g., cats, dogs. etc.), livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), and laboratory animals (e.g., mouse, rabbit, rat, guinea pig, fruit fly, etc.). In some aspects, a subject is a mammal.Attorney’s Docket No.: 21101.0498P1
[0071] In some aspects, a subject is a human. The term does not denote a particular age or sex. Thus, adult, child, adolescent and newborn subjects, as well as fetuses, whether male or female, are intended to be covered.
[0072] As used herein, the term '‘patient” refers to a subject afflicted with a disease or disorder (e.g., osteoarthritis). The term “patient” includes human and veterinary subjects. In some aspects of the disclosed methods, the “patient” has been diagnosed with a need for treatment for osteoarthritis, such as, for example, prior to the administering step.
[0073] Ranges can be expressed herein as from '‘about” or “approximately” one particular value, and / or to “about” or “approximately” another particular value. When such a range is expressed, a further aspect includes from the one particular value and / or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent '‘about,” or '‘approximately,” it will be understood that the particular value forms a further aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint and independently of the other endpoint. It is also understood that there are a number of values disclosed herein and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that each unit between two particular units is also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
[0074] “Inhibit,” “inhibiting” and “inhibition” mean to diminish or decrease an activity, response, condition, disease, or other biological parameter. This can include, but is not limited to, the complete ablation of the activity, response, condition, or disease. This may also include, for example, a 10% inhibition or reduction in the activity’, response, condition, or disease as compared to the native or control level. Thus, in an aspect, the inhibition or reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels. In an aspect, the inhibition or reduction is 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, or 90-100% as compared to native or control levels. In an aspect, the inhibition or reduction is 0-25, 25-50. 50-75, or 75-100% as compared to native or control levels.
[0075] ■‘Modulate”, “modulating” and “modulation” as used herein mean a change in activity or function or number. The change may be an increase or a decrease, an enhancement or an inhibition of the activity, function or number.
[0076] As used herein, the term “treating” refers to partially or completely alleviating, ameliorating, relieving, delaying onset of, inhibiting or slowing progression of, reducingAttorney’s Docket No.: 21101.0498P1
[0077] severity of, and / or reducing incidence of one or more symptoms or features of a particular disease, disorder, and / or condition. Treatment can be administered to a subject who does not exhibit signs of a disease, disorder, and / or condition and / or to a subject who exhibits only early signs of a disease, disorder, and / or condition for the purpose of decreasing the risk of developing pathology' associated with the disease, disorder, and / or condition. Treatment can also be administered to a subject to ameliorate one more signs of symptoms of a disease, disorder, and / or condition. For example, the disease, disorder, and / or condition can be or can relate to osteoarthritis.
[0078] All publications and patent applications mentioned in the specification are indicative of the level of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
[0079] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, certain changes and modifications may be practiced within the scope of the appended claims.
[0080] Chondrocytes of articular cartilage are surrounded by a pericellular matrix (PCM) and embedded in a dense extracellular matrix (ECM) (Wilusz, R. E., et al. (2014). Matrix Biol 39, 25-32). The high concentration of polyanionic glycosaminoglycan (GAG) sidechains on proteoglycans in the PCM / ECM generates a hyperosmotic environment in healthy cartilage (350-450mOsm) (Lewis, R., et al. (2011). Cell Physiol Biochem 28, 1111-1122; Urban, J. P. (1994). Br J Rheumatol 33, 901-908; and Urban, J. P., et al. (1993). J Cell Physiol 154, 262-270). Synovial fluid of the joint is also hyperosmotic (295-404mOsm) (Shanfield, S.. et al. (1988). Clin Orthop Relat Res, 289-295; Bertram. K. L.. and Krawetz, R. J. (2012). Biochem Biophys Res Commun 422, 455-461; and Newman, P. J., and Grana, W. A. (1988) Arthroscopy 4, 179-181). A hyperosmotic environment is thought to maintain homeostasis of the joint through positive regulation of GAG synthesis (Xu, X., et al. (2010). Osteoarthritis Cartilage 18, 433-439; and Negoro, K., et al. (2008) Clin Exp Rheumatol 26, 534-541) and by increasing expression of a select subset of chondrogenic genes while suppressing those associated with hypertrophy (Tew, et al. (2009) Am J Physiol Cell Physiol 297, C898-906; Emdt-Marino, et al. (2019) Cartilage 10, 186-195. Mongkhon, J. M., et al. (2014) Inflamm Res 63, 691-701; van der Windt. et al. (2010) Arthritis Research & Therapy 12, 100-112; Mang, T., et al. (2020) Int J Mol Sci. Jan 14;21 (2): 531; and Govindaraj, K., et al. (2024). Adv Sci (Weinh), e2306722. Mar;l 1(1 l):e2306722). This effect is likely context and tissueAttorney’s Docket No.: 21101.0498P1
[0081] dependent, as some studies have reported negative effects of a hyperosmotic environment on cultured chondrocytes including reduced cell viability and chondrogenic differentiation (Urban, J. P., et al. (1993). J Cell Physiol 154, 262-270; Jurgens, et al. (2012). J Tissue Eng Regen Med 6, 570-578; and Parameswaran, R., et al. (2021). Tissue Cell 72, 101590).
[0082] Although the joint is generally characterized as a high osmolarity environment, cells of the synovial joint are constantly exposed to changing osmolarity due to the effects of everyday activity and injury, as well as physiological changes associated with aging (Lewis, R., et al. (2011). Cell Physiol Biochem 28, 1111-1122; Urban, J. P. (1994). Br J Rheumatol 33, 901-908; Urban, J. P., et al. (1993). J Cell Physiol 154, 262-270; Shanfield, S., et al.
[0083] (1988). Clin Orthop Relat Res, 289-295; Bertram, K. L., and Krawetz, R. J. (2012). Biochem Biophys Res Commun 422, 455-461; Newman, P. J., and Grana, W. A. (1988). Arthroscopy 4, 179-181; and Dudek, M., et al. (2023). Nat Commun 14, 7237). The cells of the joint must continually respond to these changes, but the molecular and cellular pathways that directly sense and respond to changes in osmotic stress over time are unknown (Lewis, R., et al. (2011). Cell Physiol Biochem 28, 1111-1122; Hall, A. C. (2019). Curr Rheumatol Rep 21, 38; and Wilkins, R. J., Browning, et al. (2000). Biorheology 37, 67-74). Described herein are compositions and methods used to determine whether the altered response to osmotic stress contributes to loss of homeostasis and the onset of OA. Identification of the genes and pathways that sense and respond to osmotic stress is important for understanding how the joint maintains homeostasis and investigating whether response to osmotic stress may facilitate development of OA.
[0084] The With-No-Lysine (K) (WNK) protein kinases are intracellular sensors that respond to hyperosmotic stress by regulating ion channel activity and signaling pathways (Goldsmith, E. J., and Rodan, A. R. (2023). Annu Rev Physiol 85, 383-406). In response to acute hyperosmotic stress, WNKs phosphorylate and activate the kinases SPAK and OSR1, which in turn phosphorylate and regulate sodium and potassium-chloride co-transporters to modulate osmoregulation (de Los Heros, P., et al. (2014). Biochem J 458, 559-573). Though WNKs have not been associated previously with OA, ion channels targeted by WNKs are expressed in chondrocytes and upregulated in human OA tissue (Lewis, R., et al. (2011). Cell Physiol Biochem 28, 1111-1122; Bertram, K. L., et al. (2016). Channels (Austin) 10, 148-157; and Barrett-Jolley, R., et al. (2010). Front Physiol 1, 135). Further, WNK2 is acutely downregulated in response to an OA-promoting stimulus in vitro (Reed, K. S. M., et al. (2021). Osteoarthritis Cartilage 29, 235-247), suggesting it may have a role in chondrocytes.Attorney’s Docket No.: 21101.0498P1
[0085] Disclosed herein are coding variants in WNK2 that segregated strictly with disease occurrence in families with inherited erosive hand OA (EHOA) and 1stmetatarsophalangeal (MTP) joint OA. Consistent with the notion that WNK2 modulates the response to physiological changes associated with OA, the results disclosed herein show that WNK2 is normally expressed in articular chondrocytes and is expressed at elevated levels in human and mouse tissues of osteoarthritic joints. The examples disclosed herein are also tests to determine whether WNK2 functions in chondrocytes to sense and respond to hyperosmotic stress and that the combination of increased WNK2 and sustained hyperosmotic stress induces OA-associated gene expression changes in chondrocytes. Exposure of chondrocytes to hyperosmotic stress or overexpression of WNK2 initiates a transcriptional response that regulates cellular remodeling. Whereas it was found that neither hyperosmotic stress nor overexpression of WNK2 alone are sufficient to induce OA-like gene expression, it was discovered that the combination of hyperosmotic stress and overexpression of WNK2 in chondrocytes has a distinct effect on gene expression. The two factors act synergistically, driving a transcriptional response associated with promotion of OA. Consistent with the significance of the synergistic activity of hyperosmotic stress and WNK2 in promoting OA, each of the OA-associated WNK2 protein variants had altered activity: overexpression of each variant in chondrocytes is sufficient to drive OA-like gene expression without hyperosmotic stress. The data described herein provide strong evidence that WNK2 functions in the chondrocyte response to hyperosmotic stress and that altered WNK2 signaling can drive development of OA (FIG. 6).
[0086] Osteoarthritis (OA) is a disease characterized by loss of joint space, degeneration of cartilage at articular surfaces, remodeling of bone and other joint tissues, low-grade inflammation, and pain (Loeser, R. F.. et al. Arthritis Rheum 64, 1697-1707 (2012); and Neogi, T. & Zhang, Y. Rheum Dis Clin North Am 39, 1-19 (2013)). At present, there are no disease-modifying drugs available for OA, and treatment options are limited to pain management and joint replacement (Vincent, T. L. Lancet Rheumatol 2, e633-e645 (2020)). A lack of targeted therapies highlights the need to identify molecular pathways underlying OA progression and develop effective treatments (Cibrian Uhalte, et al. Hum Mol Genet 26, R193-R201 (2017); Zengini, E., et al. J Rheumatol 43, 260-266 (2016); Drevet, S., et al. Comp Med 72, 3-13 (2022); Ramos, Y. F. & Meulenbelt, I. Curr Rheumatol Rep 17, 53 (2015); and Aury-Landas, J., et al. Trends Mol Med 22, 38-52 (2016)). To address this issue, a combined genetic and functional approach was used that identified molecular pathways that are involved in joint homeostasis. Families were identified in which age-associated OAAttorney’s Docket No.: 21101.0498P1
[0087] occurs as a fully penetrant, dominantly inherited trait and whole exome sequencing was performed to discover rare coding alleles segregating with the OA phenotype (Kazmers, N. H. et al. Arthritis Rheumatol 73, 440-447 (2021); Kazmers, N. H. et al. J Hand Surg Am 45, 1-8 el (2020); Teerlink, C. C. et al. Ann Hum Genet 85, 58-72 (2021); Gavile, C. M. et al. J Hand Surg Am (2022); Jurynec, M. J. et al. Hum Mol Genet 27, 2406 (2018); Styrkarsdottir, U. et al. Ann Rheum Dis (2023); Jurynec, M. J. et al. Ann Rheum Dis (2022); Liu, H. et al. Arthritis Rheumatol (2025); and Veerabhadraiah, S. R. et al. RMD Open 11 (2025)). By focusing on familial forms of OA, the confounding effects of studying populations in which disease occurs for heterogeneous reasons was avoided. The affected genes regulate pathways that are involved in maintenance of the joint under normal behavioral conditions.
[0088] Four independent OA families with rare coding mutations in With-No-Lysine (K) 2 (WNK2) were recently identified (Veerabhadraiah, S. R. et al. RMD Open 11 (2025)). These coding variants alter evolutionarily conserved residues that are important for sensing and responding to hyperosmotic stress (Boyd-Shiwarski, C. R. et al. Cell 185, 4488-4506 e4420 (2022)). The WNK protein kinases (WNK1-4) are intracellular sensors that respond to hyperosmotic stress by regulating ion channel activity and signaling pathways (Goldsmith, E. J. & Rodan, A. R. Annu Rev Physiol 85, 383-406 (2023)). WNKs directly phosphorylate the downstream kinases STE20 / SPS1 -related Proline- Alanine-rich Kinase (SPAK) and Oxidative Stress-Responsive Kinase 1 (OSR1), which subsequently phosphorylate and regulate sodium and potassium-chloride co-transporters to modulate osmoregulation (de Los Heros, P. et al. Biochem J 458, 559-573 (2014)). The functional studies demonstrated that WNK2 function mediates a significant portion of the response to acute and chronic hyperosmotic stress in chondrocytes. It was further shown that the WNK2 OA-associated variants are hypermorphic and their expression is sufficient to promote expression of pathways associated with OA, a response that is further amplified under conditions of hyperosmotic stress (Veerabhadraiah, S. R. et al. RMD Open 11 (2025)). These results show that reduction of WNK2 activity can be a therapeutic target for the treatment of OA.
[0089] Mutations in WNK1 and WNK4 are associated with hypertension and renal salt absorption and may be drug targets (Wilson, F. H. et al. Science 293, 1107-1112 (2001)). WNK463 is a compound that inhibits the four WNK proteins with IC50 values of 5 nM (WNK1), 1 nM (WNK2), 6 nM (WNK3), and 9 nM (WNK4) (Yamada, K. et al. Nat Chem Biol 12, 896-898 (2016)). This compound has been shown to produce significant, dosedependent effects on blood pressure and heart rate in animal models. Specifically, WNK463 treatment reduces blood pressure and increases heart rate in spontaneously hypertensive ratsAttorney’s Docket No.: 21101.0498P1
[0090] (SHRs) when administered orally (1-10 mg / kg; 4 hours). Additionally, it causes an increase in urine output and sodium and potassium excretion from the urine. Although WNK463 is a potent pan-WNK inhibitor it has a short half-life of 2.1 hours in Sprague-Dawley rats (Yamada, K. et al. Nat Chem Biol 12, 896-898 (2016)). Furthermore, WNKs have other roles beyond the renal system and systemic inhibition of all WNKs may not be a viable therapeutic option (Eick, A. K., et al. Curr Biol 32, 1420-1428 el424 (2022); Izadifar, A. et al. Neuron 109, 2864-2883 e2868 (2021); and Sinha, A. S. et al. Front Mol Neurosci 15, 856262 (2022)..23-25 Overall, WNK463 has a number of limitations, making it imperative to develop more effective and targeted inhibitors for use in OA.
[0091] Disclosed herein are WNK2 inhibitors that can be used to prevent or slow the progression of OA. Also disclosed herein is the integrated workflow that led to the identification of a WNK2 inhibitor with minimal cytotoxicity. These results highlight M04 as a candidate for osteoarthritis therapy through its inhibition of WNK2, supporting further exploration of M04 and related compounds as treatments for OA.
[0092] Compositions and Pharmaceutical Compositions
[0093] Disclosed herein are compounds that inhibit WNK2 activity and / or expression. Also, disclosed herein are compounds useful in the methods described herein. In some aspects, the disclosed compounds are useful in treating osteoarthritis. In some aspects, the disclosed compounds are useful in ameliorating one or more symptoms of osteoarthritis. In some aspects, the disclosed compounds are useful in reducing pSPAK expression in damaged cartilage, menisci, bone, synovium, ligaments, tendons, fat pad, muscle, epidermis, bursa, vasculature, lymphatic system, and connective tissue. In some aspects, the disclosed compounds are useful in reducing WNK2 expression in innate and adaptive immune cells. In some aspects, the disclosed compounds are useful in reducing WNK2 expression in chondrocytes, synovial cells (including immune cells), ligaments, tenocytes, myocytes, lymphatic cells, vascular cells, epidermal cells, and adipocytes.
[0094] In some aspects, the compounds useful in the methods described herein can be one or more of the compounds having the structures set forth in Table 1. As used herein, reference to Ml and M01 refers to the same compound. Similarly, reference to M2 and M02 refers to the same compound. Reference to M3 and M03 refers to the same compound. Reference to M4 and M04 refers to the same compound. Reference to M5 and M05 refers to the same compound. Reference to M6 and M06 refers to the same compound. Reference to M7 and M07 refers to the same compound. Reference to M8 and M08 refers to the same compound. Reference to M9 and M09 refers to the same compound. For example, by way of example,Attorney’s Docket No.: 21101.0498P1 compound Ml is a compound that has the structure:
[0095]
[0096] The compound M2 is a compound that has the structure:
[0097]
[0098] Attorney’s Docket No.: 21101.0498P1
[0099] Table 1. Compounds.
[0100] S ~ -4,90 kcal / mol
[0101]
[0102] Attorney’s Docket No.: 21101.0498P1
[0103]
[0104] Attorney’s Docket No.: 21101.0498P1
[0105]
[0106] In some aspects, the compound is one or more of Ml, M3, and M4. In some aspects, the compound is M4. In some aspects, the M4 compound is a racemic mixture. R and S. In some aspects, the active form is the R form of the M4 compound..
[0107] In some aspect, the compound can be any one of Ml, M2, M3, M4, M5, M6, M7, M8, M9, MIO, Ml 1, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26. M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37. M38. M39, M40. M41. M42, M43, M44, M45, M46, M47, M48, M49, M50. M51. M52. or M53. In some aspects, the compound is M4. In some aspects, the M4 compound is a racemic mixture, R and S. In some aspects, the active form is the R form of the M4 compound.
[0108] In some aspects, the Ml, M2, M3, M4, M5, M6, M7, M8, M9, MIO, Ml 1, M12, M13, M14. M15. M16, M17, M18, M19, M20, M21, M22, M23, M24, M25. M26. M27. M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39, M40, M41, M42, M43,Attorney’s Docket No.: 21101.0498P1
[0109] M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53 compound is in the R form, the S form, or a racemic mixture of R and S forms.
[0110] In some aspects, the one or more of the compounds Ml, M2, M3, M4, M5, M6, M7, M8, M9, M10, M11, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39, M40. M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51. M52. or M53 can be used alone or in combination. In some aspects, the compound is M4. In some aspects, the M4 compound is a racemic mixture, R and S. In some aspects, the active form is the R form of the M4 compound. In some aspects, the Ml, M2, M3, M4, M5, M6, M7, M8, M9, MIO, Mil. M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23. M24, M25. M26. M27, M28, M29, M30, M31, M32, M33, M34, M35, M36. M37. M38. M39, M40, M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53 compound is in the R form, the S form, or a racemic mixture of R and S forms.
[0111] Also, disclosed herein are pharmaceutical compositions, comprising one or more of the compounds or compositions disclosed herein. For example, disclosed herein are pharmaceutical compositions, comprising one or more of the compounds: Ml, M2, M3, M4, M5, M6, M7, M8, M9, MIO, MH, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37. M38, M39, M40, M41, M42, M43, M44, M45, M46, M47, M48, M49. M50, M51. M52. or M53.
[0112] Any of the compounds or compositions disclosed herein can further comprise a pharmaceutically acceptable carrier. In some aspects, the pharmaceutical compositions can further comprise a pharmaceutically acceptable carrier.
[0113] As used herein, the term “pharmaceutically acceptable carrier” refers to solvents, dispersion media, coatings, antibacterial, isotonic and absorption delaying agents, buffers, excipients, binders, lubricants, gels, surfactants that can be used as media for a pharmaceutically acceptable substance. The pharmaceutically acceptable carriers can be lipid-based or a polymer-based colloid. Examples of colloids include liposomes, hydrogels, microparticles, nanoparticles and micelles. The compositions can be formulated for administration by any of a variety of routes of administration, and can include one or more physiologically acceptable excipients, which can vary depending on the route of administration. Any of the compounds or compositions described herein can be administered in the form of a pharmaceutical composition.Attorney’s Docket No.: 21101.0498P1
[0114] As used herein, the term “excipient’' means any compound or substance, including those that can also be referred to as “carriers” or “diluents.” Preparing pharmaceutical and physiologically acceptable compositions is considered routine in the art, and thus, one of ordinary skill in the art can consult numerous authorities for guidance if needed. The compositions can also include additional agents (e.g., preservatives).
[0115] The pharmaceutical compositions as disclosed herein can be prepared for oral or parenteral administration. Pharmaceutical compositions prepared for parenteral administration include those prepared for intravenous (or intra-arterial), intramuscular, subcutaneous, intrathecal or intraperitoneal administration. Paternal administration can be in the form of a single bolus dose, or may be, for example, by a continuous pump. In some aspects, the compositions can be prepared for parenteral administration that includes dissolving or suspending the disclosed compound in an acceptable carrier, including but not limited to an aqueous carrier, such as water, buffered water, saline, buffered saline (e.g., PBS), and the like. One or more of the excipients included can help approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents, detergents, and the like. Where the compositions include a solid component (as they may for oral administration), one or more of the excipients can act as a binder or filler (e.g., for the formulation of a tablet, a capsule, and the like). Where the compositions are formulated for application to the skin or to a mucosal surface, one or more of the excipients can be a solvent or emulsifier for the formulation of a cream, an ointment, and the like.
[0116] The compositions disclosed herein can be formulated in a variety of combinations. Disclosed herein are compositions comprising one or more of compounds Ml, M2, M3, M4, M5, M6, M7, M8, M9. MIO, MH, M12, M13, M14, M15, M16, M17, M18, M19. M20. M21, M22, M23, M24, M25, M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39, M40, M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, or M52 and a second therapeutic agent. Also disclosed herein are compositions comprising one or more of compounds Ml, M2, M3, M4, M5, M6, M7, M8, M9, MIO, Ml 1, M12. M13. M14, M15, M16, M17, M18, M19, M20, M21, M22. M23. M24. M25. M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39, M40, M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, or M52 and one or more additional therapeutic agents. In some aspects, the second therapeutic agent or additional therapeutic agents can be one that prevents catabolism (e.g., inflammation). In some aspects, the second therapeutic agent or one or more additional therapeutic agents can be meloxicam,Attorney’s Docket No.: 21101.0498P1
[0117] Celebrex, diclofenac, Mobic, celecoxib, hyaluronan, naproxen, ibuprofen, chondroitin / glucosamine, voltaren, Cymbalta, prednisone, cataflam, arthrotex, duloxetine, aleve, Medrol dosepak, aspirin, nabumetone, advil, etodolac, motrin, pennsaid, vimovo, methylprednisolone, Naprosyn, zorvolex, depo-medrol, ecotrin, A-G profen, addaprin, aspergum, aspiritab, easprin, ecpirin, enterocte, genacote, genpril, halfprin, IBU-200, indomethacin, nurpin, propinal, vazalore, acetaminophen / codeine, chondroitin / glucosamine / methylsulfonylmethane, diclofenac / misoprostol, Indocin, kenalog-40, Medrol, naprelan, piroxicam, aflaxen, anaprox-DS, aspercreme, cortisone, diclozor, diflunisal, dolobid, feldene, flanax, ketoprofen, lofena, oxaprozin, profinac, salsalate, solu-medrol, sulindac, triamcinolone, xiclo, xrylix. zilretta, aristospan, betamethasone, bioflavonoids, capsaicin, celestone soluspan, clinacort, daypro, esomeprazole / naproxen, euflexxa, Excedrin, kenalog-10, limbrel, orthovisc, osteo bi-flex advanced, sodium hyaluronate, synvisc, tolmetin, trolamine salicylate, zostrix, aceteminophen / aspirin / caffeine, acetaminophen / caffeine, arthricare cream, arthriten, boroleum, capsin, capzasin, castiva, choline magnesium trisalicylate, clinoril, cosmegen, coxanto, dactinomycin, diclofenac / menthol, diclogen, durolane, eucalptamint, exedrin, exocaine, famotidine / ibuprofen, fenoprofen, fenopron, fenortho, fenovar, flurbiprofen, glesyn-3, genace, gordogesic, heet triple action, hyalgan, hymovis, Indocin, kiprofen, meclofenamate, mentholatum, methyl salicylate, monovisc, myoflex, nalfon, Relafen, salonpas. satogesic, supartz, tolectin, varophen, or a combination thereof. The particular combination of the disclosed compounds with one or more therapeutic agents (e g., a nonsteroidal antiinflammatory agent or hyaluronic acid) can vary' according to many factors, for example, the particular the ty pe and severity of the osteoarthritis. The compositions described herein can be formulated to include a therapeutically effective amount of the disclosed compound alone or in combination with a nonsteroidal anti-inflammatory agent or hyaluronic acid. In some aspects, the disclosed compound can be contained within a pharmaceutical formulation. In some aspects, the pharmaceutical formulation can be a unit dosage formulation.
[0118] In some aspects, the disclosed compounds can be formulated for oral or parental administration. In some aspects, both the disclosed compounds and the chemotherapeutic agent can be formulated for oral or parenteral administration. In some aspects, the parenteral administration can be intravenous, subcutaneous, intramuscular, intradermal, or direct injection.
[0119] In some aspects, the compositions disclosed herein are formulated for oral or parenteral administration. In some aspects, the compositions disclosed herein are formulatedAttorney’s Docket No.: 21101.0498P1
[0120] for oral, intramuscular, intravenous, subcutaneous, intrathecal, direct injection, intradermal, intratumoral. intraarticular, transdermal. local, or intraperitoneal administration.
[0121] The pharmaceutical compositions can be sterile and sterilized by conventional sterilization techniques or sterile filtered. In some aspects, the pharmaceutical compositions can be lyophilized. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation, which is encompassed by the present disclosure, can be combined with a sterile aqueous carrier prior to administration. The pH of the pharmaceutical compositions typically will be between 3 and 11 (e.g., between about 5 and 9) or between 6 and 8 (e.g., between about 7 and 8). The resulting compositions in solid form can be packaged in multiple single dose units, each containing a fixed amount of the above-mentioned agent or agents, such as in a sealed package of tablets or capsules. The composition in solid form can also be packaged in a container for a flexible quantity, such as in a squeezable tube designed for a topically applicable cream or ointment. The compositions can also be formulated as powders, elixirs, suspensions, emulsions, solutions, syrups, aerosols, lotions, creams, ointments, gels, suppositories, sterile injectable solutions and sterile packaged powders. The active ingredient can be any of the disclosed compounds described herein in combination with one or more pharmaceutically acceptable carriers. As used herein “pharmaceutically acceptable’' means molecules and compositions that do not produce or lead to an untoward reaction (i.e., adverse, negative or allergic reaction) when administered to a subject as intended (i.e.. as appropriate).
[0122] The therapeutically effective amount or dosage of any of the disclosed compounds described herein, and any of the anti-inflammatory agents, used in the methods as disclosed herein, applied to mammals (e.g., humans) can be determined by one of ordinary skill in the art with consideration of individual differences in age, weight, sex, other drugs administered and the judgment of the attending clinician. Variations in the needed dosage may be expected. Variations in dosage levels can be adjusted using standard empirical routes for optimization. The particular dosage of a pharmaceutical composition to be administered to the patient will depend on a variety of considerations (e.g., the severity of the osteoarthritis symptoms), the age and physical characteristics of the subject and other considerations known to those of ordinary skill in the art. Dosages can be established using clinical approaches know n to one of ordinary skill in the art.
[0123] The duration of treatment with any composition provided herein can be any length of time from as short as one day to as long as the life span of the host (e.g., many years). For example, the compositions can be administered once a week (for, for example, 4 w eeks toAttorney’s Docket No.: 21101.0498P1
[0124] many months or years); once a month (for, for example, three to twelve months or for many¬ years); or once a year for a period of 5 years, ten years, or longer. It is also noted that the frequency of treatment can be variable. For example, the present compositions can be administered once (or twice, three times, etc.) daily, weekly, monthly, or yearly.
[0125] In some aspects, the therapeutically effective dose of any of the anti-inflammatory agents described herein may be less / lower when combined with any of the compounds disclosed herein compared to the dose typically administered in the absence of the compounds disclosed herein. In some aspects, the administration of any of the compounds disclosed herein can increase the efficacy of any of the anti-inflammatory agents described herein.
[0126] The total effective amount of the compositions as disclosed herein can be administered to a subject as a single dose, either as a bolus or by infusion over a relatively short period of time, or can be administered using a fractionated treatment protocol in which multiple doses are administered over a more prolonged period of time. Alternatively, continuous intravenous infusions sufficient to maintain therapeutically effective concentrations in the blood are also within the scope of the present disclosure.
[0127] The compositions described herein can be administered in conjunction with other therapeutic modalities to a subject in need of therapy. The present compounds can be given to prior to, simultaneously with or after treatment with other agents or regimes. For example, any of the compounds disclosed herein alone or with any of the compounds disclosed herein can be administered in conjunction with standard therapies used to treat osteoarthritis (e.g., an anti-infl ammatory agent). In some aspects, any of the compounds disclosed herein can be coformulated with an anti-inflammatory agent. In some aspects, any of the compounds disclosed herein can be co-formulated with a nonsteroidal anti-inflammatory agent or hyaluronic acid.
[0128] Any of the compounds or compositions described herein can be administered as a “combination.” It is to be understood that, for example, any of the compounds or compositions disclosed herein can be provided to the subject in need, either prior to administration a second therapeutic agent or any combination thereof, concomitant with administration of said second therapeutic agent or any combination thereof (coadministration) or shortly thereafter.
[0129] The dosage to be administered depends on many factors including, for example, the route of administration, the formulation, the severity of the patient's condition / disease, previous treatments, the patient's size, weight, surface area, age, and gender, other drugsAttorney’s Docket No.: 21101.0498P1
[0130] being administered, and the overall general health of the patient including the presence or absence of other diseases, disorders or illnesses. Dosage levels can be adjusted using standard empirical methods for optimization known by one skilled in the art. Administrations of the compositions described herein can be single or multiple (e.g., 2- or 3-, 4-, 6-, 8-, 10-, 20-, 50-, 100-, 150-, or more fold). Further, encapsulation of the compositions in a suitable delivery vehicle (e.g., polymeric microparticles or implantable devices) can improve the efficiency of delivery.
[0131] Method of Treatment
[0132] The methods disclosed herein can be useful for the treatment of a subject with osteoarthritis. In some aspects, the compounds disclosed herein can ameliorating one or more symptoms of osteoarthritis in a subject. In some aspects, the compounds disclosed herein can reduce MMP9. GREM1, IL6, MMP3MMP13, CCL2, IL1B, COLIO. ADAMTS5. or TNFA expression in a subject. In some aspects, the compounds disclosed herein can increase ACTA, COL2A1, TGFB1, or BMP2 expression in a subject. In some aspects, the compounds disclosed herein can reduce pSPAK expression in damaged cartilage, menisci, bone, synovium, ligaments, tendons, fat pad, muscle, epidermis, bursa, vasculature, lymphatic system, and connective tissue in a subject. In some aspects, the compounds disclosed herein can reduce WNK2 expression in chondrocytes, synovial cells (including immune cells), ligaments, tenocytes. myocytes, lymphatic cells, vascular cells, epidermal cells, and adipocytes a subject.
[0133] Disclosed herein are methods of treating osteoarthritis in a subject. In some aspects, the methods can comprise: administering to the subject a therapeutically effective amount of a compound wherein the compound is Ml, M2, M3, M4, M5, M6, M7, M8, M9, M10, M11, M12. M13. M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24. M25. M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39, M40, M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53, thereby treating osteoarthritis in the subject. In some aspects, the compound is M4. In some aspects, the M4 compound is a racemic mixture, R and S. In some aspects, the active form is the R form of the M4 compound.
[0134] Disclosed herein are methods of treating osteoarthritis in a subject. In some aspects, the methods can comprise: administering to the subject a therapeutically effective amount of a compound wherein the compound is Ml, M2, or M4, thereby treating osteoarthritis in the subject. In some aspects, the compound is M4. In some aspects, the M4 compound is aAttorney’s Docket No.: 21101.0498P1
[0135] racemic mixture, R and S. In some aspects, the active form is the R form of the M4 compound.
[0136] Disclosed herein are methods of treating osteoarthritis in a subject. In some aspects, the methods can comprise: administering to the subject a therapeutically effective amount of a one or more of the compounds Ml, M2, M3, M4, M5, M6, M7, M8, M9, MIO, Ml 1, M12, M13, M14. M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25. M26. M27, M28. M29. M30, M31, M32, M33, M34, M35, M36, M37, M38. M39. M40. M41. M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53, thereby treating osteoarthritis in the subject. In some aspects, the methods can comprise: administering to the subject a therapeutically effective amount of a one or more of the compounds Ml, M2, or M4, thereby treating osteoarthritis in the subject. In some aspects, the compound is M4. In some aspects, the M4 compound is a racemic mixture, R and S. In some aspects, the active form is the R form of the M4 compound. In some aspects, the subject has osteoarthritis or can be at risk for developing osteoarthritis. In some aspects, the subject can be identified as being in need of treatment before the administration step.
[0137] Disclosed herein are methods of ameliorating one or more symptoms of osteoarthritis in a subject. In some aspects, the methods can comprise: administering to the subject a therapeutically effective amount of a compound wherein the compound is Ml, M2, M3, M4, M5, M6, M7, M8, M9. MIO, MH, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21. M22. M23, M24, M25, M26, M27, M28, M29, M30, M31. M32. M33. M34. M35, M36, M37, M38, M39, M40, M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53, thereby ameliorating one or more symptoms of osteoarthritis in the subject. In some aspects, the methods can comprise: administering to the subject a therapeutically effective amount of a compound wherein the compound is Ml, M2, or M4. thereby ameliorating one or more symptoms of osteoarthritis in the subject. In some aspects, the compound is M4. In some aspects, the M4 compound is a racemic mixture, R and S. In some aspects, the active form is the R form of the M4 compound. Disclosed herein are methods of ameliorating one or more symptoms of osteoarthritis in a subj ect. In some aspects, the methods can comprise: administering to the subject a therapeutically effective amount one or more of the compounds Ml, M2, M3, M4, M5, M6, M7, M8, M9, MIO, Ml 1, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39, M40. M41, M42. M43. M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53, thereby ameliorating one or more symptoms of osteoarthritis in the subject. Disclosed herein areAttorney’s Docket No.: 21101.0498P1
[0138] methods of ameliorating one or more symptoms of osteoarthritis in a subject. In some aspects, the methods can comprise: administering to the subject a therapeutically effective amount one or more of the compounds Ml, M2, or M4, thereby ameliorating one or more symptoms of osteoarthritis in the subject. In some aspects, the compound is M4. In some aspects, the M4 compound is a racemic mixture, R and S. In some aspects, the active form is the R form of the M4 compound. In some aspects, the one or more symptoms of osteoarthritis can be pain, stiffness, fatigue, tenderness, loss of flexibility or mobility, bone spurs, inflammation, or swelling. In some aspects, the subject has osteoarthritis or can be at risk for developing osteoarthritis. In some aspects, the subject can be identified as being in need of treatment before the administration step.
[0139] Disclosed herein are methods of reducing pSPAK expression in damaged cartilage, menisci, bone, synovium, ligaments, tendons, fat pad, muscle, epidermis, bursa, vasculature, lymphatic system, or connective tissue. In some aspects, the methods can comprise: administering to a subject a therapeutically effective amount of a compound wherein the compound is Ml, M2, M3, M4, M5. M6, M7, M8, M9, M10, Ml 1, M12. M13, M14, M15, M16. M17. M18, M19, M20, M21, M22, M23, M24, M25. M26. M27. M28. M29. M30, M31, M32, M33, M34, M35, M36, M37, M38, M39, M40, M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53, thereby reducing pSPAK expression in damaged cartilage, menisci, bone, synovium, ligaments, tendons, fat pad, muscle, epidermis, bursa, vasculature, lymphatic system, or connective tissue. In some aspects, the methods can comprise: administering to a subject a therapeutically effective amount of a compound wherein the compound is Ml, M2, or M4, thereby reducing pSPAK expression in damaged cartilage, menisci, bone, synovium, ligaments, tendons, fat pad, muscle, epidermis, bursa, vasculature, lymphatic system, or connective tissue. In some aspects, the compound is M4. In some aspects, the M4 compound is a racemic mixture, R and S. In some aspects, the active form is the R form of the M4 compound. Disclosed herein are methods of reducing pSPAK expression in damaged cartilage, menisci, bone, synovium, ligaments, tendons, fat pad, muscle, epidermis, bursa, vasculature, lymphatic system, or connective tissue. In some aspects, the methods can comprise: administering to a subject a therapeutically effective amount one or more of compounds Ml, M2, M3, M4, M5, M6, M7, M8, M9, M10, Ml 1, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39, M40. M41, M42. M43. M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53, thereby reducing pSPAK expression in damaged cartilage, menisci, bone, synovium, ligaments, tendons, fatAttorney’s Docket No.: 21101.0498P1
[0140] pad, muscle, epidermis, bursa, vasculature, lymphatic system, or connective tissue. In some aspects, the methods can comprise: administering to a subject a therapeutically effective amount one or more of compounds Ml, M2, or M4, thereby reducing pSPAK expression in damaged cartilage, menisci, bone, synovium, ligaments, tendons, fat pad, muscle, epidermis, bursa, vasculature, lymphatic system, or connective tissue. In some aspects, the compound is M4. In some aspects, the M4 compound is a racemic mixture. R and S. In some aspects, the active form is the R form of the M4 compound. In some aspects, the subject has osteoarthritis or can be at risk for developing osteoarthritis. In some aspects, the subject can be identified as being in need of treatment before the administration step.
[0141] Disclosed herein are methods of reducing WNK2 expression in chondrocytes, synovial cells (including immune cells), ligaments, tenocytes, myocytes, lymphatic cells, vascular cells, epidermal cells, or adipocytes in a subject. In some aspects, the methods can comprise: administering to the subject a therapeutically effective amount of a compound wherein the compound is Ml, M2, M3, M4, M5, M6, M7, M8, M9, M10, M11, M12, M13, M14, M15, M16. M17. M18, M19, M20, M21, M22, M23, M24, M25, M26, M27, M28. M29. M30, M31. M32. M33, M34, M35, M36, M37, M38, M39, M40. M41. M42. M43. M44. M45, M46, M47, M48, M49, M50, M51, M52, thereby reducing WNK2 expression in chondrocytes, synovial cells (including immune cells), ligaments, tenocytes, myocytes, lymphatic cells, vascular cells, epidermal cells, or adipocytes. Disclosed herein are methods of reducing WNK2 expression in chondrocytes, synovial cells (including immune cells), ligaments, tenocytes, myocytes, lymphatic cells, vascular cells, epidermal cells, or adipocytes in a subject. In some aspects, the methods can comprise: administering to the subject a therapeutically effective amount of a compound wherein the compound is Ml, M2, or M4, thereby reducing WNK2 expression in chondrocytes, synovial cells (including immune cells), ligaments, tenocytes, myocytes, lymphatic cells, vascular cells, epidermal cells, or adipocytes in the subject. In some aspects, the compound is M4. In some aspects, the M4 compound is a racemic mixture, R and S. In some aspects, the active form is the R form of the M4 compound. Disclosed herein are methods of reducing WNK2 expression in chondrocytes, synovial cells (including immune cells), ligaments, tenocytes. myocytes, lymphatic cells, vascular cells, epidermal cells, or adipocytes in a subject. In some aspects, the methods can comprise: administering to the subject a therapeutically effective amount one or more of compounds Ml, M2, M3, M4, M5, M6, M7, M8, M9. M10, M11, M12, M13, M14, M15, M16. M17. M18, M19, M20, M21, M22, M23, M24, M25, M26, M27. M28. M29. M30, M31, M32, M33, M34, M35, M36, M37, M38, M39, M40, M41, M42, M43, M44, M45,Attorney’s Docket No.: 21101.0498P1
[0142] M46, M47, M48, M49, M50, M51, M52, thereby reducing WNK2 expression in chondrocytes, synovial cells (including immune cells), ligaments, tenocytes, myocytes, lymphatic cells, vascular cells, epidermal cells, or adipocytes. In some aspects, the methods can comprise: administering to the subject a therapeutically effective amount of a one or more of the compounds Ml, M2, or M4, thereby reducing WNK2 expression in chondrocytes, synovial cells (including immune cells), ligaments, tenocytes. myocytes, lymphatic cells, vascular cells, epidermal cells, or adipocytes in the subject. In some aspects, the compound is M4. In some aspects, the M4 compound is a racemic mixture, R and S. In some aspects, the active form is the R form of the M4 compound. In some aspects of the methods disclosed herein, the subject has osteoarthritis or can be at risk for developing osteoarthritis. In some aspects of the methods disclosed herein, the subject can be identified as being in need of treatment before the administration step.
[0143] In some aspects of the methods disclosed herein, the methods can further include the step of identifying a subject (e.g., a human patient) as being in need of treatment before the administration step. In some aspects of the methods disclosed herein, the subject has been diagnosed with osteoarthritis prior to the administering step. In some aspects of the methods disclosed herein, the subject has been identified as having elevated WNK2 expression in chondrocytes compared to a subject that does not have or is not suspected of having osteoarthritis or does not have elevated WNK2 expression in chondrocytes.
[0144] In some aspects, the subject has been identified as having elevated MMP9, GREM1, IL6, MMP3 MMP13, CCL2, IL1B, COLIO. ADAMTS5, or TNFA expression. In some aspects, the subject has also been identified as having elevated expression of MMP9, GREM1, IL6, MMP3MMP13, CCL2, IL1B, COLIO, ADAMTS5, or TNFA. In some aspects, the subject has been identified as having elevated MMP9. GREM1, IL6, MMP3 MMP13. CCL2, IL1B.
[0145] COLIO, ADAMTS5, or TNFA expression in chondrocytes compared to a subject that does not have or is not suspected of having osteoarthritis. In some aspects, the subject has been identified as having elevated MMP9, GREM1, IL6, MMP3MMP13, CCL2, IL1B, COLIO, ADAMTS5, or TNFA expression in chondrocytes, synovial cells, ligaments, tenocytes, myocytes, lymphatic cells, vascular cells, epidermal cells, or adipocytes compared to a subject that does not have or is not suspected of having osteoarthritis. In some aspects, the administration of Ml, M2, M3, M4, M5, M6, M7, M8, M9, M10, M11, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26, M27, M28. M29, M30. M31. M32, M33, M34, M35, M36, M37, M38, M39, M40, M41. M42. M43. M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53 decreases the expression of one orAttorney’s Docket No.: 21101.0498P1
[0146] more of MMP9, GREM1, IL6, MMP3MMP13, CCL2, IL1B, COLIO, ADAMTS5. or TNFA. In some aspects, the administration of Ml, M2, or M4 decreases the expression of one or more of MMP9, GREM1, IL6, MMP3MMP13, CCL2, IL1B, COLIO, ADAMTS5 or TNFA. In some aspects, the compound is M4. In some aspects, the M4 compound is a racemic mixture, R and S. In some aspects, the active form is the R form of the M4 compound. In some aspects, the expression in one or more of MMP9, GREM1, IL6, MMP3 MMP13, CCL2, IL1B. COLIO, ADAMTS5, or TNFA after the administration of Ml. M2, M3. M4, M5, M6. M7, M8, M9, M10, M11, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39. M40, M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51. M52, or M53 is decreased compared to the subject before the administration of Ml. M2, M3. M4, M5, M6, M7, M8, M9, MIO, Ml 1, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39, M40, M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, M52. or M53. In some aspects, the expression in one or more of MMP9, GREM1, IL6.
[0147] MMP3MMP13, CCL2, IL1B, COLIO. ADAMTS5, or TNFA after the administration of Ml, M2, or M4 is decreased compared to the subject before the administration of Ml, M2, or M4. In some aspects, the compound is M4. In some aspects, the M4 compound is a racemic mixture, R and S. In some aspects, the active form is the R form of the M4 compound.
[0148] In some aspects, the subject has been identified as having elevated MMP9, GREM1, IL6. MMP3 MMP13, CCL2, IL1B, COL10, ADAMTS5, or TNFA expression. In some aspects, the subject has also been identified as having elevated expression of MMP9, GREM1, IL6, MMP3MMP13, CCL2, IL1B, COLIO, ADAMTS5, or TNFA. In some aspects, the subject has been identified as having elevated MMP9. GREM1, IL6, MMP3 MMP13. CCL2, IL1B.
[0149] COLIO, ADAMTS5, or TNFA expression in synovial cells, ligaments, tenocytes, myocytes, lymphatic cells, vascular cells, epidermal cells, or adipocytes or damaged cartilage, menisci, bone, synovium, ligaments, tendons, fat pad, muscle, epidermis, bursa, vasculature, lymphatic system, or connective tissue compared to a subject that does not have or is not suspected of having osteoarthritis. In some aspects, the administration of Ml, M2, M3, M4, M5, M6, M7, M8, M9, MIO, MH, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39, M40, M41, M42, M43, M44, M45, M46, M47, M48, M49. M50, M51. M52. or M53 decreases the expression of one or more of MMP9, GREM1, IL6. MMP3 MMP13, CCL2. IL1B, COLIO, ADAMTS5. or TNFA. In some aspects, the administration ofAttorney’s Docket No.: 21101.0498P1
[0150] Ml, M2, or M4 decreases the expression of one or more of MMP9, GREM1, IL6, MMP3 MMP13, CCL2, IL1B, COLIO. ADAMTS5, or TNFA. In some aspects, the expression in one or more of MMP9, GREM1, IL6, MMP3 MMP13, CCL2. IL1B, COLIO. ADAMTS5. or TNFA after the administration of Ml, M2, M3, M4, M5, M6, M7, M8, M9, M10, M11, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26, M27, M28, M29, M30. M31, M32, M33, M34, M35, M36, M37, M38, M39, M40, M41. M42. M43, M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53 is decreased compared to the subject before the administration of Ml, M2, M3, M4, M5, M6, M7, M8, M9, M10, M11, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26, M27, M28. M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39, M40. M41, M42. M43. M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53. In some aspects, the expression in one or more of MMP9, GREM1, IL6. MMP3 MMP13, CCL2, IL1B, COLIO, ADAMTS5, or TNFA after the administration of Ml, M2, or M4 is decreased compared to the subject before the administration of Ml, M2, or M4. In some aspects, the compound is M4. In some aspects, the M4 compound is a racemic mixture, R and S. In some aspects, the active form is the R form of the M4 compound.
[0151] In some aspects of the methods disclosed herein, the subject has been identified as having reduced A CAN, COL2A1, TGFB1, or BMP2 expression. In some aspects of the methods disclosed herein, the subject has also been identified as having a decreased expression of ACAN. COL2A1, TGFB1. or BMP2. In some aspects, the subject has been identified as having reduced ACAN, COL2A 1, TGFB1, or BMP2 expression in chondrocytes compared to a subject that does not have or is not suspected of having osteoarthritis. In some aspects of the methods disclosed herein, the administration of Ml, M2, M3, M4, M5, M6, M7, M8, M9, MIO, MH, M12, M13, M14, M15, M16, M17, M18. M19. M20, M21, M22, M23, M24, M25, M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39, M40, M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53 increases the expression of one or more of ACAN, COL2A1, TGFB1, or BMP2. In some aspects of the methods disclosed herein, the administration of Ml, M2, or M4 increases the expression of one or more of ACAN, COL2A1, TGFB1, or BMP2. In some aspects of the methods disclosed herein, the expression in one or more of ACAN, COL2A1, TGFB1, or BMP2 after the administration of Ml, M2, M3, M4, M5, M6, M7, M8, M9, MIO, Ml 1, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26. M27, M28. M29. M30, M31, M32, M33, M34, M35, M36, M37, M38, M39. M40. M41. M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53 is increased compared toAttorney’s Docket No.: 21101.0498P1
[0152] the subject before the administration of Ml, M2, M3, M4, M5, M6, M7, M8, M9, M10, M11, M12. M13. M14, M15, M16, M17, M18, M19, M20, M21, M22, M23. M24. M25. M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39, M40, M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53. In some aspects of the methods disclosed herein, the expression in one or more of ACAN, COL2A1, TGFB1, or BMP 2 after the administration of Ml, M2, or M4 is increased compared to the subject before the administration of Ml, M2, or M4. In some aspects, the compound is M4. In some aspects, the M4 compound is a racemic mixture, R and S. In some aspects, the active form is the R form of the M4 compound.
[0153] In some aspects of the methods disclosed herein, the subject has been identified as having reduced A CAN. COL2A1, TGFB1, or BMP 2 expression. In some aspects of the methods disclosed herein, the subject has also been identified as having a decreased expression of ACAN, COL2A1, TGFB1, ovBMP2. In some aspects, the subject has been identified as having reduced ACAN, COL2A1, TGFB1, orBMP2 expression in synovial cells, ligaments, tenocytes. myocytes, lymphatic cells, vascular cells, epidermal cells, or adipocytes or damaged cartilage, menisci, bone, synovium, ligaments, tendons, fat pad, muscle, epidermis, bursa, vasculature, lymphatic system, or connective tissue compared to a subject that does not have or is not suspected of having osteoarthritis. In some aspects of the methods disclosed herein, the administration of Ml, M2, M3, M4, M5, M6, M7, M8, M9, MIO, Mil. M12. M13. M14, M15, M16, M17, M18, M19, M20, M21, M22. M23. M24. M25. M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39, M40, M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53 increases the expression of one or more of ACAN, COL2A1, TGFB1, or BMP2. In some aspects of the methods disclosed herein, the administration of Ml. M2, or M4 increases the expression of one or more of ACAN, COL2A1, TGFB1, o BMP2. In some aspects of the methods disclosed herein, the expression in one or more of ACAN, COL2A1, TGFB1, or BMP2 after the administration of Ml, M2, M3, M4, M5, M6, M7, M8, M9, M10, M11, M12, M13, M14, M15, M16. M17, M18, M19, M20, M21, M22, M23, M24, M25, M26, M27. M28. M29, M30. M31. M32, M33, M34, M35, M36, M37, M38, M39, M40. M41. M42. M43. M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53 is increased compared to the subject before the administration of Ml, M2, M3, M4, M5, M6, M7, M8, M9, MIO, Ml 1, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26. M27, M28. M29. M30, M31, M32, M33, M34, M35, M36, M37, M38, M39. M40. M41. M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53. In some aspects of theAttorney’s Docket No.: 21101.0498P1
[0154] methods disclosed herein, the expression in one or more of ACAN, COL2A1, TGFB1, or BMP 2 after the administration of Ml, M2, or M4 is increased compared to the subject before the administration of Ml, M2, or M4. In some aspects, the compound is M4. In some aspects, the M4 compound is a racemic mixture, R and S. In some aspects, the active form is the R form of the M4 compound.
[0155] In some aspects of the methods disclosed herein, one or more symptoms of osteoarthritis can be pain. Examples of symptoms of osteoarthritis also include, but are not limited to: stiffness, fatigue, tenderness, loss of flexibility or mobility, bone spurs, inflammation, or swelling.
[0156] Osteoarthritis occurs when the protective cartilage that cushions the ends of bones wears down over time. In some aspects, osteoarthritis can damage or effect any joint. In some aspects, the joint can be in the hands, knees, hips, spine, feet, neck or shoulder. In some aspects, osteoarthritis can be osteoarthritis of any synovial joint. In some aspects, the synovial joint can be hinge (elbow), saddle (carpometacarpal joint), planar (acromioclavicular joint), pivot (atlantoaxial joint), condyloid (metacarpophalangeal joint), or ball and socket (hip joint). In some aspects, the osteoarthritis is bilateral erosive hand osteoarthritis. In some aspects, the osteoarthritis can be osteoarthritis of a knee, a hip, a hand, or a foot, a shoulder or spine.
[0157] In some aspects, the compound useful in any of the methods disclosed herein can be Ml, M2, M3, M4, M5. M6, M7, M8, M9, MIO, Ml 1, M12. M13, M14, M15, M16, M17, M18. M19. M20, M21, M22, M23, M24, M25, M26, M27, M28. M29. M30. M31. M32, M33, M34, M35, M36, M37, M38, M39, M40, M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53. In some aspects, the compound useful in any of the methods disclosed herein can be Ml, M2, or M4. In some aspects, the compound is M4. In some aspects, the M4 compound is a racemic mixture, R and S. In some aspects, the active form is the R form of the M4 compound. In some aspects, the compound useful in any of the methods disclosed herein can be one or more of the compounds or structures disclosed in Table 1.
[0158] In some aspects, the methods disclosed herein can further comprise administering a therapeutically effective amount of a second therapeutic agent. In some aspects of the methods disclosed herein, the second therapeutic agent can be nonsteroidal anti-inflammatory agent or hyaluronic acid.
[0159] The therapeutically effective amount of any of the compounds or therapeutic agents disclosed herein can be the amount of the compounds or therapeutic agents administered to a subject that leads to a full resolution of the symptoms of the condition or disease (e.g.,Attorney’s Docket No.: 21101.0498P1
[0160] osteoarthritis), a reduction in the severity of the symptoms of the condition or disease (e.g., osteoarthritis), or a slowing of the progression of symptoms of the condition or disease (e.g.. osteoarthritis). The methods described herein can also include a monitoring step to optimize dosing. The compounds or therapeutic agents described herein can be administered as a preventive treatment or to delay or slow the progression of the condition or disease (e.g., osteoarthritis).
[0161] The compounds or therapeutic agents described herein can be formulated to include a therapeutically effective amount of one or more of Ml, M2, M3, M4, M5, M6, M7, M8, M9, M10, M11, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26. M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38. M39, M40. M41. M42, M43, M44, M45, M46, M47, M48, M49, M50, M51. or M52. The compounds or therapeutic agents described herein can be formulated to include a therapeutically effective amount of one or more of Ml, M2, or M4. In some aspects, the compound is M4. In some aspects, the M4 compound is a racemic mixture, R and S. In some aspects, the active form is the R form of the M4 compound. Therapeutic administration encompasses prophylactic applications (e.g., or preventing the development of osteoarthritis). Based on genetic testing and other prognostic methods, a physician in consultation with their patient can choose a prophylactic administration where the patient has a clinically determined predisposition or increased susceptibility (in some cases, a greatly increased susceptibility) to osteoarthritis, or damage to cartilage, bone, synovium, ligaments, tendons, fat pad. or other tissues of the synovial joint.
[0162] In the methods disclosed herein, the compounds or therapeutic agents described herein can be administered to the subject (e.g., a human patient) in an amount sufficient to delay, reduce, or preferably prevent the onset of clinical disease. Accordingly, in some aspects, the patient can be a human patient. In therapeutic applications, compounds or therapeutic agents can be administered to a subject (e.g., a human patient) already with or diagnosed w ith osteoarthritis or damage to cartilage, bone, synovium, ligaments, tendons, fat pad, and other tissues of the synovial joint or one or more symptoms of osteoarthritis in an amount sufficient to at least partially improve a sign or symptom or to inhibit the progression of (and preferably arrest) the symptoms of the condition, its complications, and consequences. An amount adequate to accomplish this is defined as a “therapeutically effective amount.” A therapeutically effective amount of a compound or therapeutic agent, or a composition (e.g., a pharmaceutical composition) can be an amount that achieves a cure, but that outcome is only one among several that can be achieved. As noted, a therapeutically effective amount includesAttorney’s Docket No.: 21101.0498P1
[0163] amounts that provide a treatment in which the onset or progression of the disease, disorder, condition or injury is delayed, hindered, or prevented, or the disease, disorder, condition or injury or a symptom of the disease, disorder, condition or injury is ameliorated or its frequency can be reduced. One or more of the symptoms can be less severe. Recovery can be accelerated in an individual who has been treated. For example, treatment of osteoarthritis or damage to cartilage, bone, synovium, ligaments, tendons, fat pad, or other tissues of the synovial joint may involve, for example, a reduction in inflammation, a reduction in cartilage degradation, or a reduction or prevention of pain.
[0164] The compounds or therapeutic agents disclosed herein can be formulated in a variety of combinations. The particular combination of the compounds or compositions disclosed herein with one or more agents approved for treating osteoarthritis, nonsteroidal antiinflammatory agent or hyaluronic acid, and can vary according to many factors, for example, the particular the type and severity of the osteoarthritis or damage to cartilage, bone, synovium, ligaments, tendons, fat pad, or other tissues of the synovial joint. The compounds or therapeutic agents described herein can be formulated to include a therapeutically effective amount of any of the compounds disclosed herein alone or in combination with one or more agents approved for treating osteoarthritis, nonsteroidal anti-inflammatory agent or hyaluronic acid.
[0165] Kits
[0166] Disclosed herein are kits that comprise any combination of the compounds described above and suitable instructions (e g., written and / or provided as audio-, visual-, or audiovisual material). Disclosed herein are kits that comprise any combination of the pharmaceutical compositions described above and suitable instructions (e.g., written and / or provided as audio-, visual-, or audiovisual material). In some aspects, the kit comprises a predetermined amount of a compound or pharmaceutical composition comprising one or more of: Ml, M2, M3, M4, M5, M6, M7, M8, M9, M10, M11, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26, M27, M28, M29, M30, M31, M32, M33. M34, M35, M36, M37, M38, M39, M40, M41, M42, M43, M44. M45. M46, M47, M48, M49, M50, M51, or M52. In some aspects, the compound is M4. In some aspects, the M4 compound is a racemic mixture, R and S. In some aspects, the active form is the R form of the M4 compound. In some aspects, the Ml, M2, M3, M4, M5, M6, M7, M8, M9, M10, M11, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23. M24, M25. M26. M27, M28, M29, M30, M31, M32, M33, M34, M35, M36. M37. M38. M39,Attorney’s Docket No.: 21101.0498P1
[0167] M40, M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53 compound is in the R form, the S form, or a racemic mixture of R and S forms.
[0168] The kit can further comprise one or more of the following: instructions, sterile fluid, syringes, a sterile container, delivery devices, and buffers or other control reagents.
[0169] In some aspects, the kit comprises (1) a predetermined amount of a compound or pharmaceutical composition comprising one or more of: Ml, M2. M3, M4, M5, M6, M7, M8, M9, MIO, MH, M12, M13, M14, M15. M16. M17. M18. M19, M20, M21, M22, M23, M24, M25, M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39, M40, M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, or M52 and (2) one or more additional therapeutic agents. In some aspects, the compound is M4. In some aspects, the M4 compound is a racemic mixture, R and S. In some aspects, the active form is the R form of the M4 compound. In some aspects, the Ml, M2, M3, M4, M5, M6, M7, M8, M9, M10, M11, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39, M40. M41. M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, M52. or M53 compound is in the R form, the S form, or a racemic mixture of R and S forms. In some aspects, the kit comprises (1) a predetermined amount of a compound or pharmaceutical composition comprising one or more of: Ml, M2, M3, M4, M5, M6, M7, M8, M9, M10, M11, M12. M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24. M25, M26. M27. M28, M29, M30, M31, M32, M33, M34, M35, M36. M37. M38. M39. M40, M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, or M52 and (2) meloxicam, Celebrex, diclofenac, Mobic, celecoxib, hyaluronan, naproxen, ibuprofen, chondroitin / glucosamine, voltaren, Cymbalta, prednisone, cataflam, arthrotex, duloxetine, aleve, Medrol dosepak, aspirin, nabumetone, advil, etodolac, motrin, pennsaid, vimovo, methylprednisolone, Naprosyn, zorvolex, depo-medrol, ecotrin, A-G profen, addaprin, aspergum, aspiritab, easprin, ecpirin, enterocte, genacote, genpril, halfprin, IBU-200, indomethacin, nurpin, propinal, vazalore, acetaminophen / codeine, chondroitin / glucosamine / methylsulfonylmethane, diclofenac / misoprostol, Indocin, kenalog-40, Medrol, naprelan, piroxicam, aflaxen, anaprox-DS, aspercreme, cortisone, diclozor, diflunisal, dolobid, feldene, flanax, ketoprofen, lofena, oxaprozin, profinac, salsalate, solu-medrol, sulindac, triamcinolone, xiclo, xrylix, zilretta, aristospan, betamethasone, bioflavonoids, capsaicin, celestone soluspan, clinacort, daypro, esomeprazole / naproxen, euflexxa. Excedrin, kenalog-10, limbrel, orthovisc, osteo bi-flex advanced, sodium hyaluronate, synvisc, tolmetin, trolamine salicylate, zostrix, aceteminophen / aspirin / caffeine,Attorney’s Docket No.: 21101.0498P1
[0170] acetaminophen / caffeine, arthricare cream, arthriten, boroleum, capsin, capzasin, castiva, choline magnesium trisalicylate, clinoril, cosmegen, coxanto, dactinomycin, diclofenac / menthol, diclogen, durolane, eucalptamint, exedrin, exocaine, famotidine / ibuprofen, fenoprofen, fenopron, fenortho, fenovar, flurbiprofen, glesyn-3, genace, gordogesic, heet triple action, hyalgan, hymovis, Indocin, kiprofen, meclofenamate, mentholatum, methyl salicylate, monovisc, myoflex, nalfon, Relafen. salonpas. satogesic, supartz, tolectin, varophen, or a combination thereof.
[0171] In some aspects, the kit comprises (1) a predetermined amount of a compound or pharmaceutical composition comprising one or more of: Ml, M2, M3, M4, M5, M6, M7, M8, M9, M10, Ml 1, M12, M13, M14, M15, M16, M17, M18. M19, M20, M21, M22, M23, M24, M25. M26. M27, M28, M29, M30, M31, M32, M33, M34, M35, M36. M37. M38. M39, M40, M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, or M52 and (2) a nonsteroidal anti-inflammatory agent or hyaluronic acid. In some aspects, the compound is M4. In some aspects, the M4 compound is a racemic mixture, R and S. In some aspects, the active form is the R form of the M4 compound. In some aspects, the Ml, M2, M3, M4, M5, M6, M7. M8, M9, M10. Mil. M12. M13. M14. M15, M16, M17, M18, M19, M20, M21. M22, M23, M24, M25, M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39, M40, M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53 compound is in the R form, the S form, or a racemic mixture of R and S forms.
[0172] The compounds described herein can be packaged in a suitable container labeled, for example, for use as a therapy to treating osteoarthritis or damage to cartilage, bone, synovium, ligaments, tendons, fat pad, and other tissues of the synovial joint or any of the methods disclosed herein. Accordingly, packaged products (e.g., sterile containers containing the composition described herein and packaged for storage, shipment, or sale at concentrated or ready-to-use concentrations) and kits, including at least one or more of Ml, M2, M3, M4, M5, M6, M7, M8, M9, M10, Mil, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26, M27, M28, M29, M30, M31, M32, M33, M34, M35. M36, M37, M38, M39, M40, M41, M42, M43, M44, M45, M46. M47. M48, M49, M50, M51, or M52 as described herein and instructions for use, are also within the scope of the disclosure. In some aspects, the Ml, M2, M3, M4, M5, M6, M7, M8, M9, M10, Mil, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39. M40, M41. M42. M43, M44, M45, M46, M47, M48, M49, M50, M51, M52. or M53 compound is in the R form, the S form, or a racemic mixture of R and S forms. In some aspects, theAttorney’s Docket No.: 21101.0498P1
[0173] compound is M4. In some aspects, the M4 compound is a racemic mixture, R and S. In some aspects, the active form is the R form of the M4 compound. A product can include a container (e.g., a vial, jar, bottle, bag, or the like) containing the compound or composition described herein. In addition, an article of manufacture further may include, for example, packaging materials, instructions for use, syringes, buffers or other control reagents for treating or monitoring the condition for which prophylaxis or treatment is required. The product may also include a legend (e.g., a printed label or insert or other medium describing the product's use (e.g., an audio- or videotape)). The legend can be associated with the container (e.g., affixed to the container) and can describe the manner in which the compound therein should be administered (e.g., the frequency and route of administration), indications therefor, and other uses. The compounds and compositions can be ready for administration (e.g., present in dose-appropriate units), and may include a pharmaceutically acceptable adjuvant, carrier or other diluent. Alternatively, the compounds and compositions can be provided in a concentrated form with a diluent and instructions for dilution.
[0174] EXAMPLES
[0175] It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventors to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
[0176] Example 1: WNK2 variants that alter the chondrocyte response to hyperosmotic stress are associated with familial osteoarthritis
[0177] Chondrocytes of the synovial joint sense and respond to changes in osmolarity to maintain joint homeostasis. It was tested whether an abnormal response to osmotic stress is a contributing factor to loss of joint homeostasis and the development of osteoarthritis (OA). Described herein are genetic variants affecting the response to osmotic stress associated with susceptibility to OA.
[0178] Design. Genomic analysis of independent families with dominant inheritance of OA revealed WNK2 coding variants that segregated with occurrence of OA. WNK2 expression was examined by immunohistochemistry on normal and osteoarthritic tissue isolated from humans and mice. WT and variant WNK2 functions were analyzed by overexpression effectsAttorney’s Docket No.: 21101.0498P1
[0179] in T / C-28a2 chondrocyte cells; loss-of-function effects were analyzed in WNK2 mutant T / C-28a2 cells. Transcriptomic analyses were used to identify genes and pathways dependent upon WNK2 function and hyperosmotic stress.
[0180] Results. Coding variants of WNK2 associated with familial erosive hand OA and foot OA were identified. WNK2 is expressed in articular chondrocytes and its expression is highly elevated in end-stage human and mouse OA joints. When challenged by hyperosmotic stress, cultured chondrocytes initiate a remodeling response, altering expression of both anabolic and catabolic genes and pathways. However, the combination of elevated WNK2 expression and hyperosmotic stress promotes a WNK2-dependent OA-associated transcriptional response that is exacerbated by expression of the OA-associated WNK2 variants.
[0181] Conclusions. The data described herein show that altered WNK2 signaling confers heightened susceptibility to OA. The synergistic effects of hyperosmotic stress and high WNK2 activity' promote development of OA.
[0182] Diagnostic and procedure codes used to identify individuals with osteoarthritis. The coding strategy used to identify individuals with erosive hand, 1stMTP joint, distal and proximal interphalangeal joint, thumb joint, and shoulder osteoarthritis (OA) has been described (Gavile, C M., et al. (2022). J Hand Surg Am 47, 923-933; Jurynec, M. J., et al. (2022). Ann Rheum Dis 81, 1465-1473; and Kazmers, N. H., et al. (2021). Arthritis Rheumatol 73, 440-447). This study utilizes data drawn from the Utah Population Database (UPDB) (uofuhealth.utah.edu / huntsman / utah-population-database / ). The UPDB provides person-based interlinked records documenting genealogy, medical records, and vital statistics for over 11 million individuals from the late 18th century to the present. Affected individuals and families were identified from the UPDB using medical coding, which includes diagnostic and surgical procedure codes. To make sure a high degree of sensitivity and specificity was used, affected individuals were initially identified based on a specific form of OA (e.g., erosive hand OA, shoulder OA, interphalangeal joint OA, and 1stMTP joint OA) and then statistical analyses was used to identify' pedigrees that have a significant enrichment of that form of OA ((Gavile, C M., et al. (2022). J Hand Surg Am 47, 923-933; Jurynec. M. J., et al. (2022). Ann Rheum Dis 81, 1465-1473; Kazmers, N. H., et al. (2021). Arthritis Rheumatol 73, 440-447; Jurynec, M. J., et al. (2024). medRxiv. 10.1101 / 2024.09.03.24312969; and Kazmers, N. H., et al. (2020). J Hand Surg Am 45, 1-8).
[0183] The following diagnostic codes (ICD-9 and ICD-10) and procedure codes (CPT -Current Procedural Terminology) were used to identify affected individuals.Attorney’s Docket No.: 21101.0498P1
[0184] 1stMTP joint OA (synonymous with hallux rigidus): CPT: 28289 (hallux rigidus correction with cheilectomy. debridement and capsular release 1stmetatarsophalangeal joint) and 28750 (arthrodesis, great toe). ICD-9: 735.2 (hallux rigidus)._ICD-10: not used.
[0185] Erosive hand OA: ICD-10 M15.4 (Erosive (osteo)arthritis).
[0186] Exclusion criteria: Individuals diagnosed with any of the following codes were excluded:_ICD-9: 714.0 (rheumatoid arthritis), 714.2 and 714.3 (rheumatoid arthritis and other inflammatory polyarthropathies). ICD-10: M05 and any sub diagnoses (rheumatoid polyneuropathy with rheumatoid arthritis), M06 and any sub diagnoses (other rheumatoid arthritis), or M08 and any sub diagnoses (juvenile arthritis). Individuals were asked if they were diagnosed with psoriatic arthritis, gout, or had a traumatic injury' to the affected joint. If they answered yes. they were excluded from the study.
[0187] Sequence analysis of families with inherited OA. Families with high incidence of OA that appeared to segregate as a simple dominant Mendelian trait were identified (Gavile, C. M., et al. (2022). J Hand Surg Am 47, 923-933; Jurynec, M. J., et al. (2022). Ann Rheum Dis 81, 1465-1473; Kazmers, N. H., et al. (2021). Arthritis Rheumatol 73, 440-447; and Jurynec, M. J., et al. (2018). Hum Mol Genet 27, 2406). Selected members were subjected to whole exome sequencing (WES) and candidate causative variants were identified (Jury nec, M. J., et al. (2022). Ann Rheum Dis 81, 1465-1473; and Jurynec, M. J., et al. (2018). Hum Mol Genet 27, 2406). Briefly, WES and analyses were performed using genomic DNA isolated from whole blood or saliva (Jurynec, M. J., et al. (2022). Ann Rheum Dis 81, 1465-1473; and Jurynec, M. J., et al. (2018). Hum Mol Genet 27, 2406). Libraries were prepared using the Agilent SureSelect XT Human All Exon + UTR (v8) kit followed by Illumina NovaSeq 6000 150 cycle paired end sequencing. Analysis of variants was performed with ANNOVAR (Wang. K.. Li, M., and Hakonarson, H. (2010). Nucleic Acids Res 38, el64) (annovar.openbioinformatics.org / en / latest / ) and pVAAST (Hu, H., et al. (2014). Nat Biotechnol 32, 663-669) (hufflab.org / software / pvaast / ) in concert with PHEVOR2 (Singleton, M. V., et al. (2014). Am J Hum Genet 94, 599-610).
[0188] (weatherby. genetics. Utah, edu / phevor2 / index. html).
[0189] Statistical analysis. Statistical analyses were performed using GraphPad Prism 10 software (vl0.3.1).
[0190] qPCR analysis of Wnk2 expression in the mouse knee joint: Statistically significant differences of / ? < 0.05 (*) were determined by one-way ANOVA with Tukey’s multiple comparisons test, n=3 biological replicates.Attorney’s Docket No.: 21101.0498P1
[0191] qPCR analysis of OA-associated genes 5 days post- ACL rupture in the mouse knee joint: Statistically significant differences of < 0.05 (*) were determined by a two-tailed unpaired t-test, n=4 biological replicates.
[0192] RNA-seq analysis: Differential gene expression was determined using median-rationormalization (Maza, E., et al. (2013). Commun Integr Biol 6, e25849) with DESeq2 vl.30.0 (Maza, E., et al. (2013). Commun Integr Biol 6, e25849). Fold-changes were calculated by comparing counts in the treatment groups normalized to the respective counterpart. DESeq2 utilizes Benjamini -Hochberg multiple testing correction within each comparison. Genes with an adjusted p value < 0.05 were considered differentially expressed, n=4 biological replicates.
[0193] qPCR analysis of gene expression in T / C-28a2 cells: Statistically significant differences of p < 0.05 (*) were determined by one-way ANOVA with Tukey’s multiple comparisons test, n = 3-9 samples / condition.
[0194] qRT-PCR analysis of gene expression in primary human chondrocytes: Statistically significant differences of / i < 0.05 (*) were determined by a two-tailed unpaired t-test, n=4 biological replicates.
[0195] Isolation ofRNAjrom mouse knee joints. Mice were euthanized, the skin was removed from the hindlimb, and the entire limb was placed in RNAlater solution (ThermoFisher Scientific). The knee joint was exposed by removing the majority' of muscle surrounding the joint with minimal disruption of the ligaments, tendons, synovium, and infrapatellar fat pad. The femur and tibia were cut approximately 0.5 - 1 cm distal from the articular surface. The joint was then transferred to new RNAlater solution, rinsed, cut into small fragments, transferred to a tube containing Trizol and 2.8mm stainless steel beads, and homogenized using the BeadBug microtube homogenizer. Total RNA was isolated using Direct-zol RNA Miniprep Kit (Zymo Research) and quantified using The
[0196] Agilent TapeStation.
[0197] Generation ofWNK2 null T / C-28a2 chondrocytes using CRISPR Cas9 genome editing. WNK2 null (WNK2~) T / C-28a2 chondrocytes (MilliporeSigma, SCC042) were generated by the Genomics Core Facility’ at the University’ of Utah. Briefly, electroporation of CRISPR / Cas9 ribonucleoproteins targeting the introns surrounding exon 2 of WNK2 were used to generate a deletion of exon 2 (FIG. 2A and FIG. 8). Following electroporation T / C-28a2 chondrocytes were grow n for three passages, single clones were isolated by flow cytometry', and clonal lines were established. Deletion of exon 2 was verified by PCR and Sanger sequencing (Table 2 and FIG. 8).Attorney’s Docket No.: 21101.0498P1 Table 2. qPCR and PCR primer sequences used in this study.
[0198]
[0199] Attomey’s Docket No.: 21101.0498P1
[0200]
[0201] Preparation of cell lysates and immunoblot analysis. To test if WNK2 chondrocytes lack WNK2 function, WT and WNK2~ chondrocytes were cultured as described herein and the cells were subjected to osmotic stress (Boyd-Shiwarski, C. R., et al. (2022). Cell 185, 4488-Attorney’s Docket No.: 21101.0498P1
[0202] 4506). Briefly, once chondrocytes reached 70% confluence, they were replaced with fresh complete medium (isotonic / 300mOsm) or with sorbitol (50mM / 350mOsm.
[0203] 200mM / 500mOsm, and 500mM / 800mOsm). For WNK inhibitors experiments, WT chondrocytes were preincubated for 15 minutes with lOOpM WNK463 (MedChemExpress, HY- 100626) and treated with sorbitol as described herein. WNK463 is a pan-WNK (WNK1-4) inhibitor with IC50s of 5nM, 1nM, 6nM, and 9nM for WNK1, WNK2, WNK3, and WNK4, respectively (Yamada, K., et al. (2016). Nat Chem Biol 12, 896-898). Chondrocytes were incubated for five minutes in an isotonic or stress-inducing medium and harvested and pelleted at 4°C. The total exposure of osmotic stress was 15 minutes. Proteins were isolated using RIPA buffer supplemented with protease and phosphatase inhibitors. The isolated proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using a 10% acrylamide gel and transferred to a PVDF (0.45um) membrane. The membrane was blocked with 3% BSA in Tris-buffered saline with 0.1% Tween-20 (TBST) overnight at 4°C. The membranes were incubated overnight at 4°C with primary antibodies against SPAK (Abeam abl92798) or pSPAK antibodies (EMD Millipore, 07-2273). Blots were washed 3X with TBST and then incubated with secondary antibodies conjugated with horseradish peroxidase (anti-mouse / rabbit IgG FIRP, ThermoFisher Scientific). Signal detection was achieved through enhanced chemiluminescence (SuperSignal West Pico Chemiluminescent Substrate 34080, ThermoFisher Scientific). GAPDH (Santa Cruz Biotechnology, 365062) served as the loading control. The bands were quantified using ImageJ by measuring the Integrated Density (Area x Mean Gray Value) of each band. The values were normalized to the Iso treatment within their respective groups for relative quantification.
[0204] Immunohistochemistry and Safranin O and Fast Green staining. Human tissue -Human humeral heads were collected during total shoulder arthroplasties at the University of Utah Orthopaedic Center. Tissue was collected directly into 10% neutral buffered formalin and incubated at 4°C for 10 days, processed through an ethanol series, demineralized using FormiCal, equilibrated in xylenes, and embedded in paraffin. 5-6 pm thick tissue sections were cut and mounted onto slides. For histological analysis, slides were stained with Fast Green for 2 minutes and rinsed with acetic acid. Slides were then stained with Safranin-0 for 8 minutes and dehydrated with sequential washings of 95% ethanol (EtOH) and 100% EtOH. Slides were fixed with Histochoice for 4 minutes (2X) and then mounted. Mouse tissue -Animals were euthanized and knees were dissected and fixed in 10% neutral buffered formalin at 4°C for 48 hours, processed through an ethanol series, demineralized usingAttorney’s Docket No.: 21101.0498P1
[0205] FormiCal, equilibrated in xylenes, and embedded in paraffin. 5-6 pm thick tissue sections were cut and mounted onto slides. The tissue sections were deparaffinized and rehydrated as follows: Xylene 3X 5 minutes, 95% EtOH 2X 3 minutes, 70% EtOH 2X 3 minutes, ddEhO IX 2 minutes, and IX PBS for 5 minutes. For immunohistochemistry, antigen retrieval was according to the antibody manufacturer’s protocol. The following primary antibodies w ere used: WNK2 (Abeam, ab239037), SPAK (Abeam, abl92798), and pSPAK (EMD Millipore, 07-2273). Tissue sections were incubated with primary antibody at 4°C, for 18-24 hours in a humidified chamber, rinsed 3X with PBS, and then blocked with 2.5% horse serum (Vector Laboratories, MP-7401) for 20 minutes at 25°C. Control tissues sections (mouse and human) were not incubated with primary antibody and processed with the appropriate secondary antibody. Block solution was replaced with ImmPRESS-HRP Horse anti-rabbit / mouse secondary antibody (Vector Laboratories, MP-7401 / MP-7402-15) and incubated for 30 minutes at room temperature followed by 2X 5 minutes rinses with PBS. Slides were stained with DAB (Vector Laboratories, SK-4100) for 10-20 minutes, rinsed for 5 minutes with PBS, dried, and mounted.
[0206] Anterior cruciate ligament rupture. Non-invasive ACL rupture was induced by a single overload cycle of tibial compression (Jurynec, M. J., et al. (2022). Ann Rheum Dis 81, 1465-1473; and Christiansen, B. A., et al. (2015). Osteoarthritis Cartilage 23, 1627-1638). Sixteen-week old male mice were used in the ACL rupture experiments.
[0207] T / C-28a2 chondrocyte cell culture. The human chondrocyte cell line. T / C-28a2 (MilliporeSigma, SCC042), was cultured in Dulbecco's modified Eagle's medium (DMEM) (Coming Life Sciences) supplemented with 10% fetal bovine serum (FBS; Avantor), 4.5 g / L glucose, IrnM sodium pyruvate, and 100 U / mL penicillin / streptomycin in a 5% CO2 humidified atmosphere incubator at 37°C. Cell passage was performed on 70% confluent cells by trypsinization with 0.25% trypsin-EDTA (ThermoFisher Scientific).
[0208] Transfection arid treatment of T / C-28a2 chondrocytes. Twelve hours after seeding 200 x 103WT or WNK2-deficient T / C-28a2 chondrocytes in T-25 tissue culture plates, the cells were transfected with 2pg of WNK2 expression plasmids using Lipofectamine 2000 (Thermo Fisher Scientific). After 48 hours, transfection media was replaced with fresh DMEM media supplemented with 2% fetal bovine serum, 4.5 g / L glucose, ImM sodium pyruvate, and 100 U / mL penicillin / streptomycin containing varying amounts of sorbitol for an additional 7 days. Sorbitol was added to the medium to alter osmolarity (Boyd-Shiw-arski, C. R.. et al. (2022). Cell 185. 4488-4506 e4420 as WNKs are inhibited by Cl-ions (Piala. A. T., et al. (2014). Sci Signal 7, ra41). After incubation cells were collected by trypsinization,Attorney’s Docket No.: 21101.0498P1
[0209] snap frozen, and RNA expression was analyzed as described herein. To ensure equal transfection between replicates and experiments, the normalized read counts for WNK2 were determined.
[0210] Quantitative PCR (qPCR). To optimize the sorbitol dose, 5xl03T / C-28a2 chondrocytes (MilliporeSigma, SCC042),were plated in T-25 plates, after 12 hours (settling time), cells were treated with 25, 50. 100, and 150mM sorbitol, no treatment was considered as isotonic, in DMEM + 2% FBS with antibiotics and incubated for 7 days at 37°C. After incubation, cells were lysed using Trizol (ThermoFisher Scientific), and RNA was collected using Direct-zol RNA Miniprep Kits (Zymo Research), and RNA quantity and purity was assessed using the Nanodrop 2000 (ThermoFisher Scientific) and The Agilent TapeStation.
[0211] 500ng of total RNA was reverse transcribed using the Maxima First Strand cDNA Synthesis Kit (ThermoFisher Scientific). Gene-specific primers (Table 2) were used to amplify cDNA using Luna Universal qPCR Master mix (New England BioLabs). 3-6 biological replicates were used in each treatment group. Gene expression was normalized to f-ACTIN, and the relative expression was estimated using the AACq method (Livak, K. J.. and Schmittgen, T. D. (2001). Methods 25, 402-408). The mRNA levels are expressed as fold-change mean with 95% confidence interval relative to isotonic conditions.
[0212] Generation ofWNK2 mutant constructs. WT and mutant WNK2 constructs were synthesized using GenScript’s CloneEZ service. The WT WNK2 construct was derived from a plasmid sequence deposited in Addgene (Catalog #24569) and subsequently modified by GenScript to generate the OA-associated variants, WNK2H758N, WNK2L1005F, and WNK2R2054. Clones were verified by Sanger sequencing.
[0213] Primary human chondrocyte cell culture. Primary human chondrocytes (CELLvo™ HC-a (Pl)) were obtained from StemBioSys, Inc. CELLvo™ Chondrocytes were isolated from cadaveric articular cartilage of healthy donors (<40 years old). CELLvo™ HC-a chondrocytes were cultured on CELLvo™ ChondroMatrix coated plasticware (StemBioSys, Inc.) in low' glucose Dulbecco's Modification of Eagle's Medium (DMEM) (Coming) supplemented with 1 g / L glucose, ImM sodium pyruvate. 4 mM L-glutamine, 15% fetal bovine serum and 100 U / mL penicillin / streptomycin in a 5% CO2 humidified atmosphere incubator at 37°C. Cell passage was performed on 70% confluent cells by trypsinization with 0.05% trypsin-EDTA (ThermoFisher Scientific).
[0214] Electroporation of primary human chondrocytes. Electroporation of CELLvo™ HC-a chondrocytes was carried out with the Neon™ Transfection System using the lOpL Kit (ThermoFisher Scientific) following the manufacturer’s protocol. Briefly, 200 x 103Attorney’s Docket No.: 21101.0498P1
[0215] CELLvo™ HC-a chondrocytes and 2ug of WNK2 or WNK2R2054Q plasmids suspended in buffer R were electroporated using the following parameters: 1600 V, 10 msec, 5 pulse. These conditions resulted in >95% electroporation efficiency as assayed by the total number of GFP+cells. Cells were then transferred into a 6-well flask with 5 ml of prewarmed media. After 48 hours, transfection media was replaced with fresh low glucose DMEM media supplemented with 2% fetal bovine serum, 4.5 g / L glucose, ImM sodium pyruvate, 4 mM L-glutamine, and 100 U / mL penicillin / streptomycin containing varying amounts of sorbitol for an additional 7 days. After incubation cells were collected by try psinization, RNA was isolated and analyzed by qRT-PCR as described herein.
[0216] Quantitative Reverse Transcription PCR (qRT-PCR). Electroporated primary CELLvo™ HC-a chondrocytes were lysed using Trizol (ThermoFisher Scientific), and total RNA was collected using the Direct- zol RNA Miniprep Kit (Zymo Research). RNA quantity' and purity was assessed using the Nanodrop 2000 (ThermoFisher). A total of 50ng of RNA was combined with PrimeTime Master Mix (IDT) and gene-specific primers (IDT; see below) and qRT-PCR was performed according to the manufacture’s protocol. Gene expression was normalized to ACTB. and relative expression was calculated using the AACq method. mRNA levels are reported as Fold-Change (mean with 95% confidence interval) relative to each control condition. Statistically significant differences ofp < 0.05 (*) and p < 0.01 (**) w ere determined by a two-tailed unpaired t-test. n=4 biological replicates.
[0217] Table 3. Gene name and assay ID.
[0218]
[0219] RNA-sequencing and data analysis. WT, WNK2⁻ or transfected T / C-28a2 chondrocytes (5x103cells) were plated in T-25 tissue culture plates and treated as described herein. The RNA-seq experiments were performed in quadruplicate (see PC A plot FIG. 12). RNA extraction, quality control, and RNA-sequencing (RNA-seq) was performed by Novogene. Aligned reads were counted using HTSeq v0.11.3 (Anders, S., Pyl, P. T., and Huber, W. (2015). Bioinformatics 31, 166-169. 10.1093 / bioinformatics / btu638).Attorney’s Docket No.: 21101.0498P1
[0220] Several different analyses were performed in DESeq2 v1.30.0 (Love, M L, Huber, W., and Anders, S. (2014). Genome Biol 15. 550. 10.1186 / s13059-014-0550-8). First, the factors (samples, treatment, and genotype) and ran DESeq2 were combined to obtain the regularized logs (rlog) for sample visualizations. The rlog values are similar to log2 normalized counts except the variance in low count genes is reduced. Then, the first two principal components were plotted using the rlog values from the top 500 variable genes (FIG. 12). The PCA plot indicates that there is minimal variation between samples and therefore dispersion is not inflated. Next, the 48 samples were combined and pairwise comparisons were run. Two interaction models were performed. One with genotype vs treatment (model 1) and the other with transfection vs treatment (model 2). Interaction plots were created with the top 25 genes (FIG. 12). An interaction model tests if the slopes of these lines (log2 fold changes) are different.
[0221] The raw RNA-seq counts were then analyzed for differential gene expression using median-ratio-normalization (Maza, E., et al. (2013). Commun Integr Biol 6, e25849 with DESeq2 v1.30.0 (Love, M L, et al. (2014). Genome Biol 15, 550). Fold-changes were calculated by comparing counts in the treatment groups normalized to the respective counterpart. DESeq2 utilizes Benjamini -Hochberg multiple testing correction within each comparison. Genes with an adjusted p value < 0.05 were considered differentially expressed. RNA-seq datasets are deposited on the Gene Expression Omnibus (GSE244584). WNK2 expression levels were comparable between transfected cells as analyzed by comparison of normalized read counts from RNA-seq data (Table 4).
[0222] Table 4. WNK2 mRNA expression levels in WT and WNK2' T / C-29a2 chondrocytes after various treatments. There is no statistically significant change in WNK2 expression after sorbitol (Sor) treatment or WNK2 transfection (WNK2 trans). However, there is significant decrease in WNK2 expression in WNK2' cells compared with WT.
[0223]
[0224] Attorney’s Docket No.: 21101.0498P1
[0225] Identification of differentially expressed genes in previously published osteoarthritis RNA-seq datasets. 80 up- and 52 down-regulated DEGs were identified from five independent previously published five independent studies using RNA-seq and microarray technologies, focusing on knee and hip cartilage from human osteoarthritis tissues (Table 5) (Fisch, K. M., et al. (2018). Osteoarthritis Cartilage 26, 1531-1538; Ramos, Y. F., et al. (2014). PLoS One 9, el03056; Reed, K. S. M., et al. (2021). Osteoarthritis Cartilage 29, 235-247; Steinberg, J., et al. (2017). Sci Rep 7, 8935; and Wang, K., et al. (2021). Cartilage 13, 5505-5625). Genes were included if they had a p value less than 0.05 and were present in at least three studies. These included DEGs in primary chondrocytes from normal human femoral cartilage treated with fibronectin (FN-f) (Reed, K. S. M., et al. (2021). Osteoarthritis Cartilage 29, 235-247), preserved cartilage from OA-affected hip and knee joints versus healthy cartilage (Ramos, Y. F., et al. (2014). PLoS One 9, el03056), paired intact and degraded articular cartilage from 38 patients undergoing joint replacement surgery (12 knee OA, 17 knee OA, 9 hip OA) (Steinberg, J., et al. (2017). Sci Rep 7, 8935), cartilage biopsies from OA patients undergoing knee replacement compared to healthy cartilage from ACL-reconstruction patients (Wang. K., et al. (2021). Cartilage 13, 5505-5625) and 18 normal versus 20 OA human knee cartilage tissues (Fisch, K. M., et al. (2018). Osteoarthritis Cartilage 26, 1531-1538).Attorney’s Docket No.: 21101.0498P1
[0226] Table 5. 80 up-regulated and 52 down-regulated differentially expressed genes (DEGs) derived from five independent previously published RNA-seq datasets of human osteoarthritis tissues.
[0227]
[0228] Attorney’s Docket No.: 21101.0498P1
[0229] Rare coding alleles ofWNK2 are associated with familial OA. Gene variants associated with dominant forms of familial OA were identified by utilizing a medical genetics database, the Utah Population Database (Gavile, C. M., et al. (2022). J Hand Surg Am 47, 923-933; Jurynec, M. J., et al. (2022). Ann Rheum Dis 81, 1465-1473; Jurynec, M. J., et al. (2018). Hum Mol Genet 27, 2406; and Kazmers, N. H., et al. (2021). Arthritis Rheumatol 73, 440-447). From 151 families analyzed, rare WNK2 coding variants were identified in four families diagnosed with bilateral EHOA or 1stMTP joint OA (Table 6). Among the analyzed family members, WNK2 variants were carried by the individuals with OA and absent from disease-free individuals. The three variants affect regions of the protein highly enriched in glutamines (Q-rich domains), which are important for phase separation and volume recovery in response to hyperosmotic stress in vitro (Boyd-Shiwarski, et al. (2022). Cell Nov 23;185(24):4488-4506.e20; and Yarikipati, P„ et al. (2023). PLoS Genet Oct ll;19(10):el010975). While the affected individuals that have OA in the primary joint used for identification, family members often exhibited OA in additional joints, including knee, hip, shoulder, and spine OA (Table 7). These genetic studies indicate a striking correlation between inheritance of variants in WNK2 and the occurrence of disease within families exhibiting OA in both weight-bearing and non-weight-bearing joints.
[0230] Table 6. WNK2 Variants Identified in Osteoarthritis Families
[0231]
[0232] Attorney’s Docket No.: 21101.0498P1 Table 7. OA Families and Phenotype Details
[0233]
[0234] Attorney’s Docket No.: 21101.0498P1
[0235]
[0236] WNK2 expression is elevated in osteoarthritic tissue. Given the association of WNK2 variants and OA susceptibility, expression of WNK2 was characterized in normal and osteoarthritic joints (FIGS. 1A-1G and FIG. 7). In normal human humeral head cartilage, WNK2 is present at low levels in chondrocytes (FIGS. 1A and IB). In contrast, it is strongly expressed in hypertrophic chondrocytes in damaged human osteoarthntic tissue (humeral head) harvested at the time of total shoulder arthroplasty (FIG. IB). Similarly, WNK2 is expressed at modest levels in the superficial layer of articular chondrocytes in the uninjured mouse knee joint, but it is highly expressed in hypertrophic chondrocytes (FIGS. 1C and ID) and osteophyte tissue (FIG. IE) 8 weeks after induction of OA by surgical destabilization of the medial meniscus (DMM) (Jurynec, M. J., et ak. (2022). Ann Rheum Dis 81, 1465-1473).
[0237] WNK2 expression is downregulated immediately after joint injury. WNK2 is acutely down regulated in primary chondrocytes treated in vitro with fibronectin fragments (Reed, K. S. M., et al. (2021). Osteoarthritis Cartilage 29, 235-247) and in human cartilage treated with IL 1 P (Table 8). It was tested whether modulation of WNK2 expression was dynamically regulated after acute injury’ in vivo. Wnk2 mRNA was downregulated 5 days post- ACL rupture and recovers 21 days post-ACL rupture, despite the continued upregulation of inflammatory and catabolic genes (FIGS. IF and 1G).
[0238] Table 8. WN 2 expression in SkeletalVis datasets (Soul, J., et al. (2019).
[0239] Bioinformatics 35, 2283-2290).
[0240]
[0241] Attorney’s Docket No.: 21101.0498P1
[0242]
[0243] Attorney’s Docket No.: 21101.0498P1
[0244]
[0245] WNK2 mediates the acute response to hyperosmotic stress in chondrocytes. To determine the role of WNK2 in the response of chondrocytes to osmotic stress. T / C-28a2 human chondrocyte cells that lacked WNK2 function were generated to compare with the parental cells. CRISPR / Cas9 technology7was used to delete exon 2, which includes the native start codon of WNK2 (FIG. 2A and FIG. 8) (Goldring, M B., et al. (1994). J Clin Invest 94, 2307-2316). Analysis of RNA expression indicated mutant transcripts lacking exon 2 sequences were generated in the WNK2 null cells (WNK2) (FIG. 8).
[0246] As an immediate response to acute hyperosmotic stress, WNK proteins directly phosphory late the kinase effector proteins, SPAK and OSR1, which in turn modify ion channel functions to maintain osmotic balance (Rinehart, J., et al. (2011). J Biol Chem 286, 30171-30180). Similar to WNK2, SPAK and pSPAKare expressed in undamaged and damaged tissue from human OA joints (FIG. 9). The dose-dependent accumulation ofAttorney’s Docket No.: 21101.0498P1
[0247] phospho-SPAK (pSPAK) in WT or WNK2~ “chondrocytes exposed to acute hyperosmotic stress (Boyd-Shiwarski, C. R., et al. (2022). Cell Nov 23;185(24):4488-4506.e20) was examined. Cells were treated with isotonic media (Iso / 300m0sm) or media supplemented with increasing levels of sorbitol (50mM / 350mOsm, 200mM / 500mOsm, or 500mM / 800mOsm) for 5 minutes, and protein extracts were collected for immunoblot analyses. Sorbitol was added to the medium to alter osmolarity (Boyd-Shiwarski, C. R., et al. (2022). Cell Nov 23;185(24):4488-4506.e20) as WNKs are inhibited by Cl’ ions (Piala, A. T., et al. (2014). Sci Signal May 6;7(324):ra41). WT chondrocytes have a basal level of pSPAK (Iso) and respond to osmotic stress by increasing levels of pSPAK relative to isotonic conditions (FIG. 2B). In the presence of isotonic media WNK2' chondrocytes have a similar level of pSPAK compared with WT (FIG. 2B). However, when challenged with media containing 50 or 200mM sorbitol, WNK2 chondrocytes have reduced levels of pSPAK relative to isotonic conditions (FIG. 2B and FIG. 10). This reduction is similar to pSPAK levels in chondrocytes exposed to hyperosmotic stress (50 or 200mM) in the presence of a WNK1-4 inhibitor (WNK463, 100μM) (Yamada, K., et al. (2016). Nat Chem Biol 12, 896-898) (FIG. 2C and FIG. 10), indicating that WNK2 is largely responsible for SPAK phosphorylation at physiological levels of hyperosmotic stress. In contrast, both WT and WNK2~ chondrocytes have high levels of pSPAK when exposed to supraphysiological levels of hyperosmotic stress (500mM sorbitol), which is reduced by inhibiting WNK1-4 (FIG. 2C and FIG. 10). Phosphorylation of SPAK in WT and WNK2' chondrocytes exposed to supraphysiological levels of hyperosmotic stress may be due to the presence of other WNKs, as the four WNKs are expressed at similar levels between WT and WNK chondrocytes (Table 9). The results show that WNK2 activity is important for chondrocytes to mount the normal response to acute, physiological levels of hyperosmotic stress.
[0248] Table 9. WNK1-4 mRNA expression in WT and WNK2~ T / C-29a2 chondrocytes. There is no statistically significant upregulation of WNK1, WNK3, or WNK4 in WNK2~ cells.
[0249]
[0250] Attorney’s Docket No.: 21101.0498P1
[0251]
[0252] Chronic hyperosmotic stress induces a remodeling response in chondrocytes.
[0253] Chondrocytes of the synovial joint are normally exposed to a hyperosmotic environment, although the osmolarity fluctuates in response to physical activity and pathological changes of the joint (Lewis, R., et al. (2011). Cell Physiol Biochem 28, 1111-1122; Urban, J. P.
[0254] (1994). Br J Rheumatol 33, 901-908; Urban, J. P., et al. (1993). J Cell Physiol 154, 262-270; Shanfield, S., et al. (1988). Clin Orthop Relat Res, 289-295; Bertram, K. L., and Krawetz, R. J. (2012). Biochem Biophys Res Commun 422, 455-461; Newman, P. J., and Grana, W. A. (1988). Arthroscopy 4, 179-181; and Dudek, M., et al. (2023). Nat Commun 14, 7237). To determine if T / C-28a2 chondrocytes respond to chronic hyperosmotic stress, targeted quantitative RT-PCR analysis was performed using chondrocytes exposed to hyperosmotic stress (lOOmM sorbitol / 400mOsm) for 7 days. Chronic hyperosmotic stress induced transcriptional changes similar to those observed in primary human chondrocytes treated with NaCl (FIG. 11) (van der Windt, A. E., Haak, E., Das, R. H., Kops, N., Welting, T. J., Caron, M. M., van Til, N. P., Verhaar, J. A., Weinans, H., and Jahr, H. (2010). Physiological tonicity improves human chondrogenic marker expression through nuclear factor of activated T-cells 5 in vitro. Arthritis Research & Therapy 12. 100-112), including altered expression of OA-associated catabolic and anabolic markers (MMP13, ADMATS1, and SOX9).
[0255] RNA-seq analysis was performed to determine the genome wide transcriptional response of WT T / C-28a2 cells to hyperosmotic stress (FIG. 12). Hyperosmotic stress resulted in upregulation of many anabolic genes (ACAN, FGF2, BMP2, and HIF1A) and downregulation of catabolic genes known to have a role on OA pathogenesis (MMP13.
[0256] CXCL8, and NFKB1), although catabolic factors were also upregulated (MMP3, MMP9, and ADAMTS5) (FIG. 3A). To discover pathways regulated by chronic hyperosmotic stress, IPA software was used to identity' the top-ranking pathways determined by Z-score, which predicts the significance and directionality of pathway activation or inhibition. The response to chronic conditions of hyperosmotic stress is complex. Despite upregulation of some anabolic genes, chronic hyperosmotic stress also affected pathways linked to OA pathogenesis. The latter set of changes included upregulation of mitochondrial dysfunction, production of NO and ROS, thrombin signaling and a downregulation of oxidative phosphorylation, microRNA biogenesis, and cholesterol biosynthesis (FIG. 3B), indicatingAttorney’s Docket No.: 21101.0498P1
[0257] that chondrocytes respond to chronic hyperosmotic stress by initiating a cellular remodeling response.
[0258] WNK2 plays a role in OA-associated gene expression in chondrocytes exposed to chronic hyperosmotic stress. To identify the WNK2-dependent pathways that mediate the chondrocyte response to chronic hyperosmotic stress, RNA-seq analysis of WNK2' chondrocytes cultured in isotonic or chronic hyperosmotic conditions was performed. In comparison with the parental WT cells, WNK2~ chondrocytes cultured in isotonic media express lower levels of genes associated with OA pathogenesis (MMP13, RUNX2, ADAMTS5, and CXCL8) (FIG. 3C). IPA analysis indicated the top pathways downreg ulated in WNK2~ chondrocytes cultured in isotonic conditions are those associated with OA, the role of chondrocytes in rheumatoid arthritis signaling, pulmonary fibrosis (WNT signaling), and the unfolded protein response, while the top upregulated pathways are the RAC, Integrin, and Ephrin signaling pathways (FIG. 3D). This pattern of gene expression is mostly unchanged in WNK2' chondrocytes challenged with hyperosmotic stress (FIG. 3E). Even when exposed to chronic hyperosmotic stress, WNK2' chondrocytes maintained lower expression of genes associated with OA, pulmonary fibrosis, and pathogen induced cytokine storm, while NOTCH, RAC, RAN, and Integrin singling pathways were upregulated (Fig. 3F). These results are consistent with the acute downregulation of Wnk2 after injury being a protective response of chondrocytes and when WNK2 activity is increased in later stages of the disease that it regulates a catabolic response in chondrocytes (FIGS. 1 C- IF).
[0259] WNK2 overexpression induces a remodeling response in chondrocytes. Given loss of WNK2 function in chondrocytes reduces OA-associated gene expression (FIGS. 3C-3F) and WNK2 is expressed at high levels in hypertrophic chondrocytes at advanced stages of OA in mouse and human OA tissue (FIGS. IB and 1C), the transcriptional response of chondrocytes with elevated WNK2 was examined. RNA-seq analysis was performed on untransfected control chondrocytes or chondrocytes transfected with a plasmid encoding WNK2, both of which were cultured in isotonic conditions. WNK2 overexpression caused transcriptional changes like those observed in chondrocytes exposed to chronic hyperosmotic stress, resulting in upregulation of anabolic genes (ACAN, COL2A1, TGFB1, and BMP2) and downregulation of catabolic genes known to have a role on OA pathogenesis (MMP9, GREM1, an lLIB) (FIGS. 3A and 3G). WNK2 overexpression resulted in the alteration of pathways that maintain chondrocyte homeostasis including the upregulation of CREB and PKA signaling, the alternative macrophage activation pathway, wound healing, and downregulation of cholesterol biosynthesis, IL- 17 signaling, and the pattern recognitionAttorney’s Docket No.: 21101.0498P1
[0260] receptor pathway (FIG. 3H). These data indicate that chondrocytes respond to chronic hyperosmotic stress or WNK2 overexpression by regulating genes and pathways involved in cellular remodeling to maintain chondrocyte homeostasis. Chronic hyperosmotic stress had a greater effect on pro-OA pathways, while WNK2 overexpression positively regulated more anabolic / homeostatic pathways.
[0261] Elevated WNK2 and hyperosmotic stress interact to promote OA-associated gene expression. The results demonstrate that WNK2 overexpression or hyperosmotic stress in chondrocytes initiates a remodeling response (FIGS. 3A, 3B and 3G, 3H) and loss of WNK2 function (FIGS. 3C-3F) reduces OA-associated gene expression. Although WNK2 downregulation is an acute response to injury, elevated WNK2 expression is a hallmark of the hypertrophic chondrocytes of OA tissue. It was tested whether the increased WNK2 expression over time interacts with continued hyperosmotic stress. The consequences of the combination of these factors was investigated. When chondrocytes overexpressing WNK2 were exposed to chronic hyperosmotic stress, analysis of selected genes indicated the catabolic response was amplified as compared with untransfected cells (FIG. 13). Thus, the genome-wide effect on gene expression of chronic hyperosmotic stress on chondrocytes overexpressing WNK2 was examined. RNA-seq analysis indicated that in comparison with the parental line of T / C-28a2 cells, many catabolic genes were upregulated, including MMP3, 9. and 13, ILIA, ILl, RUNX2, WNT5B, RIPK2, and GREM1, while many anabolic genes were downregulated. including COL2A1, ACAN, COMP, and MATN3 (FIGS. 4A and 4D). IPA pathway analysis indicated that many pathways downregulated in response either to chronic hyperosmotic stress or WNK2 overexpression were upregulated when chondrocytes overexpressing WNK2 were exposed to hyperosmotic stress. Several upregulated pathways are involved in OA pathogenesis, including inflammation (IL-17. TLR. LPS / IL-1 pathways), cell death (death receptor signaling), RAC signaling, and cholesterol biosynthesis. In contrast to hyperosmotic stress or increased WNK2 activity, CREB, NOTCH, and PPARy / RXRy signaling pathways were downregulated in chondrocytes exposed to both hyperosmotic stress and WNK2 overexpression (FIGS. 3A, 3G, and 4B).
[0262] The combination of WNK2 overexpression and chronic hyperosmotic stress in chondrocytes in vitro resulted in gene expression changes that might promote OA pathogenesis. It was determined if these genes w ere similarly regulated in primary human chondrocytes and human OA tissue. Primary’ human chondrocytes respond very similarly as the expression of most genes was concordant with RNA-seq data from T / C-28a2 cells (FIG.Attorney’s Docket No.: 21101.0498P1
[0263] 14). Acore set of OA-associated genes was identified from five previously published RNA-seq datasets (80 upregulated and 52 downregulated. Table 7) (Reed, K. S. M., et al. (2021). Osteoarthritis Cartilage 29, 235-247; Fisch, K. M., et al. (2018). Osteoarthritis Cartilage 26, 1531-1538; Ramos, Y. F., et al. (2014). PLoS One Jul 23;9(7):el03056; Steinberg, J., et al. (2017). Sci Rep 7, 8935; and Wang, K., et al. (2021). Cartilage 13, 5505-5625). Neither WNK2 overexpression nor exposure to chronic hyperosmotic stress alone recapitulated the expression patterns observed in human OA tissue. In contrast, the gene expression pattern of chondrocytes subjected in vitro to chronic hyperosmotic stress and elevated WNK2 had a significant association with the pattern of expression observed in OA tissue (FIG. 4C). The association was dependent on WNK2, as genes expressed in WNK2~ chondrocytes exposed to hyperosmotic stress were not significantly associated with our OA dataset (FIG. 4C). These results indicate that WNK2 and hyperosmotic stress act synergistically to induce transcriptional changes associated with OA, as neither overexpression of WNK2 nor hyperosmotic stress alone could induce similar transcriptional responses.
[0264] WNK2 variants associated with familial OA amplify the pro-OA transcriptional response to hyperosmotic stress. Given that WNK2 and hyperosmotic stress act synergistically to drive an OA-like pattern of gene expression (FIG. 4), it was tested whether the OA-associated WNK2 variants might alter the effect on gene expression in response to isotonic or hyperosmotic conditions. To test this, the WT or each variant WNK2 allele was overexpressed in chondrocytes and cultured in the absence of osmotic stress or exposed to chronic hyperosmotic stress (FIGS. 5 A-5F). RNA-seq analysis indicated that simple overexpression of the OA-associated WNK2 variants cultured in the absence of hyperosmotic stress promoted expression of pathways associated with OA (FIGS. 5A-5C). This includes upregulation of proinflammatory pathways (iNOS, IL-17. IL-8. IL-1, and IL-6), the cholesterol biosynthesis pathway, and RANK signaling pathways, while pathways that maintain joint homeostasis were downregulated (PPARy, NOTCH, and IL-10 signaling pathways) (FIGS. 5A-5C). This pro-OA gene expression response was further amplified when chondrocytes expressing the OA-associated WNK2 variants were exposed to chronic hyperosmotic stress (FIGS. 5D-5F and FIGS. 12, 14, and 15), indicating the mutations as likely gain-of-function. For example, expression of WNK2H758Nand WNK2LI005Fvariants in chondrocytes exposed to hyperosmotic stress led to further upregulation of IL-1, IL-8, IL- 17, LPS signaling and downregulation of PPARy signaling (FIGS. 5A, 5C, 5D, and 5F). WNT signaling has a known role in OA pathogenesis (Li, X., et al. (2023). Front Cell Dev Biol If 1181619) and WNK activity regulates WNT signaling (Yarikipati, P., et al. (2023). PLoSAttorney’s Docket No.: 21101.0498P1
[0265] Genet Oct 11; 19(10): el 010975; Sato, A., et al. (2020). Commun Biol 3, 666; and Serysheva, E., et al. (2013). EMBO Rep 14. 718-725). In contrast to the effect of WNK2 variant expression in isotonic conditions expression of WNK2R2054Qand WNK2"R'2m chondrocytes exposed to chronic hyperosmotic stress upregulated many genes in the WNT pathway (FIGS.
[0266] 5E and 5G). In sum, these data demonstrate that the three WNK2 variants have a significant functional impact on WNK2 activity and that this altered WNK2 activity is sufficient to induce OA-associated gene expression in the absence of hyperosmotic stress.
[0267] The synovial joint contains a hyperosmotic environment that is subjected to modulation. Changes in osmolarity' occur during mechanical loading, breakdown and synthesis of ECM, and pathological changes associated with aging and OA (Lewis, R., et al. (2011). Cell Physiol Biochem 28, 1111-1122; Urban, J. P. (1994). Br J Rheumatol 33, 901-908; Urban, J. P., Hall, AC., and Gehl, K. A. (1993). J Cell Physiol 154, 262-270; Shanfield, S., et al. (1988). Clin Orthop Relat Res, 289-295; Bertram, K. L., and Krawetz, R. J. (2012). Biochem Biophys Res Commun 422, 455-461; Newman, P. J., and Grana, W. A. (1988). Arthroscopy 4, 179-181; and Dudek, M., et al. (2023). Nat Commun 14, 7237). Cells are necessarily stressed in this dynamic environment, but the proteins that mediate responses to osmotic changes in the joint are largely unknown (Lewis, R., et al. (2011). Cell Physiol Biochem 28, 1111-1122; Hall, A. C. (2019). Curr Rheumatol Rep 21, 38; and Wilkins, R. J., et al. (2000). Biorheology 37, 67-74). It was tested whether under normal physiological conditions chondrocytes utilize WNK2 to sense and mediate the response to hyperosmotic stress to maintain joint homeostasis, including the response to normal mechanical loading and every' day damage. The data showed when WT chondrocytes are exposed to increasing osmotic stress they respond by elevating WNK2 activity'. The data also show that chronic exposure to hyperosmotic stress or overexpression of WNK2 in chondrocytes under isotonic conditions results in gene expression changes indicative of a remodeling response (e.g., expression of both catabolic and anabolic markers) (FIG. 3). Further, the genome wide transcriptional studies demonstrate that the chondrocyte response to chronic osmotic stress is more complex than simply an anabolic response.
[0268] The results described herein show that WNK2 variants are associated with the recurrent onset of hereditary OA. The origin of how' WNK2 activity might contribute to the OA phenotype was investigated. The results show' that WNK2 is highly expressed in damaged human OA cartilage and in hypertrophic chondrocytes in a mouse model of OA (FIG. 1). However, neither stress nor overexpression of WNK2 in vitro alone was sufficient to recapitulate the OA-like gene expression pattern. Remarkably, the combination of WNK2Attorney’s Docket No.: 21101.0498P1
[0269] overexpression and chronic hyperosmotic stress has a distinct effect on gene expression. The two factors act synergistically to induce transcriptional changes associated with OA in vitro. As elevated WNK2 expression combined with chronic hyperosmotic stress is a character of advanced OA tissue, gene expression profiles of the in vitro model and OA tissue were compared. The transcriptional profile of cultured chondrocytes with elevated WNK2 expression combined with chronic hyperosmotic stress overlaps significantly wi th genes expressed in human OA samples (FIG. 4) (Reed, K. S. M., et al. (2021). Osteoarthritis Cartilage 29, 235-247; Fisch, K. M., et al. (2018). Osteoarthritis Cartilage 26, 1531-1538; Ramos, Y. F., et al. (2014). PLoS One Jul 23;9(7):el03056; Steinberg, J., et al. (2017). Sci Rep 7, 8935; and Wang, K., et al. (2021). Cartilage 13, 5505-5625). The interaction between hyperosmotic stress and elevated WNK2 activity is an important driver of the OA phenotype. During disease progression this interaction drives a catabolic response that degrades the ECM leading to loss of GAGs and reduction in joint osmolarity, which is observed in end-stage OA tissues (Lewis, R., et al. (2011). Cell Physiol Biochem 28, 1111-1122; Urban, J. P. (1994). Br J Rheumatol 33, 901-908; Urban, J. P.. et al. (1993). J Cell Physiol 154. 262-270; Shanfield, S., et al. (1988). Clin Orthop Relat Res, 289-295. Bertram, K. L., and Krawetz, R. J. (2012). Biochem Biophys Res Commun 422, 455-461; Newman, P. J., and Grana, W. A. (1988). Arthroscopy 4, 179-181; and Dudek, M., et al. (2023). Nat Commun 14, 7237).
[0270] Loss of WNK under normal conditions suppresses expression of OA-associated genes. Chondrocytes lacking WNK2 have a significant downregulation of pathways associated with OA, rheumatoid arthritis, immunogenic cell death, and fibrosis, and this response is not abrogated by hyperosmotic treatment (FIG. 3). Although pathway analysis show that WNK2' chondrocytes regulate some pathways that may be protective against development of OA, they also have decreased expression of some anabolic markers (COI.2A1, ACAN, and BMP2) and upregulation of markers (MMP3, MMP9, GREM1, ILIA, IL1B, and RIPK2) and pathways (mitochondrial dysfunction and integrin signaling) that are associated with the OA phenotype. These data demonstrate that a proper balance of WNK2 activity and hyperosmotic conditions are important to maintain joint homeostasis.
[0271] WNK2 is downregulated in the early stages of injury-induced OA in the mouse and in an in vitro model of OA (Reed, K. S. M., et al. (2021). Osteoarthritis Cartilage 29, 235-247), yet it is upregulated in advanced stages of OA (FIG. 1). The initial downregulation of WNK2 may be a protective mechanism to maintain joint homeostasis in response to acute injury (FIGS. 1 and 3). Over time WNK2 is upregulated in the joint and it responds to changes in osmotically stressed environment by upregulating an OA-associated transcriptional response.Attorney’s Docket No.: 21101.0498P1
[0272] which disrupts joint homeostasis. It is known that healthy and OA joint tissues respond differentially to hyperosmotic stress (Bertram, K. L., and Krawetz, R. J. (2012). Biochem Biophys Res Commun 422, 455-461; and Tew, S. R., et al. (2009). Am J Physiol Cell Physiol 297. C898-906), but the genes and pathways associated with this differential response remain unresolved. Changes in WNK2 expression during OA progression may partially mediate this response.
[0273] Several pathways were identified in chondrocytes that were oppositely regulated by hyperosmotic stress or WNK2 overexpression compared with the combination of WNK2 overexpression with hyperosmotic stress. The cholesterol biosynthetic pathway and several inflammatory' pathways were downregulated in response to hyperosmotic stress or WNK2 overexpression but upregulated in the combined treatment. Mouse studies have demonstrated molecular pathways linking increased cholesterol metabolism to accelerated OA development (Cao, C., et al. (2022). Nat Commun 13, 7139; and Choi, W. S., et al. (2019). Nature 566, 254-258). Further inflammatory signaling pathways have emerged as risk factors for OA susceptibility in humans and animal models (Jurynec, M. J., et al. (2022). Ann Rheum Dis 81, 1465-1473; Jurynec, M. J., et al. (2018). Hum Mol Genet 27, 2406; Terkawi, M. A., et al. (2022). Biomedicines 10; and Vincent, T. L. (2020). Lancet Rheumatol 2, e633-e645). The data shows that normal WNK2 activity' and hyperosmotic stress is involved in repression of the cholesterol biosynthetic and several inflammatory pathways (e.g.. IL-17 and pattern recognition receptor pathways). The upregulation of WNK2 during OA may cause coordinated expression of these pathways to disrupt joint homeostasis leading to accelerated progression of OA.
[0274] From the in vitro studies with WT WNK2 overexpression combined with hyperosmotic stress, it was thought that the WNK2 variants would have elevated activity and promote the expression of OA-associated pathways. Indeed, functional analysis of the three OA-associated WNK2 variants demonstrated they are sufficient to induce OA-like gene expression even in the absence of hyperosmotic stress. Furthermore, this response is amplified when chondrocytes expressing the WNK2 variants are challenged with chronic hyperosmotic stress (FIG. 5 and FIGS. 12. 14, and 15). Although these data suggest the WNK2 variants are gain-of-function, further in vivo studies are needed to determine how they affect the acute and chronic repose to hyperosmotic conditions. The three variants affect highly conserved amino acids in regions enriched in glutamines (Q-rich domains). The Q-rich domains are important for phase separation and volume recovery in vitro (Boyd-Shiwarski, C. R., et al. (2022). Cell Nov 23;185(24):4488-4506.e20) and the C-terminus (where theAttorney’s Docket No.: 21101.0498P1
[0275] WNK2R2054Qvariant is located) is important for Wnk activity in Drosophila (Yarikipati, P., et al. (2023). PLoS Genet Oct 11; 19( 10): el 010975). WNT signaling has an established role in OA pathogenesis and inhibition of the pathway has been the focus of recent clinical trials (Yazici, Y., et al. (2020). Arthritis Rheumatol 72, 1694-1706; and Yazici, Y., et al. (2021). Osteoarthritis Cartilage 29, 654-666). The data described herein show that WNK2 activity and chronic hyperosmotic stress may be an important modulator of WNT signaling and the onset or progression of OA.
[0276] The functional studies were performed in T / C-28a2 human chondrocytes with a limited set of genes validated in primary' human chondrocytes, and demonstrate that the coding variants in NK2 associated with familial erosive hand OA and foot OA alter the biological function of WNK2. Whereas the focus on WNK2 was in chondrocytes, WNK2 may have roles in other cells of the synovial joint. Generation of mice harboring human OA alleles will allow the determination of the precise role of WNK2 in joint homeostasis and OA development (Jurynec, M. J., et al. (2022). Ann Rheum Dis 81, 1465-1473).
[0277] The findings described herein demonstrate that WNK2 is a major hyperosmotic sensor in chondrocytes that maintains joint homeostasis and that WNK2 activity, in combination with other factors such as chronic hyperosmotic stress, has a determinative role in the development of OA. Three coding variants were identified in WNK2 that alter its function and are associated with familial OA. It was also found that WNK2 and chronic hyperosmotic treatment act synergistically to induce transcriptional changes resembling those observed in OA. A dysregulation of genes associated with cholesterol biosynthesis, inflammation, WNT signaling, and other cellular processes may contribute to OA pathogenesis through WNK2 and osmotic stress. Generation and analysis of loss- and gain-of-function alleles of Wnk2 will help to define the role of WNK2 in vivo in the context of the synovial joint and show that modulation of WNK2 activity as a therapeutic target.
[0278] Example 2: Identification and validation of WNK2 inhibitors using computational-experimental approach
[0279] Osteoarthritis (OA) is a degenerative joint disease marked by cartilage destruction, joint pain, and diminished joint function. Despite its widespread impact, no known therapeutic targets address the underlying molecular mechanisms behind OA, highlighting the urgent need for new treatments. Osmotic stress responses are important to cartilage homeostasis, and disruptions in these processes contribute to cartilage degeneration. The results described herein demonstrate that dysregulated WNK2 signaling is strongly associated with OA susceptibility in articular chondrocytes when they are subjected to osmotic stress.Attorney’s Docket No.: 21101.0498P1
[0280] Genetic analysis of familial OA cases revealed WNK2 coding variants associated with disease susceptibility, emphasizing WNK2's important role in healthy joints. These findings confirm that genetic predispositions and mechanical stresses both contribute to OA progression.
[0281] To address the unmet need for effective OA treatments, WNK2 was targeted.
[0282] Currently, no drugs or inhibitors specifically target WNK2. In this study, a selective inhibitor of WNK2 was identified by using a combination of computational and experimental approaches by focusing on the WNK2 protein kinase domain (PKD). AlphaFold2 was used to structurally model the WNK2-PKD domain, achieving a pLDDT score above 90, indicating high confidence. This enabled the virtual screening of 4.8 million compounds sourced from the ZINC database. Pharmacophore modeling and molecular docking were performed using Molecular Operating Environment (MOE) and AutoDock Vina. Inhibitors were chosen if they interacted specifically with Glu245, and Glu249, which are unique to WNK2. This process led to the identification of 53 candidate compounds with binding energies ranging from -4 to -8 kcal / mol. For the first batch, 15 prioritized inhibitors were selected for experimental validation to assess their ability to inhibit WNK2 activity. Molecule-04 (M04) emerged as apotent and specific inhibitor of WNK2, demonstrating significant therapeutic potential. The structural analysis of M04 showed that it exhibits WNK2 specificity7through ionic interactions with the residue Glu249. Hydrophobic interactions from its fluorinated rings and polar contacts involving Lys244 and Lys251 also contributed to this stability. M04 effectively reduced pSPAK (phosphorylated- STE20 / SPS 1 -related proline / alanine-rich kinase) levels in a dose-dependent manner, with significant reductions observed at 100 pM. SPAK, being a direct downstream target of WNK2, sen es as an indicator of its kinase activity. It exhibited no cytotoxic effects on human chondrocyte T / C-28a2 cells, even at high concentrations of 100 pM for 24 hrs, highlighting its safety profile. Based on these studies, M04 was identified as an inhibitor of WNK2 and a therapy for osteoarthritis.
[0283] Osteoarthritis is a multifactorial, degenerative condition of the joints that mainly affects the cartilage, causing inflammation, pain, and wear and tear. It is characterized by cartilage breakdown, abnormalities in subchondral bone, and osteophytes, all of which lead to joint dysfunction (Loeser, R. F., et al. Arthritis Rheum 64, 1697-1707 (2012)). Chondrocytes, which are resident cells in cartilage surrounded by a pericellular matrix (PCM) and embedded within dense extracellular matrix (ECM), play an important role in sustaining joint homeostasis through response to mechanical, biochemical, and osmotic stresses (Akkiraju. H. and Nohe, A. J Dev Biol 3, 177-192 (2015); and Wilusz, R. E., et al. Matrix Biol 39, 25-32Attorney’s Docket No.: 21101.0498P1
[0284] (2014)). In healthy cartilage, the high concentration of poly anionic glycosaminoglycan sidechains in PCM / ECM creates an hyperosmotic environment (350-450 mOsm) (Lewis, R.. et al. Cell Physiol Biochem 28, 1111-1122 (2011); Urban, J. P. Br J Rheumatol 33, 901-908 (1994); and Urban, J. P., et al. J Cell Physiol 154, 262-270 (1993)) and also in the synovial fluid in a joint (295-404 mOsm) (Bertram, K. L. and Krawetz, R. J. Biochem Biophys Res Commun 422, 455-461 (2012); Newman, P. J. and Grana, W. A. Arthroscopy 4, 179-181 (1988); and Shanfield, S., et al. Clin Orthop Relat Res, 289-295 (1988)). Hyperosmotic environments maintain joint homeostasis by encouraging GAG synthesis (Xu, X., et al. Osteoarthritis Cartilage 18, 433-439 (2010); andNegoro, K., et al. Clin Exp Rheumatol 26, 534-541 (2008) and activating certain genes associated with chondrogenesis and inhibiting those associated with hypertrophy (Tew, S. R. et al. Am J Physiol Cell Physiol 297, C898-906 (2009); Emdt-Marino, J., et al. Cartilage 10, 186-195 (2019); Mongkhon, J. M. et al. Inflamm Res 63, 691-701 (2014); and Govindaraj, K. et al. Adv Sci (Weinh) 11, e2306722 (2024)). However, some studies have reported adverse effects of a hyperosmotic environment in cultured chondrocytes, including decreased viability and abnormal differentiation of chondrogenic tissue (Urban, J. P., et al. J Cell Physio! 154, 262-270 (1993); Jurgens, W. J. et al. J Tissue Eng Regen Med 6, 570-578 (2012); and Parameswaran, R., et al. Tissue Cell 'll, 101590 (2021)).
[0285] Although joints are typically considered an environment of high osmolarity, day-to-day activities, injury, and age-related physiological changes constantly fluctuate their osmolarity levels (Lewis, R., et al. Cell Physiol Biochem 28, 1111-1122 (2011); Urban, J. P. Br J Rheumatol 33, 901-908 (1994); Urban, J. P., et al. J Cell Physiol 154, 262-270 (1993); Bertram, K. L. and Krawetz, R. J. Biochem Biophys Res Commun 422, 455-461 (2012); Newman, P. J. and Grana, W. A. Arthroscopy 4, 179-181 (1988); Shanfield, S., et al. Clin Orthop Relat Res, 289-295 (1988); and Dudek, M. et al. Nat Commun 14, 7237 (2023)). It is important for these cells to constantly adapt to these changes, yet the molecular and cellular mechanisms that detect and respond to osmotic stress remain poorly understood (Lewis, R., et al. Cell Physiol Biochem 28. Il l 1-1122 (2011); Hall, A. C. Curr Rheumatol Rep 21. 38 (2019); and Wilkins, R. J., et al. Biorheology 37, 67-74 (2000)). The genetic and genomic studies conducted have provided significant insight into the molecular basis of osteoarthritis (OA), and one major breakthrough was the identification of novel genetic variations associated with OA susceptibility, particularly those associated with With No Lysine Kinase 2 (WNK2) gene.Attorney’s Docket No.: 21101.0498P1
[0286] WNK2. a member of the WNK kinase family, plays an important role in regulating cellular responses to osmotic stress and maintaining ion homeostasis by regulating ion channel activity and signaling pathways (Goldsmith, E. J. and Rodan, A. R. Amu Rev Physiol 85, 383-406 (2023)). It has been reported that WNK2 mRNA and protein levels are elevated in chondrocytes from humans and mice with end-stage OA, demonstrating that WNK2 regulates chondrocyte behavior during osmotic stress. Under normal hyperosmotic conditions, chondrocytes initiate a remodeling response to preserve homeostasis. In contrast, aberrant WNK2 activity causes cartilage degradation and joint degeneration associated with OA, resulting from genetic variants. It is noteworthy that WNK2-null chondrocytes exhibit significant inhibition of pathways associated with OA, rheumatoid arthritis, immunogenic cell death, and fibrosis, and this effect is not countered by hyperosmotic treatment. Based on these findings, it was tested whether inhibiting WNK2 activity in chondrocytes may offer protection against OA. Our findings demonstrate that disruption of osmotic stress can contribute to homeostasis loss and the onset of OA. In order to unravel the mechanisms behind joint homeostasis and to better understand how these disruptions are associated with OA, it is important to understand the genes and pathways involved in sensing osmotic stress and responding to it. Thus, developing inhibitors targeting WNK2 could be a step in mitigating the progression of OA.
[0287] At the present time, WNK463 is the most known WNK inhibitor, which inhibits the four WNK isoforms with IC50 values of 5 nM (for WNK1), 1 nM (for WNK2), 6 nM (for WNK3), and 9 nM (for WNK4) (Yamada, K. et al. Nat Chem Riol 12, 896-898 (2016)). This compound has been shown to produce significant, dose-dependent effects on blood pressure and heart rate in animal models. Specifically, WNK463 treatment reduces blood pressure and increases heart rate in spontaneously hypertensive rats (SHRs) when administered orally (1-10 mg / kg; 4 hours). Additionally, it causes an increase in urine output and sodium and potassium excretion from the urine. However, WNK463, although potent, has a short half-life of 2.1 hours in Sprague-Dawley rats (Yamada, K. et al. Nat Chem Biol 12, 896-898 (2016)). The oral gavage administration of WNK463 in C57BL / 6 mice resulted in a poor survival rate, suggesting the possibility of toxicity or other adverse effects. Overall, WNK463 has a number of limitations, making it imperative to develop more effective and targeted therapies. Thus, developing inhibitors of WNK2 with specific targeting potential is important.
[0288] In light of the understanding of WNK2's role in OA, it was tested whether inhibiting the activity of WNK2 could mitigate its pathogenic contribution. To investigate this, advanced computational techniques were employed to resolve the three-dimensional structureAttorney’s Docket No.: 21101.0498P1
[0289] of the WNK2 protein kinase domain (WNK2-PKD). To identify inhibitors of the WNK2 kinase, the molecular features of its residues were analyzed and compounds that could specifically target its activity were identified. Virtual screening of millions of compounds and pharmacophore modeling enabled identify' and validate candidates. In particular, one inhibitor inhibited WNK2 activity shown by reducing SPAK phosphory lation (STE20 / SPSl-related proline-alanine-rich kinase). Selectivity is important for reducing off-target effects, which is a common challenge in developing kinase inhibitors. In addition, an XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) assay was performed to assess the inhibitor's safety profile T / C-28a2 cells. Results showed that the compound was well tolerated at effective concentrations, demonstrating its therapeutic utility. Together, these findings highlight the inhibitor's specificity and safety, providing a solid foundation to further develop it. Further testing was conducted using molecular dynamics simulations to determine the inhibitor's stability. In conclusion, these results highlight WNK2 as a drug target and its use as a treatment for OA.
[0290] Materials and Methods. Preparation of protein. AlphaFold2 was used to predict WNK2's protein structure and its protein kinase domain (WNK2-PKD) (ammo acids 195-454) (version 2.3.2) (Jumper, J. et al. Nature 596, 583-589 (2021)). The computation used the GPU resources provided by the Universify of Utah Center for High-Performance Computing (CHPC), using 7 A800 GPUs and 764 GB of system memory in conjunction with NCBI's Fasta sequences (NP 001269323) as input. To assess the reliability of the predicted structures, the Predicted Local Distance Difference Test (pLDDT) scores generated by AlphaFold2 were analyzed. FIG. 23 shows the sequence analysis of WNK family proteins and identification of target residues for WNK-2 inhibitor design.
[0291] Protein preparation was conducted using Molecular Operating Environment (MOE) (version 2024.06) to ensure no residues or atoms were missing, and appropriate adjustments were made. As part of this comprehensive preparation process, hydrogen atoms were added, water molecules were removed, 3D protonation was performed, and gas-phase charges were assigned using the MMFF94 force field, followed by a systematic minimization of the structure (Aziz, M. et al. Sci Rep 12. 6404 (2022)).
[0292] Preparation of ligands. Ligands were sourced from the ZINC database (zinc.docking.org), focusing on commercially available compounds that met Christopher Lipinski's Rule of Five (RO5) (Irwin, J. J. et al. JChemlnfModel 60, 6065-6073 (2020)). A total of 4.7 million compounds were downloaded and prepared for docking. The ligand preparation was done with Open Babel (version 3.1.0), a chemical toolbox that allowsAttorney’s Docket No.: 21101.0498P1
[0293] manipulation of molecules. In each ligand, hydrogen atoms were added in order to ensure correct protonation states, followed by the assignment of atomic charges to illustrate electrostatic interactions, and energy7minimization to simplify geometries and minimize steric clashes. Additionally, solvation was performed to simulate a realistic environment for molecular interactions. The compounds were saved to SDF format and converted to appropriate formats for docking programs, such as PDBQT for autodock and,mol2 for Molecular Dynamic simulations. In preparing the ligands, standard criteria were followed, ensuring reproducibility and accuracy of the prepared structures.
[0294] WNK2 binding pocket identification. The binding pockets of WNK2-PKD were identified using MOE’s site finder program. Protein surfaces are scanned by this algorithm to identify’ cavities based on their size, shape, residue composition, and chemical properties. To understand which sites are more druggable, the ’’Protein-Ligand Binding” score (PLB), the number of hydrophobic alpha spheres (Hyd) and total number of alpha spheres (Side) was calculated.
[0295] Each candidate pocket was visually inspected and computationally evaluated to ensure it was open and accessible for small-molecule binding. Pymol (Version 3.0.3) was used to confirm that the cavities identified were not occluded and could accommodate ligands by calculating solvent-accessible surface area (SASA). An open and accessible binding pocket (BP-4) was discovered in WNK2, distinguished by two residues, Glu245 and Glu249, not found in other WNK family members, and was utilized for inhibitor screening.
[0296] Molecular docking protocol. Molecular docking was performed in two sequential stages. In the first stage, a pharmacophore search was conducted using the MOE tool. The pharmacophore model was designed with specific interaction criteria: the 5-carbon (C51 and C52) and fycarbon of Leull6 were selected for likely hydrophobic interactions. In Glu245 and Glu249 residues, the C5 carboxylate and hydroxyl groups were targeted for both anionic and hydrogen bond interactions, while the -carbon and y-carbon atoms of these residues were included for additional hydrogen bonding potential. A minimum interaction distance of 3 to 5 A was defined, along with volume exclusion criteria restricting inhibitors to bind exclusively within BP4, with a 5 A exclusion zone (Table 10). In total. 100K-150K compounds determined to match the pharmacophore model met at least five criteria.
[0297] As a second step, the 100K-150K compounds identified from the pharmacophore search were docked into BP4 using the same selection criteria defined using induced fit refinement. For each compound, a minimum of 100 docking poses was generated to ensure accurate binding predictions. The compounds with the highest binding energies (AG), rangingAttorney’s Docket No.: 21101.0498P1
[0298] from -3 to -10 kcal / mol, were visualized using MOE. A total of 53 compounds were selected for further analysis. The selected 53 compounds were re-docked using AutoDock Vina (version 4.2.6). In AutoDock Vina, the binding free energy results aligned well with MOE, confirming their accuracy.Attorney’s Docket No.: 21101.0498P1
[0299] Table 10. Details of the top 53 inhibitors (M01-M53) including their compound IDs. Mcule or Zinc IDs, SMILES notation, and Rule of Five violations.
[0300]
[0301] Attorney’s Docket No.: 21101.0498P1
[0302]
[0303] Molecular dynamics simulation. The stability and interactions of the selected molecule M04 was investigated through molecular dynamics (MD) simulations using GROMACS (version 2022.3) with the charmm36-jul2022 force field. The process started with cleaned WNK2-PKD protein structure, which was augmented with hydrogen atoms and underwent energy minimization. The protein topology’ was prepared using the CHARMM36 force field. The cleaned ligands were then formatted for topology using the CGenFF web server using CHARMM36 force field, which generated the topology files. Then, proteinligand complexes were constructed and placed in a dodecahedron box filled with water, resulting in a charged protein solvated system. Ions were introduced to neutralize the system. Energy minimization was conducted to alleviate stenc clashes, followed by a two-phase equilibration: NVT (constant temperature and volume) for 20 ns and NPT (constant pressure and temperature) for an additional 20 ns. After equilibration, 100 ns of production MD simulations were performed on the equilibrated systems. The evaluations, including stability and interaction assessments, were performed with GROMACS tools. Root Mean Square Fluctuation (RMSF), a measure of protein-ligand interactions stability, was analyzed usingAttorney’s Docket No.: 21101.0498P1
[0304] GROMACS both in the presence and absence of selected inhibitors. The fluctuations in residue indicate flexibility, with higher RMSF indicating increased interaction potential and lower RMSF indicating decreased interaction potential. Root Mean Square Deviation (RMSD) which measures the deviation of the protein or complex from its initial conformation and Radius of Gyration (Rg) which measure the compactness of the protein structure by measuring the distribution of atomic mass around the center of mass were calculated during the molecular dynamics simulation to evaluate the structural stability and binding affinity of the system over time. RMSD measures the, with lower values indicating greater structural stability. Rg provides insight into the where consistent values show a stable and compact structure. The simulations were performed in triplicate to ensure reproducibility and reliability of the results.
[0305] T C-28a2 chondrocyte cell culture. To test the inhibitors of WNK2, the human chondrocyte cell line T / C-28a2 (MilliporeSigma) was utilized. T / C-28a2 cells express WNK2 at the protein level. The T / C-28a2 was cultured in Dulbecco's modified Eagle's medium (DMEM) (Coming Life Sciences) supplemented with 10% fetal bovine serum (FBS;
[0306] Avantor), 4.5 g / L glucose, ImM sodium pyruvate, and 100 U / mL penicillin / streptomycin in a 5% CO2 humidified atmosphere incubator at 37°C. Cell passage was performed on 70% confluent cells by trypsini / ation with 0.25% trypsin-EDTA (ThermoFisher).
[0307] Cell viability measurement (XTT assay). To evaluate cell viability at various inhibitor concentrations, an XTT assay (ThermoFisher) was performed according to the manufacturer's protocol. Human chondrocyte cells (T / C-28a2) were cultured as described herein and exposed to different concentrations of inhibitors (ranging from 0.1 pM to 100 pM in DMSO) and for 24 hours at 37°C. DMSO treated cells were treated as controls. After incubation, XTT reagent was prepared by mixing 6 mL of XTT reagent with 1 mL of Electron Coupling Reagent. The working solution (70 pL) was added to each well and incubated for an additional 4 hours at 37°C. Absorbance was measured at both 450 nm and 660 nm. The specific absorbance, which reflects cell viability, was then calculated using the following formula. Specific Absorbance=[A450 nm(Test)-A450 nm(Blank)]-A660 nm(Test)]. The calculated specific absorbance values for each inhibitor concentration were normalized to the untreated control to obtain percent viability. These data were then plotted against the inhibitor concentration. Nonlinear regression analyses inhibitor vs. normalized response - Variable slope were conducted using GraphPad Prism to determine the half-maximal inhibitory concentration (IC50).Attorney’s Docket No.: 21101.0498P1
[0308] Preparation of cell lysates and immunoblot analysis. To determine whether the selected inhibitors affect WNK2 phosphorylation of SPAK. the immediate target of WNK2, SPAK phosphorylation was measured by performing Western blot analysis. WT chondrocytes were cultured as described herein and the cells were subjected to osmotic stress. In brief, once the chondrocytes reached 70% confluence, the culture medium was replaced with fresh complete medium containing various concentrations of inhibitors (ranging from 0.1 pM to 100 pM in DMSO) for 15 minutes. After this, the media were replaced with the same concentrations of inhibitors, either in isotonic medium (300 mOsm) or with sorbitol (200 mM / 500 mOsm). The chondrocytes were incubated for an additional 10 minutes in either isotonic or stress-inducing medium, then harvested and pelleted at 4°C. The total exposure to osmotic stress was 15 minutes. Proteins were isolated using RIP A buffer supplemented with protease and phosphatase inhibitors. The isolated proteins were separated by sodium dodecyl sulfate-poly acrylamide gel electrophoresis (SDS-PAGE) using a 10% acry lamide gel and transferred to a PVDF (0.45um) membrane. The membrane was blocked with 3% BSA in Tris-buffered saline with 0.1% Tween-20 (TBST) overnight at 4°C. The membranes were incubated overnight at 4°C with primary’ antibodies against SPAK (Abeam abl92798) or pSPAK antibodies (EMD Millipore 07-2273). Blots were washed 3X with TBST and then incubated with secondary’ antibodies conjugated with horseradish peroxidase (anti-mouse / rabbit IgG HRP, ThermoFisher Scientific). Signal detection was achieved through enhanced chemiluminescence (SuperSignal West Pico Chemiluminescent Substrate 34080, ThermoFisher Scientific). GAPDH (Santa Cruz Biotechnology 365062) served as the loading control and band intensities were quantified using ImageJ analysis software.
[0309] Protein kinase assay. Kinase activity was assessed using the ADP-Glo™ Kinase Assay Kit (Promega), following the manufacturer's instructions with minor optimizations. Recombinant human WNK1-4 proteins were obtained from Abeam. The reactions were performed with 250 pM ATP, 25 pM SPAK peptide substrate, and recombinant proteins: 50 ng of WNK1, 100 ng of WNK2, 50 ng of WNK3, or 100 ng of WNK4. Test compounds or DMSO (vehicle control) were added at indicated M04 inhibitor concentrations (1, 10, 50, 100, and 200 pM), or the WNK-specific inhibitor WNK463 (200 pM) as a positive control (n=4 for each reactions). Luminescence (RLU- Relative Light Units) was measured using a plate luminometer, and background signals were subtracted from the readings.
[0310] Results. 3D structure ofWNK2 protein whole and PKD domain. Accuracy of AlphaFold2 prediction was confirmed by the pLDDT scores which provides valuable insights into the reliability of these predicted features. The average pLDDT score for the entireAttorney’s Docket No.: 21101.0498P1
[0311] WNK2 protein was 44.43, indicating a low level of confidence and a disordered visual structure (FIG. 16A). In contrast, the average pLDDT score for the protein kinase domain was significantly higher at 89.79 (FIGS. 16B-C). Most amino acids within this domain had pLDDT scores exceeding 90, reflecting a more confidently predicted structure (FIG. 16C). Consequently, the WNK2-PKD domain was targeted for inhibitor discovery7. A direct comparison and TM-score measurement of WNK2 were not performed because no crystal structure was available.
[0312] 3D structure of selected binding pocket WNK2 PKD domain. Among several open binding pockets found, Binding Pocket-4 (BP4) was selected due to two interacting amino acids Glu245, and Glu249 that are exclusively present in WNK2 and not in other WNKs (FIG. 17). These residues are considered targetable sites, making BP4 a candidate for inhibitor design and molecular docking studies. The amino acid residues in BP4 include Leul 16, Hisll9, Thrl20, Aspl80, Glul81, Serl82, Vall85, Lys244, Glu245, Arg247, Tyr248, Glu249, Ile250, and Lys251. TheXYZ spatial coordinates of BP4 are (-5.17, 5.97, -10.70), and it has an approximate diameter of 54 A.
[0313] Top 53 final inhibitor candidates. Among 100K-150K inhibitors, fifty were selected for their favorable binding energies, docking poses, and interactions with important residues (Glu245, and Glu249) within the WNK2-PKD binding pocket. The structures of these inhibitors are displayed in Table 1. The binding affinities of these top candidates, determined using both MOE and AutoDock Vina, ranged from approximately -3 to -10 kcal / mol (Table 1 1).
[0314] Table 11. Binding energies (kcal / mol) of compounds M01-M20 calculated using Molecular Operating Environment (MOE) and AutoDock Vina. The table highlights the comparative results from both docking tools.
[0315]
[0316] Attorney’s Docket No.: 21101.0498P1
[0317]
[0318] Interpretation of top 6 protein-inhibitor interactions. The selected 53 compounds were visually inspected to validate their binding modes and interactions. Among these, six inhibitors’ (M01-M06) interactions with WNK2-PKD binding pocket are shown in FIG. 18. MOI Forms hydrogen bonds with Glu245 and Ile250, stabilized by polar contacts from Glul81, Lys244, Arg247, Tyr248, and Glu249, along with hydrophobic support from Leull6 and Vall85 (FIG. 18A). M02 engages hydrogen bonds with Serl82 and Glu249, further supported by polar and charged residues (Glul81, Lys244, Arg247, Tyr248, Glu245) and hydrophobic contacts (Leull6, Vail 85, Ile250) (FIG. 18B). M03 anchors via hydrogen bonds to Aspl80, Glu245, and Glu249, supplemented by polar interactions with Ile250 and other surrounding residues, and stabilized by Leull6 and Vai 185 (FIG. 18C). M04 exhibits specificity through an ionic interaction with the WNK2-unique residue Glu249, complemented by hydrophobic fluorinated rings and polar contacts from Lys244 and Lys251 (FIG. 18D). M05 secured by hydrogen bonds to Glul81, Glu245, and Aspl80, with additional polar interactions from Glu249, Lys244, and hydrophobic contacts from Leul 16 and Vai 185 (FIG. 18E). M06 establishes an important hydrogen bond with Glu245 and gainsAttorney’s Docket No.: 21101.0498P1
[0319] stability- from polar residues (Asp 180, Glul81, Glu249, Lys244, Seri 82) and hydrophobic surfaces (Leull6, Vall85) (FIG. 18F). Collectively, these six inhibitors demonstrate stable and selective binding within the WNK2-PKD pocket, making them candidates for further optimization and development.
[0320] Cell viability of top 6 inhibitors. The cell viability of the top six inhibitors was evaluated using the XTT assay, revealing varying levels of inhibition in a dose-dependent manner (O. OlpM, O.lpM, IpM, lOpM, 50 pM, and lOOpM). IC50 values, representing the concentration at which 50% of cell viability is inhibited, were calculated for each inhibitor. Among the tested compounds, M04 exhibited the lowest IC50 value, indicating the highest potency and efficacy in reducing cell viability. In contrast, M06 demonstrated relatively weaker activity with a higher IC50 value. The remaining inhibitors. M01, M02, M03, and M05, displayed intermediate inhibitory effects, with IC50 values falling between those of M04 and M06. The dose-response curves (FIG. 19) further illustrate the distinct inhibit ory profiles of the compounds, with M04 emerging as the most effective inhibitor.
[0321] Inhibitor effects of top 6 inhibitors. Western blot analysis was conducted to quantify pSPAK levels, an important marker of WNK2 protein kinase activity, in response to treatment with the top six inhibitors. WNK proteins phosphorylate SPAK and OSR1 as part of the acute hyperosmotic stress response, modulating ion channel functions to maintain osmotic balance. The dose-dependent accumulation of phospho-SPAK (pSPAK) in T / C-28a2 chondrocytes exposed to acute hyperosmotic stress was examined. Cells were treated with isotonic media (Iso / 300m0sm) or media supplemented with increasing levels of sorbitol (200mM / 500mOsm) for 5 minutes, and protein extracts were collected for immunoblot analyses. Among the tested compounds, M04 demonstrated a significant reduction in pSPAK levels compared to the other inhibitors, indicating effective inhibition of WNK2 protein kinase activity. As a positive control, WNK463, a known WNK inhibitor, showed a marked decrease in pSPAK levels, validating the assay's sensitivity. These results confirm that M04 selectively and effectively inhibits WNK2 protein kinase activity, demonstrating its therapeutic activity. FIG. 20 shows WNK2 activity and M01 to M06 inhibitions on WNKs using pSPAK level under osmotic stress conditions.
[0322] Specificity ofM04 inhibitors. To determine M04's isoform selectivity, luminescencebased kinase assays were performed against the four members of the WNK kinase family (WNK1-4). M04 was originally developed with the aim of selectively targeting WNK2. In accordance with this intent, WNK2 activity was markedly reduced at a variety of inhibitor concentrations. Interestingly, M04 also suppressed WNK3 and WNK4 activity dose-Attorney’s Docket No.: 21101.0498P1
[0323] dependently, although the extent of inhibitory effects differed from that of WNK2. This indicates that M04 is able to bind to multiple WNK isoforms in an appreciable manner. By contrast, WNK1 activity remained largely unchanged, demonstrating minimal interaction at the tested doses. Together, these results show that, although M04 inhibits WNK2, it also partially inhibits WNK3 and WNK4, demonstrating that the binding sites of these kinases overlap.
[0324] Stability evaluation of protein-ligand complex. The analysis of inhibitor M04 is presented due to its protein kinase inhibitory' effects, as validated by Western blot analysis. A RMSF analysis revealed that Glu249, Lys244, and Lys251, whose RMSF values are 0.086, 0.094, and 0.0921 nm, respectively, demonstrate strong structural stability and integrity without ligand (FIG. 24A). In the presence of M04, these values decreased slightly to 0.089 nm, 0.126 nm, and 0.087 nm, respectively, indicating further stabilization of these residues by the protein-ligand interaction without compromising the protein's structural integrity (FIG.
[0325] 24A). A reduced flexibility of Glu249, Lys244, and Lys251 upon ligand binding shows that these residues contribute directly to protein-ligand interaction, contributing to structural stability. RMSD analysis performed over a 100-ns simulation revealed minimal deviations from the initial conformation, confirming the sustained stability of the protein-ligand complex throughout the simulation (FIG. 24B). Furthermore, the radius of gy ration (Rg) analysis showed no significant changes in protein compactness, indicating that M04 binding did not disrupt the overall structural architecture of the protein (FIG. 24C). In sum. these findings provide evidence of M04 as a strong and stable inhibitor with significant therapeutic activity'.
[0326] WNK2 was identified as an important regulator of osmotic stress responses in chondrocytes, emphasizing its therapeutic activity for the treatment of OA. Currently, no drug is available to inhibit WNK2. The present study identified an inhibitor named M04, targeting the WNK2-PKD, through a combination of computational and experimental methods. M04 effectively reduces dow nstream phosphorylation of SPAK, exhibits high specificity over other WNK family kinases, and demonstrates minimal cytotoxicity in cellbased assays. Based on these findings, M04 can address degenerative joint diseases by targeting WNK2 protein kinase.
[0327] Biological and clinical implications. Protein kinase family is an important regulator of cellular processes, and dysregulation of it is associated with many diseases, including cancer, neurodegenerative diseases, and cardiovascular disease (Sarkar, N.. et al. Drug Res (Stuttg) 73, 189-199 (2023); Dagda, R. K. and Das Banerjee, T. Rev Neurosci 26, 359-370 (2015);Attorney’s Docket No.: 21101.0498P1
[0328] and Amin, F. et al. Curr Pharm Des 25, 174-183 (2019)). In OA, several ty pes of protein kinases play a role in the disease onset / progression, including mitogen-activated protein kinases (MAPKs) (Stanton, L. A. et al. Dev Biol 263, 165-175 (2003); et al., Nakamura, K. et al. Exp Cell Res 250, 351-363 (1999); and S. Murakami, et al. Proc Natl Acad Sci USA 97, 1113-1118 (2000)), receptor-tyrosine kinases (RTKs) (Thomas M. DeChiara, R. B. K., et al. Nature Genetics 24, 271-274 (2000)), and Janus kinases (JAKs) (Lefebvre, V. and de Crombrugghe, B. Matrix Biol 16, 529-540 (1998); and Kypriotou, M. et al. DNA Cell Biol 22, 119-129 (2003)). These kinases regulate a variety of cellular processes, from cytokine gene expression to matrix metalloproteinase (MMP) production to apoptosis. MAPKs, such as ERK, JNK, and p38, interact with chondrocytes to respond to inflammatory cytokines, which are involved in OA pathogenesis (Stanton, L. A., et al. Dev Biol 263, 165-175 (2003); Koji Nakamura, T. S., Stanton, L. A. et al. Dev Biol 263, 165-175 (2003); et al., Nakamura, K. et al. Exp Cell Res 250, 351-363 (1999); S. Murakami, et al. Proc Natl Acad Sci USA 97, 1113-1118 (2000); and Malemud, C. J. Protein kinases in chondrocyte signaling and osteoarthritis. Clin Orthop Relat Res, S 145-151 (2004)). The role that MAPK pathway inhibitors play in normal cellular functions may make them unviable. The development of inhibitors targeting upstream regulators such as MKK3 or MKK6 may allow for antiinflammatory effects of P38 to be avoided during the treatment of rheumatoid arthritis (Guma, M. et al. Arthritis Rheum 64, 2887-2895 (2012)). Additionally, targeting more than one MAPK may reduce adverse effects associated with less selective MAPK inhibitors, as they could overcome signaling network redundancy (Cohen, S. Expert Opin Investig Drugs 21, 23-31 (2012); and Hammaker, D., Boyle, D. L. and Firestein, G. S. Rheumatology! (Oxford) 51, 610-618 (2012)). Although these insights are compelling, no protein kinase-targeting drugs are FDA-approved or in clinical trials for OA, highlighting the importance of finding targets that can be effectively inhibited without adverse side effects.
[0329] Protein kinase-targeting drugs are becoming increasingly popular in the 21st century, with approximately 25% to 33% of drug development efforts focused on these enzy mes in the United States and worldwide (Roskoski. R., Jr. Pharmacol Res 100, 1-23 (2015); and Cohen, P. Nat Rev Drug Discov 1. 309-315 (2002)). Over 80 FDA-approved drugs target about two dozen protein kinases, while 180 orally effective kinase inhibitors are in clinical trials worldwide, representing a small fraction of the 518 members of the protein kinase enz me family (Carles, F., et al. Molecules 23 (2018); and Roskoski, R., Jr. Pharmacol Res 200, 107059 (2024)). There are currently treatments for RA that target upstream regulators of MAPK, such as fostamatinib (a Syk inhibitor) and tofacitinib (a JAK3 inhibitor). TofacitinibAttorney’s Docket No.: 21101.0498P1
[0330] is FDA-approved for treating RA but not osteoarthritis, while futamatinib is approved for treating chronic immune thrombocytopenia. However, both have been used off-label for pain management in OA (Bussel, J. et al. Am J Hematol 93, 921-930 (2018); and Ogdie, A. et al. RMD Open 6 (2020)). As of yet, no protein kinase-targeting drugs have been approved or are in clinical trials to treat OA, and there is little publicly available information regarding this type of treatment. As a desperate strategy for the treatment of OA, however, diseasemodifying drugs such as tanezumab (Berenbaum, F. et al. Eur J Pain 25, 1525-1539 (2021)) and fasinumab (DiMartino, S. J. et al. Osteoarthr Cartil Open 6, 100533 (2024)), which inhibit nerve growth factor (NGF), and MIV-711 (Conaghan, P. G. et al. Ann Intern Med 172, 86-95 (2020)), which prevents cartilage breakdown are being explored. Currently, there are no FDA-approved drugs that target OA, and existing treatments primarily target pain. Described herein are results demonstrating WNK2 protein kinase has a therapeutic target for OA.
[0331] Computational approaches. A comprehensive computational pipeline was created combining structure prediction, pharmacophore modeling, and virtual screening. A high-confidence model with > 90 PLDDT score was generated with AlphaFold 2 and 4.7 million compounds from the ZINC database were screened using MOE. The compounds used here meet Lipinski's Rule of Five, with molecular weights between 300 and 500 Daltons and lipophilicity scores <5. indicating favorable bioavailability. Docking and binding energy calculations using AutoDock Vina and MOE further refined the selection. The differences observed between AutoDock Vina and MOE's binding energy' calculations highlight the nuances of computation (Table 11). As MOE incorporates parameters such as solvation energy and entropy corrections, it results in a lower negative binding energy value than AutoDock Vina, which focuses primarily on van der Waals and electrostatic interactions. It is imperative to use complementary computational approaches in ligand ranking and inhibitor selection in order to ensure robust predictions. The top 20 compounds ranks were similar between MOE and Autodock vina (Table 10). Protein-ligand interactions were examined using molecular dynamics simulations, and minimal fluctuations (RMSF) were found for important residues, including Glu249. Lys244 and Lys251 also showed minimal fluctuations (FIG. 25 A). Its specificity is further emphasized by its ionic interaction with Glu249. This residue is unique to WNK2 and is likely to be responsible for specific binding. Moreover, polar contacts with Lys244 and Lys251 reinforce the hydrophobic interaction, creating a robust network of stabilizing forces. Besides its selective binding, M04 enhances the structural stability of the protein while maintaining its overall stability through a combinationAttorney’s Docket No.: 21101.0498P1
[0332] of ionic and hydrophobic interactions. The stability of the model was further verified through the root-mean-square deviation (RMSD) analysis and the gyration radius analysis (FIG. 25C). Notably, binding pocket-4 exists exclusively in WNK2, the inhibitor can bind selectively and minimize off-target effects. These findings, supported by experimental results, highlight the synergy' between computational and experimental methodologies in confirming M04’s mechanism of action and specificity.
[0333] Experimental validation. A significant binding of M04 to WNK2 was demonstrated by its IC50 value and Kd, and effective reduction of SPAK phosphorylation was also demonstrated in cellular assays. It is important to note that M04 maintained high cell viability at concentrations above 100 mM, which supports its safety profile. These results were achieved by using an assay designed tailored to assess WNK2 activity and inhibitor specificity. M04 exhibits favorable cell viability, as demonstrated by T / C-28a2 cell viability assays despite concentrations of 10 pM (FIG. 19). Furthermore, protein kinase assays confirm that M04 is specifically directed against WNK2 (FIG. 21). This study underscores the translational potential of WNK2 as a therapeutic target in OA.
[0334] WNK2 comprises Glu245 and Glu249, and thus a distinct structural feature compared to other WNKs. These structural features can be used to enhance therapeutic precision within an open binding pocket. There is no evidence that WNK2 deletion results in deleterious effects, as demonstrated by studies on WNK2 knockout mice (MGI= 1922857, Jackson). Further, it was found that T / C-28a2 chondrocytes lacking WNK2 do not upregulate OA-related genes under osmotic stress, highlighting WNK2's role in cartilage degradation.
[0335] An important strength of this study is the integration of computational and experimental approaches. The drug discovery process described herein has been streamlined for protein kinases lacking crystal structures using advanced tools like AlphaFold 2. As a result of this approach, M04 identified more quickly, and insights into WNK2’s structural and functional roles were gained. FIG. 22 depicts a schematic representation of the computational and experimental workflow used for discovering WNK2 inhibitors. The workflow begins with solving the WNK2 protein structure using AlphaFold2 and identifying binding pockets. A library of 4.7 million compounds from Zinc, ChEMBL, and PubChem underwent Pharmacophore search, narrowing down to l,00K-150K candidates. Docking further reduced this to 53 compounds, followed by molecular dynamics simulations using MOE, GROMACS, and VMD on selected inhibitors. These were validated through in vitro assays for screening, kinase activity, and specificity, culminating in in vivo studies to confirm efficacy and safety, ensuring the identification of potent WNK2 inhibitors.Attorney’s Docket No.: 21101.0498P1
[0336] In addition to OA, WNK2's role in cellular signaling demonstrates therapeutic applications in other diseases involving dysregulated kinases.
[0337] The present study shows the results for targeting WNK2 for OA therapy and the effectiveness of integrating computational and experimental approaches in drug discovery. The finding that M04 is a selective inhibitor of WNK2 helps establish a foundation for developing precision therapies for degenerative joint diseases.
[0338] Example 3: Identification and validation of a WNK2 inhibitor for the treatment of osteoarthritis
[0339] OA is a disease characterized by loss of joint space, degeneration of cartilage at articular surfaces, remodeling of bone and other joint tissues, low-grade inflammation, and pain. It is a leading cause of disability in the aging population. Currently, effective diseasemodifying drugs are not available because a comprehensive understanding of the genetic pathways underlying OA development is lacking. It was demonstrated that dominant hypermorphic mutations in the osmotic stress sensing kinase, WNK2, are associated with OA susceptibility. To explore WNK2 inhibition as a disease-modifying osteoarthritis target, a WNK2 inhibitor was identified by using a combination of computational and experimental approaches. AlphaFold2 was used to model the WNK2 kinase domain with high confidence (pLDDT score >90), allowing virtual screening of 4.8 million compounds in the ZINC database. Structure-based filtering prioritized 53 candidates specifically interacting with WNK2-specific residues Glu245 and Glu249. with binding energies from -4 to -8 kcal / mol. As disclosed herein, M04, (l-(6-((3,5-bis(trifluoromethyl)benzyl)(methyl)amino)pyrimidin-4-yl)pyrrolidin-2-yl)methanol, emerged as a partially selective WNK2 inhibitor with minimal cytotoxicity in human T / C-28a2 chondrocyte cells (cell viability’ IC50 = 416 pM). M04 inhibited ILip mediated proinflammatory gene expression in primary human chondrocytes. Further, the R-enantiomer was identified as the active form of M04. These findings position M04 as a lead for WNK2-targeted OA therapy, supporting further in vivo studies for optimization and validation.
[0340] 3D structure of the WNK2 protein and the protein kinase domain (PKD). WNK2 is a large protein (2,122 amnio acids) that has several conserved domains, including an N-terminal serine / threonine-protein kinase domain (PKD), a chloride-binding / regulatory region, a C-terminal autoinhibitory domain, coiled-coil domains, a SPAK / OSR1 binding motif, and a intrinsically disordered C-terminus that is important for phase separation and volume recovery (Boyd-Shiwarski, C. R. et al. Cell 185, 4488-4506 e4420 (2022)). AlphaFold2 was used to generate a 3D structure of the full length WNK2 protein and the WNK2 PKD.Attorney’s Docket No.: 21101.0498P1
[0341] Accuracy of AlphaFold2 prediction was confirmed by the Predicted Local Distance Difference Test (pLDDT) scores which provides valuable insights into the reliability of these predicted features. The average pLDDT score for the full length WNK2 protein was 44.43, indicating a low level of confidence and a disordered visual structure (FIG. 16A) (Boyd-Shiwarski, C. R. et al. Cell 185, 4488-4506 e4420 (2022)). In contrast, the average pLDDT score for the protein kinase domain was significantly higher at 89.79 (FIGS. 1B-C). Most amino acids within this domain had pLDDT scores exceeding 90, reflecting a more confidently predicted structure (FIG. 16C). Therefore, the WNK2-PKD domain was the focus for drug discovery. A direct comparison and TM-score measurement of WNK2 were not performed because no crystal structure of the WNK2 PKD is available.
[0342] 3D structure of a selected binding pocket in the WNK2 PKD. As the protein kinase domains of WNK1-WNK4 are highly conserved, sharing approximately 85-90% sequence identity7(He, G., et al. J Clin Invest 117, 1078-1087 (2007)), identifying a binding pocket that contains amino acids unique to WNK2 was sought (FIGS. 23A-B). Among several open binding pockets found. Binding Pocket-4 (BP4) was selected due to two amino acids, Glu245 and Glu249, that are exclusively present in WNK2 and not in other WNKs (FIG. 17 and FIGS. 23A-B). These residues are considered targetable sites, making BP4 a candidate for inhibitor design and molecular docking studies. The amino acid residues in BP4 include Leull6, Hisll9, Thrl20, Aspl80, Glul81, Serl82, Vall85, Lys244, Glu245, Arg247, Tyr248, Glu249. Ile250, and Lys251. The XYZ spatial coordinates of BP4 are (-5.17, 5.97, -10.70), and it has an approximate diameter of 54 A.
[0343] Identification of candidate WNK2 interacting molecules. After selecting BP4 as the screening site, a virtual screen of 4.8 million commercially available compounds from the ZINC database that met Lipinski's Rule of Five criteria was carried out.27 Using the Using Molecular Operating Environment (MOE), a pharmacophore-based search was first applied to enrich for compounds with features compatible with the BP4 pocket, reducing the library to approximately 100,000-150,000 candidates. These compounds were then docked to BP4 using induced-fit refinement in MOE, with at least 100 poses generated for each compound. Candidate molecules were ranked based on docking score, binding orientation, and predicted interactions within the pocket, and 53 compounds were selected for further analysis (Table 11).
[0344] Top 53 candidate WNK2 interacting molecules. Among -150K candidate molecules, 53 were selected for their favorable binding energies, docking poses, and interactions with key residues (Glu245, and Glu249) within the WNK2-PKD binding pocket. The structures ofAttorney’s Docket No.: 21101.0498P1
[0345] these molecules are displayed in Table 1. The binding affinities of these top candidates, determined using both MOE and AutoDock Vina, ranged from approximately -3 to -10 kcal / mol (Table 11).
[0346] Identification of the top 6 protein-molecule interactions. The selected 53 molecules were visually inspected to validate their binding modes and interactions. Among these, six inhibitor (M01-M06) interactions with WNK2-PKD binding pocket were shown in FIGS. 18A-F: MOI Forms hydrogen bonds with Glu245 and Ile250, stabilized by polar contacts from Glul81, Lys244, Arg247, Tyr248, and Glu249, along with hydrophobic support from Leul 16 and Vai 185 (FIG. 18A). M02 engages hydrogen bonds with Seri 82 and Glu249, further supported by polar and charged residues (Glul81, Lys244, Arg247, Tyr248, Glu245) and hydrophobic contacts (Leul 16, Vall85. Ile250) (FIG. 18B). M03 anchors via hydrogen bonds to Asp 180, Glu245, and Glu249, supplemented by polar interactions with Ile250 and other surrounding residues, and stabilized by Leul 16 and Vai 185 (FIG. 18C). M04 exhibits specificity7through an ionic interaction with the WNK2-unique residue Glu249, complemented by hydrophobic fluorinated rings and polar contacts from Lys244 and Lys251 (FIG. 18D). M05 secured by hydrogen bonds to Glul81, Glu245, and Aspl80, with additional polar interactions from Glu249, Lys244, and hydrophobic contacts from Leul 16 and Vai 185 (FIG. 18E). M06 establishes a hydrogen bond with Glu245 and gains stability from polar residues (Asp 180, Glul81, Glu249, Lys244, Seri 82) and hydrophobic surfaces (Leul 16. Vall85) (FIG. 18F). Collectively, these six molecules demonstrate favorable binding within the WNK2-PKD pocket, making them candidates for further optimization and development.
[0347] Cell toxicity of selected inhibitors. To determine if any of the top WNK2-PKD interacting molecules had cytotoxic effects, cell viability in human T / C-28a2 chondrocytes was determined using the XTT viability assay over a range of concentrations (0.01 pM to 400 pM). To evaluate tolerability7, ICso values — representing the concentration needed to decrease cell viability7by 50% — were calculated for each compound. M04 displayed the highest ICso (416 pM), showing minimal cytotoxicity7and favorable tolerability in chondrocytes. In comparison, M05 and M01 exhibited lower ICso values of 12.77 pM and 12.80 pM, respectively, indicating higher levels of cytotoxicity. The remaining compounds showed moderate profiles, with IC50 values of 39 pM for M03, 329.5 pM for M02, and 388.8 pM for M34 (FIG. 26). These findings underscore M04 as the most suitable candidate for continued investigation based on its low cytotoxicity in chondrocytes.Attorney’s Docket No.: 21101.0498P1
[0348] M04 is a WNK2 inhibitor. WNKs directly phosphory late and activate the kinases SPAK and OSR1 to modulate osmoregulation through direct modulation of ion channels and altering gene expression (FIG. 20A) (Veerabhadraiah, S. R. et al. RMD Open 11 (2025); Goldsmith, E. J. & Rodan, A. R. Annu Rev Physiol 85, 383-406 (2023); and de Los Heros, P. et al. Biochem J 458, 559-573 (2014)). To determine if selected WNK2-PKD interacting molecules can inhibit the kinase activity of WNK2, the accumulation of phosphorylated SPAK (pSPAK) was examined in T / C-28a2 chondrocytes under isotonic conditions and acute osmotic stress. Previous studies indicated the majority of SPAK phosphorylation in T / C-28a2 chondrocytes is due to WNK2 activity' (Veerabhadraiah, S. R. et al. RMD Open 11 (2025)). T / C-28a2 chondrocytes were treated with isotonic media (Iso / 300m0sm) or media supplemented with sorbitol (200mM / 500mOsm) for 5 minutes in the presence of DMSO control, candidate inhibitors M01 (20 pM), M02 (100 pM), M03 (20 pM), M04 (100 pM), M05 (20 pM), M06 (20 pM), or the pan-WNKl-4 inhibitor WNK463 (100 pM) (Yamada, K. et al. Nat Chem Biol 12, 896-898 (2016)), and protein extracts were collected for immunoblot analyses (FIG. 20B). Among the tested compounds. M04 demonstrated a significant reduction in pSPAK levels under isotonic conditions and acute osmotic stress (FIG.
[0349] 20C). Treatment of chondrocytes with 200-400 pM M04 reduced pSPAK comparable to WNK463 (FIGS. 20B and 20C). M01 and M03 also reduced pSPAK levels but failed to inhibit pSPAK to the same degree as M04 and WNK463 (FIGS. 20E. 20D and FIG. 24). These results confirm that M04 effectively’ inhibits WNK2 protein kinase activity, supporting its use as a targeted therapeutic candidate.
[0350] In vitro WNK1-4 inhibition assays. M04 was originally developed with the aim of selectively targeting WNK2 by utilizing amino acids that are unique to WNK2. To test the specificity of M04. luminescence-based kinase assays using the recombinant kinase domains of WNK1-4 and SPAK as the substrate were performed. The assay was validated by performing the kinase assay in the presence of 200 pM WNK463. The results show that WNK463 inhibited WNK1-4 (FIGS. 21). The results show a dose-dependent reduction in WNK2 activity in the presence of MO4 (FIG. 2 IB). MO4 did not affect WNK1 activity (FIG.
[0351] 21 A). The results also show a dose-dependent reduction in WNK3 and WNK4 activity, although the extent of inhibition was not as complete as WNK2 and did not reach the same level as WNK463 (FIGS. 21C and 21D). These results demonstrate that M04 is able to interact with multiple WNK proteins and inhibit their kinase activity. Together, these results show that, although M04 inhibits WNK2, it also partially inhibits WNK3 and WNK4, demonstrating that the binding sites of these kinases overlap.Attorney’s Docket No.: 21101.0498P1
[0352] Enantios elective synthesis and inhibition of pSPAK with the M04 R-enantiomer. It was tested which enantiomer of M04 was the active form of the molecule. Racemic, (R)-, and (S)-l-(6-((3,5-bis(trifluoromethyl)benzyl)(methyl)amino)pyrimidin-4-yl)pyrrolidin-2-yl)methanol (5, (R-)-M04) and (S)-l-(6-((3,5-bis(trifluoromethyl)benzyl)(methyl)amino)pyrimidin-4-yl)pyrrolidin-2-yl)methanol M04 compounds (Scheme 1) were synthesized. The structural identity of M04 was confirmed by 1H NMR spectroscopy.
[0353] Next, it was tested whether the racemic, (R)-, or (S)-M04 enantiomer was able to inhibit pSPAK accumulation in T / C-28a2 chondrocytes under acute osmotic stress. T / C-28a2 chondrocytes were treated with media supplemented with sorbitol (200mM / 500mOsm) for 5 minutes in the presence of DMSO control, 400uM racemic M04, 400uM (R)-M04. 400uM (S)-M04, or lOOuM WNK463 and protein extracts were collected for immunoblot analyses (FIG. 27). Treatment of chondrocytes with either the racemic or (R-)-M04 demonstrated a reduction in pSPAK levels comparable to WNK463(FIG. 27). The (S-)-M04 enantiomer had a minor effect on pSPAK levels (FIG. 27). These results confirm that the (R-)-M04 enantiomer is the active form of M04.
[0354] Stability evaluation of Protein-ligand complex. To determine the stability of the WNK2-PKD-M04 interaction, Root Mean Square Fluctuation (RMSF) analysis was performed. It was determined that Glu249, Lys244, and Lys251, whose RMSF values are 0.086, 0.094. and 0.0921 nm respectively, demonstrate strong structural stability and integrity without ligand (FIG. 25 A). In the presence of M04, these values decreased slightly to 0.089 nm, 0.126 nm, and 0.087 nm, respectively, indicating further stabilization of these residues by the protein-ligand interaction without compromising the protein's structural integrity (FIG.
[0355] 25A). A reduced flexibility of Glu249, Lys244, and Lys251 upon ligand binding demonstrates that these residues contribute directly to protein-ligand interaction, thereby promoting structural stability. RMSD analysis performed over a 100-ns simulation revealed minimal deviations from the initial conformation, confirming the sustained stability of the protein-ligand complex throughout the simulation (FIG. 25B). Furthermore, the radius of gyration (Rg) analysis showed no significant changes in protein compactness, indicating that M04 binding did not disrupt the overall structural architecture of the protein (FIG. 25C). In sum, these findings highlight M04's ability to act as a strong and stable inhibitor and a therapeutic agent.
[0356] M04 inhibition ofWNK2 reduces IL If mediated proinflammatory gene expression in chondrocytes. IL 10 expression in the synovial joint is associated with the OA phenotype andAttorney’s Docket No.: 21101.0498P1
[0357] is used to induce a catabolic, injury -associated OA transcriptional response in cultured chondrocytes (Vincenti, M. P. & Brinckerhoff, C. E. Arthritis Res 3, 381-388 (2001);
[0358] Shlopov, B. V., et al. Arthritis Rheum 43, 195-205 (2000); Seid, J. M. et al. Arthritis Rheum 36, 35-43 (1993); Kang, W. et al. Sci Rep 14, 18853 (2024); and Wang, L. et al. FASEBJ38, e70013 (2024)). It has been shown that the OA-associated WNK2 variants are hypermorphic and increased pro-OA gene expression in chondrocytes, including proinflammatory pathways (Veerabhadraiah, S. R. et al. RMD Open 11 (2025)). It was tested whether M04 inhibition of WNK2 can reduce IL10-induced proinflammatory' gene expression in T / C-28a2 chondrocytes and primary' human chondrocytes. T / C-28a2 chondrocytes were cultured in hyperosmotic media (lOOmM sorbitol), treated with IL10 for 24 hours (lOpg / mL) in the presence of DMSO (control). 100 pM M04, or 100 pM WNK463, and changes in gene expression were quantified by RT-qPCR analysis. Treatment of T / C-28a2 chondrocytes with IL10 resulted in the upregulation of II.6. CCL2, and downregulation of the main proteoglycan of cartilage, ACAN (FIG. 28 A). Treatment of IL 10 stimulated chondrocytes with M04 resulted in a significant reduction IL6 and CCL2 expression back to control levels compared with IL 10 treated control chondrocytes. In addition to the reduction in proinflammatory gene expression, M04 treatment resulted in increased expression of the main collagen in cartilage, COL2A1, and prevented the IL10-induced downregulation of ACAN (FIG. 28A).
[0359] Chondrocytes were also treated with the pan-WNKl-4 inhibitor, WNK463. Similar to M04, WNK463 did not alter gene expression in control chondrocytes. In IL 10 stimulated chondrocytes, WNK463 treatment led to a significant upregulation of J lfi, IL6, and ACAN and reduced the expression of CCL2.
[0360] There are no disease-modifying drugs available for OA (Vincent, T. L. Lancet Rheumatol 2. e633-e645 (2020)). A lack of targeted therapies highlights the need to identify genetic pathways underlying OA progression and develop effective treatments (Cibrian Uhalte, E., et al. Hum Mol Genet 26, R193-R201 (2017); Zengini, E., et al. J Rheumatol 43, 260-266 (2016); Drevet, S., et al. Comp Med 72, 3-13 (2022); Ramos, Y. F. & Meulenbelt, I. Curr Rheumatol Rep 17, 53 (2015); and Aury-Landas, J., et al. Trends Mol Med 22, 38-52 (2016)). Identification of disease causing genes provides rational targets for effective drug development; drugs that target disease causing proteins more than doubles the success rate in clinical trials independent of the source of the mutation (e.g., rare vs common alleles) (King, E. A., et al. PLoS Genet 15, el008489 (2019); Minikel, E. V., et al. Nature 629, 624-629 (2024); and Nelson, M. R. et al. Nat Genet 47, 856-860 (2015)). The genetic analysis of families with dominant forms of OA allows highly penetrant coding alleles to be identifiedAttorney’s Docket No.: 21101.0498P1
[0361] that have a determinate effect on promoting OA, independent of prior biases on how protein activity may affect the OA phenotype or the tissues specific requirement of the mutant alleles (Gavile, C. M. et al. J Hand Surg Am (2022); Jurynec. M. J. et al. Hum Mol Genet 27, 2406 (2018); Jurynec, M. J. et al. Ann Rheum Dis (2022); Liu, H. et al. Arthritis Rheumatol (2025); Veerabhadraiah, S. R. et al. RMD Open 11 (2025); Kazmers, N. H. et al. Arthritis Rheumatol (2020); Nissi, R. et al. Scand J Rheumatol 40, 22-25 (2011); Ramos, Y. F. et al. Ann Rheum Dis 74, 1756-1762 (2015); Ruault, V. et al. Arthritis Rheumatol (2020); and Sliz. E. et al. PLoS One 12, e0175474 (2017)). Four independent OA families with rare coding mutations in WNK2 were identified. It was demonstrated that WNK2 is a mediator of the chondrocyte response to hyperosmotic stress and the OA-associated alleles are hypermorphic, which regulate gene expression of OA-associated pathways (Veerabhadraiah, S. R. et al. RMD Open 11 (2025)). This data show that WNK2 inhibition may be a therapeutic target in OA.
[0362] Currently, there are no chemical inhibitors specifically targeting WNK2.
[0363] The disclosed computational approach effectively combined pharmacophore modeling, virtual screening, molecular dynamics, and experimental validation to identify potentially selective WNK2 inhibitors. In this study, M04, (l-(6-((3,5-bis(trifluoromethyl)benzyl)(methyl)amino)pyrimidin-4-yl)pyrrolidin-2-yl)methanol was identified as an inhibitor of the WNK2 kinase domain. M04’s interaction with WNK2 was confirmed through its ability to reduce SPAK phosphorylation in cell-based assays, indicating effective target engagement (FIG. 20C). Notably, M04 exhibited an ICso of 416 pM in chondrocyte viability assays, demonstrating low cytotoxicity. In vitro kinase assays indicated that M04 preferentially inhibited WNK2, but it also affected WNK3 and WNK4 activity (FIG. 26D).
[0364] Using a pan-WNK inhibitor (WNK463) and WNK2 null chondrocytes, it was shown that WNK2 is largely responsible for SPAK phosphorylation at physiological levels of hyperosmotic stress (Veerabhadraiah, S. R. et al. RMD Open 11 (2025)). Consistent with this data, inhibition of WNK2 with M04 was effective in suppressing OA-associated ILip-mediated proinflammatory gene expression in cultured and primary human chondrocytes M04. Based on these results, M04 inhibition of WNK2 can be used to reduce or limit the onset or progression of OA.
[0365] Generation of the WNK23D structure. AlphaFold2 was used to predict the WNK2 (NP_001269323) 3D structure and its protein kinase domain (WNK2-PKD) (amino acids 195-454) (version 2.3.2) (Jumper, J. et al. Nature 596, 583-589 (2021)). To assess the reliability of the predicted structures, the Predicted Local Distance Difference Test (pLDDT)Attorney’s Docket No.: 21101.0498P1
[0366] scores generated by AlphaFold2 were analyzed. Protein preparation was conducted using Molecular Operating Environment (MOE) (version 2024.06) to ensure no residues or atoms were missing, and adjustments were made. As part of this comprehensive preparation process, hydrogen atoms were added, water molecules were removed, 3D protonation was performed, and gas-phase charges were assigned using the MMFF94 force field, followed by a systematic minimization of the structure (Aziz, M. et al. Sci Rep 12, 6404 (2022)).
[0367] Preparation of Ligands. Ligands were sourced from the ZINC database (zinc.docking.org), focusing on commercially available compounds that met Christopher Lipinski's Rule of Five (RO5) (Irwin. J. J. et al. J Chem Inf Model 60, 6065-6073 (2020)). A total of 4.8 million compounds were downloaded and prepared for docking. The ligand preparation was done with Open Babel (version 3.1.0), a chemical toolbox that allows manipulation of molecules. For each ligand, hydrogen atoms were added in order to ensure correct protonation states, followed by the assignment of atomic charges to illustrate electrostatic interactions, and energy minimization to simplify geometries and minimize steric clashes. Additionally, solvation was performed to simulate a realistic environment for molecular interactions. The compounds were saved to SDF format and converted to appropriate formats for docking program, such as PDBQT for autodock and,mol2 for Molecular Dynamic simulations. In preparing the ligands, standard criteria were followed, ensuring reproducibility and accuracy of the prepared structures.
[0368] WNK2 binding pocket identification. The potential binding pockets of WNK2-PKD were identified using MOE’s site finder program. Protein surfaces are scanned by this algorithm to identify potential cavities based on their size, shape, residue composition, and chemical properties. From this, sites which may be more druggable can be identified by calculating the " Protein-Ligand Binding“ score (PLB), the number of hydrophobic alpha spheres (Hyd) and total number of alpha spheres (Side). Each candidate pocket was visually inspected and computationally evaluated to ensure it was open and accessible for small-molecule binding. Pymol (Version 3.0.3) was used to confirm that the cavities identified were not occluded and could accommodate ligands by calculating solvent-accessible surface area (SASA). An open and accessible binding pocket (BP-4) was discovered in WNK2, distinguished by two residues, Glu245 and Glu249, not found in other WNK family members, and was utilized for the screening process.
[0369] Molecular Docking Protocol. Molecular docking was performed in two sequential stages. In the first stage, a pharmacophore search was conducted using the MOE tool. The pharmacophore model was designed with specific interaction criteria: the 5-carbon (C51 andAttorney’s Docket No.: 21101.0498P1
[0370] C52) and P-carbon of Leull6 were selected for likely hydrophobic interactions. In Glu245 and Glu249 residues, the C5 carboxylate and hydroxyl groups were targeted for both anionic and hydrogen bond interactions, while the P-carbon and y-carbon atoms of these residues were included for additional hydrogen bonding potential. A minimum interaction distance of 3 to 5 A was defined, along with volume exclusion criteria restricting inhibitors to bind exclusively within BP4, with a 5 A exclusion zone (Table 10). In total, 100K-150K compounds determined to match the pharmacophore model met at least five criteria. As a second step, the 100K-150K compounds identified from the pharmacophore search were docked into BP4 using the same selection criteria previously defined using induced fit refinement. For each compound, a minimum of 100 docking poses was generated to ensure accurate binding predictions. The compounds with the highest binding energies (AG), ranging from -3 to -10 kcal / mol, were visualized using MOE. A total of 53 compounds were selected for further analysis. The selected 53 compounds were re-docked using AutoDock Vina (version 4.2.6). In AutoDock Vina, the binding free energy results aligned well with MOE, confirming their accuracy.
[0371] T / C-28a2 chondrocyte cell culture. To test the inhibitors of WNK2, the human chondrocyte cell line T / C-28a2 (MilliporeSigma) was utilized. Previous studies have shown that T / C-28a2 cells express WNK2.17 The T / C-28a2 was cultured in Dulbecco's modified Eagle's medium (DMEM) (Coming Life Sciences) supplemented with 10% fetal bovine serum (FBS; Avantor). 4.5 g / L glucose, ImM sodium pyruvate, and 100 U / mL penicillin / streptomycin in a 5% CO2 humidified atmosphere incubator at 37°C. Cell passage was performed on 70% confluent cells by trypsinization with 0.25% trypsin-EDTA (ThermoFisher).
[0372] Primary human chondrocyte cell culture. Primary human chondrocytes (CELLvo™ HC-a (passage 1)) were obtained from StemBioSys, Inc. CELLvo™ Chondrocytes were isolated from cadaveric knee articular cartilage of a healthy 28-year-old female African American donor. CELLvo™ HC-a chondrocytes were cultured on CELLvo™ ChondroMatrix coated plasticware (StemBioSys, Inc.) in low glucose Dulbecco's Modification of Eagle's Medium (DMEM) (Coming) supplemented with 1 g / L glucose, ImM sodium pymvate, 4 mM L-glutamine, 15% fetal bovine serum and 100 U / mL penicillin / streptomycin in a 5% CO2 humidified atmosphere incubator at 37°C.
[0373] Cell Viability Measurement (XTT Assay). To evaluate cell viability at various inhibitor concentrations, an XTT assay (Thermo Fisher) was performed according to the manufacturer's protocol. Human chondrocyte cells (T / C-28a2) were cultured as describedAttorney’s Docket No.: 21101.0498P1
[0374] above and exposed to different concentrations of inhibitors (ranging from 0.1 pM to 100 pM in DMSO) and for 24 hours at 37°C. DMSO treated cells were treated as controls. After incubation, XTT reagent was prepared by mixing 6 mL of XTT reagent with 1 mL of Electron Coupling Reagent. The working solution (70 pL) was added to each well and incubated for an additional 4 hours at 37°C. Absorbance was measured at both 450 nm and 660 nm. The specific absorbance, which reflects cell viability, was then calculated using the following formula. Specific Absorbance=[A450 nm(Test)-A450 nm(Blank)]-A660 nm(Test)]. The calculated specific absorbance values for each inhibitor concentration were normalized to the untreated control to obtain percent viability7. These data were then plotted against the inhibitor concentration. Nonlinear regression analyses inhibitor vs. normalized response - Variable slope were conducted using GraphPad Prism to determine the half-maximal inhibitory7concentration (IC50).
[0375] Preparation of cell lysates and immunoblot analysis. To determine whether the selected inhibitors affect WNK2 phosphorylation of SPAK, the immediate target of WNK2, SPAK phosphorylation was measured by performing immunoblot analysis. Chondrocytes were cultured as described above and the cells were subjected to osmotic stress(Veerabhadraiah, S. R. et al. RMD Open 11 (2025)). In brief, once the chondrocytes reached 70% confluence, the culture medium was replaced with fresh complete medium containing various concentrations of inhibitors (ranging from 0.1 pM to 100 pM in DMSO) for 15 minutes. After this, the media were replaced with the same concentrations of inhibitors, either in isotonic medium (300 mOsm) or with sorbitol (200 mM / 500 mOsm). The chondrocytes were incubated for an additional 10 minutes in either isotonic or stress-inducing medium, then harvested and pelleted at 4°C. The total exposure to osmotic stress was 15 minutes. Proteins were isolated using RIPA buffer supplemented with protease and phosphatase inhibitors. The isolated proteins were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) using a 10% acrylamide gel and transferred to a PVDF (0.45um) membrane. The membrane was blocked with 3% BSA in Tris-buffered saline with 0.1% Tween-20 (TBST) overnight at 4°C. The membranes were incubated overnight at 4°C with anti-pSPAK (EMD Millipore 07-2273). Blots were washed 3X with TBST and then incubated with secondary antibodies conjugated with horseradish peroxidase (anti-mouse / rabbit IgG HRP, ThermoFisher Scientific). Signal detection was achieved through enhanced chemiluminescence (SuperSignal West Pico Chemiluminescent Substrate 34080, ThermoFisher Scientific). GAPDH (Santa Cruz Biotechnology 365062) served as the loading control.Attorney’s Docket No.: 21101.0498P1
[0376] Protein Kinase Assay. Kinase activity was assessed using the ADP-Glo™ Kinase Assay Kit (Promega), following the manufacturer's instructions with minor optimizations. Recombinant kinase domains of human WNK1-4 proteins were obtained from Abeam. The reactions were performed with 100 pM ATP, 10 pM SPAK peptide substrate, and recombinant proteins: 50 ng of WNK1, 100 ng of WNK2, 50 ng of WNK3, or 100 ng of WNK4. Test compounds or DMSO (vehicle control) were added at indicated M04 inhibitor concentrations (1, 10, 50, 100, and 200 pM), or the pan-WNKl-4 inhibitor WNK463 (200 pM) as a positive control (n=4 for each reaction). Luminescence (RLU- Relative Light Units) was measured using a plate luminometer, and background signals were subtracted from all readings. Statistical analysis was performed using ordinary one-way ANOVA with DMSO as the control, followed by Dunnett's multiple-comparisons test.
[0377] Molecular Dynamics Simulation. The stability and interactions of the selected molecule M04 was investigated through molecular dynamics (MD) simulations using GROMACS (version 2022.3) with the charmm36-jul2022 force field. Cleaned WNK2-PKD protein structure was used and then augmented with hydrogen atoms and underwent energy minimization. The protein topology was prepared using the CHARMM36 force field. The cleaned ligands were then formatted for topology using the CGenFF web server using CHARMM36 force field, which generated the topology7files. Then, protein-ligand complexes were constructed and placed in a dodecahedron box filled with water, resulting in a charged protein solvated system. Ions were introduced to neutralize the system. Energy minimization was conducted to alleviate steric clashes, followed by a two-phase equilibration: NVT (constant temperature and volume) for 20 ns and NPT (constant pressure and temperature) for an additional 20 ns. After equilibration, 100 ns of production MD simulations were performed on the equilibrated systems.
[0378] The evaluations, including stability and interaction assessments, were performed with GROMACS tools. Root Mean Square Fluctuation (RMSF), a measure of protein-ligand interactions stability, was analyzed using GROMACS both in the presence and absence of selected inhibitors. The fluctuations in residue indicate flexibility, with higher RMSF indicating increased interaction potential and lower RMSF indicating decreased interaction potential. Root Mean Square Deviation (RMSD), which measures the deviation of the protein or complex from its initial conformation, and Radius of Gyration (Rg), which measure the compactness of the protein structure by measuring the distribution of atomic mass around the center of mass, were calculated during the molecular dynamics simulation to evaluate theAttorney’s Docket No.: 21101.0498P1
[0379] structural stability and binding affinity of the system over time. The simulations were performed in triplicate to ensure reproducibility and reliability of the results.
[0380] Quantitative Reverse Transcription PCR (qRT-PCR). T / C-28a2 and primary human chondrocytes were lysed using Trizol (ThermoFisher Scientific), and total RNA was collected using the Direct-zol RNA Miniprep Kit (Zymo Research). RNA quantity and purity was assessed using the Nanodrop 2000 (ThermoFisher). A total of 50ng of RNA was combined with PrimeTime Master Mix (IDT) and gene-specific primers (IDT; see Table 12) and qRT-PCR was performed according to the manufacture’s protocol. Gene expression was normalized to ACTB, and relative expression was calculated using the AACq method. mRNA levels are reported as Fold-Change (mean with 95% confidence interval) relative to each control condition.
[0381] Table 12. Gene name and assay ID.
[0382]
[0383] Statistical Analysis. Nonlinear regression was used to calculate the half-maximal inhibitory concentration (I Go) values, fitting inhibitor concentration against normalized cellular response using a four-parameter logistic model in GraphPad Prism (version 10.3.1). Each experiment included at least three independent replicates, with results reported as mean ± standard deviation (SD).
[0384] qPCR analysis of gene expression in T / C-28a2 chondrocytes and primary human chondrocytes: Gene expression was normalized to ACTB and relative expression was calculated using the AACq method. mRNA levels are reported as fold-change (mean ± SEM) relative to DMSO treated Ctrl samples. Statistically significant differences of p < 0.05 (*), p < 0.01 (**), p < 0.001 (***). and p < 0.0001 (****) were determined by two-way ANOVAAttorney’s Docket No.: 21101.0498P1
[0385] with Tukey’s multiple comparisons test, n=3 or 4 biological replicates as indicated in the scatter plots.
[0386]
[0387] Scheme 1: Reagents and conditions: (a) NaH, THF, RT, 16 h; (b) DIPEA, Cui, DMF, 120°C, 16 hours. 5 indicates the (R)-l-(6-((3,5-bis(trifluoromethyl)benzyl)(methyl)amino)pyrimidin-4-yl)pyrrolidin-2-yl)methanol (5, (R-)-M04) and (S)-l-(6-((3,5-bis(trifluoromethyl)benzyl)(methyl)amino)pyrimidin-4-yl)pyrrolidin-2-yl)methanol M04 molecule.
[0388] Step-1: Synthesis of N-(3.5-bis(trifluoromethyl)benzyl)-6-chloro-N-methylpyrimidin-
[0389]
[0390] To a stirred solution of 6-chloro-N-methylpyrimidin-4-amine (1.0 g, 7.0 mmol, 1.0 equiv) in anhydrous THF (10 mL) under nitrogen at 0 °C was added sodium hydride (0.25 g, 10.4 mmol, 1.5 equiv) portion wise. After stirring briefly, l-(chloromethyl)-3,5-bis(trifluoromethyl)benzene (1.8 g, 7.0 mmol, 1.0 equiv) was added, and the reaction mixture was allowed to warm to 25 °C and stirred for 16 h. Reaction progress was monitored by TLC (40% ethyl acetate / hexane). The reaction was quenched with water and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried over Na2SO4, fdtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (hexane / ethyl acetate) to afford N-(3,5-bis(trifluoromethyl)benzyl)-6-chloro-N-methylpyrimidin-4-amine (2.0 g, 5.4 mmol, 77.7% yield).
[0391] 91Attorney’s Docket No.: 21101.0498P1
[0392] Step-2: Synthesis of racemic. (R). and (S)-(l-(6-((3.5-bis(trifluoromethvl)benzyl)(methvl)amino)pyrimidin-4-vl)pyrrolidin-2-yl)methanol (M04):
[0393] The 3 isomers were synthesized separately. There is a difference in coupling at step 2. For the R isomer, (R)-pyrrolidin-2-ylmethanol was used, for S isomer used, (S)-pyrrolidin-2-ylmethanol was used, and for the racemic mixture: pyrrolidin-2-ylmethanol was used. To synthesize the R isomer, a solution of N-(3,5-bis(trifluoromethyl)benzyl)-6-chloro-N-methylpyrimidin-4-amine (500 mg, 1.35 mmol, 1.0 equiv) in DMF (6 mL) was treated with (R)-pyrrolidin-2-ylmethanol (4) (150 mg, 1.49 mmol, 1.1 equiv), copper (I) iodide (38.7 mg, 0.203 mmol, 0.15 equiv), and N, N-diisopropylethylamine (524 mg, 4.06 mmol, 3.0 equiv). The reaction mixture was stirred at 120 °C for 16 h. Reaction progress was monitored by TLC (60% ethyl acetate / hexane). Upon completion, the reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (50% ethyl acetate / hexane). Trituration with n-heptane afforded (R)-(l-(6-(3,5-bis(trifluoromethyl)benzyl) (methyl) amino) pyrimidin-4-yl) pyrrolidin-2-yl) methanol as an amorphous white solid (260 mg, 0.599 mmol, 44.3% yield). The stereochemistry was retained from the starting (R)-pyrrohdin-2-ylmethanol.
[0394] 'H NMR (400 MHz, DMSO-d6): 58.04 (s, 1H), 8.0 (s, 1H), 7.87 (s, 1H), 5.48 (s, 1H), 5.00-4.90 (m, 3H), 4.12-4.07 (m, 1H), 3.54-3.09 (m, 4H), 2.67 (s, 3H), 2.48-2.43 (m, 2H), 1.98-1.82 (m, 4H).
[0395] NMR (125 MHz. DMSO-d6) 6 162.2, 161.1, 157.2, 143.3, 131.1. 130.8, 130.6. 130.3, 128.3, 124.8, 122.7, 121.1, 111.4, 81.0, 61.9, 59.3, 51.2, 47.2, 27.8, 23.0 ppm
[0396] LCMS: m / z: calcd for C19H20F6N4O [M + H]+435.39; found 435.7. Mp: 84°C All of the methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
Claims
Attorney’s Docket No.: 21101.0498P1CLAIMSWHAT IS CLAIMED IS:
1. A method of treating osteoarthritis in a subject, the method comprising:administering to the subject a therapeutically effective amount of a compound wherein the compound is M4, Ml, M2, M3, M5, M6, M7, M8, M9, M10, M11, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26, M27, M28. M29. M30. M31, M32, M33, M34, M35, M36, M37, M38, M39, M40. M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53, thereby treating osteoarthritis in the subject.
2. A method of ameliorating one or more symptoms of osteoarthritis in a subject, the method comprising: administering to the subject a therapeutically effective amount of a compound wherein the compound is M4, Ml, M2, M3, M5, M6, M7, M8, M9, M10, M11, M12, M13, M14, M15, M16, M17, Ml 8, M19, M20, M21, M22, M23, M24, M25, M26, M27. M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39. M40. M41. M42, M43, M44, M45, M46, M47, M48, M49, M50. M51. M52, or M53, thereby ameliorating one or more symptoms of osteoarthritis in the subject.
3. A method of reducing pSPAK expression in damaged cartilage, menisci, bone, synovium, ligaments, tendons, fat pad, muscle, epidermis, bursa, vasculature, lymphatic system, or connective tissue, the method comprising: administering to a subject a therapeutically effective amount of a compound wherein the compound is M4, Ml, M2. M3, M5, M6, M7, M8, M9, M10, M11, M12, M13. M14, M15, M16, M17. M18. M19. M20. M21, M22, M23, M24, M25, M26, M27, M28, M29. M30. M31, M32, M33, M34, M35, M36, M37, M38, M39, M40, M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53, thereby reducing pSPAK expression in damaged cartilage, menisci, bone, synovium, ligaments, tendons, fat pad, muscle, epidermis, bursa, vasculature, lymphatic system, or connective tissue.
4. A method of reducing WNK2 expression in chondrocytes, synovial cells, ligaments, tenocytes, myocytes, lymphatic cells, vascular cells, epidermal cells, or adipocytes inAttorney’s Docket No.: 21101.0498P1a subject, the method comprising: administering to the subject a therapeutically effective amount of a compound wherein the compound is M4, Ml. M2, M3. M5, M6, M7, M8, M9, M10, M11, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21, M22, M23, M24, M25, M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39, M40, M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51. or M52, thereby reducing WNK2 expression in chondrocytes, synovial cells, ligaments, tenocytes, myocytes, lymphatic cells, vascular cells, epidermal cells, or adipocytes.
5. The method of any of the preceding claims, further comprising administering a therapeutically effective amount of a second therapeutic agent.
6. The method of claim 5, wherein the second therapeutic agent is a nonsteroidal antiinflammatory agent or hyaluronic acid.
7. The method of any of the preceding claims, wherein the subject is identified as being in need of treatment before the administration step.
8. The method of any of the preceding claims, wherein the subject has been identified as having elevated WNK2 expression in chondrocytes compared to a subject that does not have elevated WNK2 expression in chondrocytes or is not suspected of having osteoarthritis.
9. The method of any of the preceding claims, the subject has been diagnosed with osteoarthritis prior to the administering step.
10. The method of any of claims 1 to 9, wherein the compound is administered in a pharmaceutically acceptable composition.
11. The method of claim 10, wherein the pharmaceutical composition is lyophilized.
12. The method of any of the preceding claims, wherein the compound is administered orally, intravenously, intradermally, intratumorally, intramuscularly, intraperitoneally, subcutaneously, intraarticularly, transdermally, or locally.Attorney’s Docket No.: 21101.0498P113. The method of claim 2, wherein the one or more symptoms of osteoarthritis is pain, stiffness, fatigue, tenderness, loss of flexibility’ or mobility', bone spurs, inflammation, or swelling.
14. The method of claim 1 or 9, wherein the osteoarthritis is osteoarthritis of a synovial joint.
15. The method of claim 14, wherein the synovial joint is ahingejoint, carpometacarpal joint, acromioclavicular joint, atlantoaxial joint, metacarpophalangeal joint or a hip joint.
16. The method of claim 1 or claim 9, wherein the osteoarthritis is osteoarthritis of a knee, a hip, a hand, or a foot, a shoulder or spine.
17. The method of claim 8, wherein the subject has also been identified as having elevated expression of MMP9, GREM1, IL6. MMP3MMP13, CCL2, IL1B, COLIO, ADAMTS5. or TNFA.
18. The method of claim 17, wherein the subject has also been identified as having elevated expression of MMP9, GREM1, IL6, MMP3MMP13, CCL2, IL1B, COLIO, ADAMTS5, or TNFA compared to a subject that does not have or is not suspected of having osteoarthritis.
19. The method of claim 8, wherein the subject has also been identified as having a decreased expression of AC AN, COL2A1, TGFB1, or BMP 2.
20. The method of claim 19, wherein the subject has also been identified as having a decreased expression of 4 (24 COL2A1, TGFB1, or BMP 2 compared to a subject that does not have or is not suspected of having osteoarthritis.
21. The method of claim 17, wherein the administration of Ml, M2, M3, M4, M5, M6, M7, M8, M9, M10, Mil, M12, M13, M14, M15, M16, M17, M18, M19, M20, M21,Attorney’s Docket No.: 21101.0498P1M22, M23, M24, M25, M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37. M38. M39. M40, M41, M42, M43, M44, M45, M46, M47, M48, M49. M50, M51, M52, or M53 decreases the expression of one or more of MMP9, GREM1, IL6, MMP3MMP13, CCL2, IL1B, COLIO, ADAMTS5, or TNFA.
22. The method of claim 19, wherein the administration of Ml, M2, M3, M4. M5, M6, M7, M8, M9. M10, M11, M12, M13, M14, M15, M16, M17, M18. M19. M20. M21. M22, M23, M24, M25, M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39, M40, M41, M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, M52, or M53 increases the expression of one or more of ACAN, COL2A1, TGFB1, or BMP 2.
23. The method of any of the preceding claims, wherein the subject is a human.
